[
  {
    "id": "40580757",
    "title_en": "The effect of graphene oxide-polyethylene glycol on lung cell and treatment of sulforaphane.",
    "pub_date": "2026 Jan",
    "abstract_en": "This study explores the cytotoxic and biochemical effects of PEGylated graphene oxide (GO-PEG) nanoparticles, sulforaphane, and Raphanus sativus L. (black radish) juice on BEAS-2B human bronchial epithelial cells. Sulforaphane was extracted from radish juice through pH-adjusted aqueous treatment followed by organic solvent extraction, and quantified via high-performance liquid chromatography (HPLC) at 202Â nm, with a retention time of 11.0Â min. GO-PEG nanoparticles produced from graphites (50Â nm and 400Â nm) were tested at concentrations ranging from 50-225 Î¼gÂ mL<sup>-1</sup> and 100-1000 Î¼gÂ mL<sup>-1</sup> to have IC<sub>50</sub> values, respectively. Sulforaphane and black radish juice were also administered. The MTT assay revealed IC<sub>50</sub> values of 8.7Â Î¼gÂ mL<sup>-1</sup> for sulforaphane, 197.0 mgÂ mL<sup>-1</sup> for black radish juice, 175.8Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (50Â nm), and 650.6Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (400Â nm). Biochemical analyses showed that sulforaphane and radish juice decreased IL-6 levels and increased antioxidant enzyme activities (GSH-Px and CAT). These results highlight the therapeutic potential of GO-PEG, sulforaphane, and black radish juice for anti-inflammatory and antioxidant applications.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„æ½›åœ¨å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼é é˜²èˆ‡ç™¼ç‚ç›¸é—œçš„ç–¾ç—…å…·æœ‰é‡è¦æ„ç¾©ã€‚é€éäº†è§£é€™äº›ç‰©è³ªçš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æ”¹å–„å‘¼å¸ç³»çµ±çš„å¥åº·ï¼Œä¸¦æ¸›å°‘ç›¸é—œç–¾ç—…çš„é¢¨éšªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ ä»¥åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œé€™å°æ–¼å‘¼å¸é“å¥åº·è‡³é—œé‡è¦ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°ä¸åŒæ¿ƒåº¦çš„GO-PEGå¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±é€²è¡Œæ¸¬è©¦ã€‚è˜¿è””ç¡«ç´ æ˜¯å¾é»‘è˜¿è””æ±ä¸­æå–çš„ï¼Œä¸¦é€éé«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶è€…ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦é€²è¡Œç”ŸåŒ–åˆ†æä»¥æ¸¬é‡ç´°èƒå…§çš„ç™¼ç‚æŒ‡æ¨™å’ŒæŠ—æ°§åŒ–é…¶æ´»æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœçªé¡¯äº†GO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ‡‰ç”¨ä¸­çš„æ½›åœ¨ç™‚æ•ˆï¼Œé›–ç„¶é€™äº›çµæœéœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœå’Œæ‡‰ç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†å°å¥åº·å’Œç–¾ç—…é é˜²çš„æ½›åœ¨å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„é ˜åŸŸã€‚ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶æˆåˆ†å¦‚è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½å°å‘¼å¸é“ç´°èƒæœ‰ä¿è­·ä½œç”¨ï¼Œé€™å°æ–¼é é˜²èˆ‡ç™¼ç‚ç›¸é—œçš„ç–¾ç—…å…·æœ‰é‡è¦æ„ç¾©ã€‚é€éäº†è§£é€™äº›ç‰©è³ªçš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æ”¹å–„å‘¼å¸ç³»çµ±çš„å¥åº·ï¼Œä¸¦æ¸›å°‘ç›¸é—œç–¾ç—…çš„é¢¨éšªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ ä»¥åŠé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒBEAS-2Bçš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œé€™å°æ–¼å‘¼å¸é“å¥åº·è‡³é—œé‡è¦ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°ä¸åŒæ¿ƒåº¦çš„GO-PEGå¥ˆç±³é¡†ç²’ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±é€²è¡Œæ¸¬è©¦ã€‚è˜¿è””ç¡«ç´ æ˜¯å¾é»‘è˜¿è””æ±ä¸­æå–çš„ï¼Œä¸¦é€éé«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚ç ”ç©¶è€…ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦é€²è¡Œç”ŸåŒ–åˆ†æä»¥æ¸¬é‡ç´°èƒå…§çš„ç™¼ç‚æŒ‡æ¨™å’ŒæŠ—æ°§åŒ–é…¶æ´»æ€§ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½é™ä½IL-6çš„æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰ã€‚é€™äº›çµæœçªé¡¯äº†GO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ‡‰ç”¨ä¸­çš„æ½›åœ¨ç™‚æ•ˆï¼Œé›–ç„¶é€™äº›çµæœéœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœå’Œæ‡‰ç”¨ã€‚",
    "fb_post": "ğŸŒ±ä½ çŸ¥é“å—ï¼Ÿé»‘è˜¿è””è£¡é¢è—è‘—ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„ç¥å¥‡æˆåˆ†ï¼Œå¯èƒ½å°æˆ‘å€‘çš„å‘¼å¸é“å¥åº·æœ‰å¤§å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼æ¢è¨è˜¿è””ç¡«ç´ ã€é»‘è˜¿è””æ±å’Œä¸€ç¨®å¥ˆç±³é¡†ç²’å°æˆ‘å€‘å‘¼å¸ç³»çµ±ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶è€…å€‘ç”¨äººé¡çš„æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒé€²è¡Œå¯¦é©—ï¼Œæ¸¬è©¦äº†ä¸åŒæ¿ƒåº¦çš„é€™äº›æˆåˆ†ï¼Œä¸¦è§€å¯Ÿå®ƒå€‘çš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±ä¸åƒ…èƒ½é™ä½ç™¼ç‚æŒ‡æ¨™IL-6çš„æ°´å¹³ï¼Œé‚„èƒ½æå‡æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼é€™æ„å‘³è‘—å®ƒå€‘å¯èƒ½åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢æœ‰æ½›åœ¨çš„ç™‚æ•ˆã€‚ä¸éï¼Œé€™äº›çµæœé‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå“¦ï¼\n\nâœ¨å¸¶èµ°é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å‘¼å¸é“å¥åº·ã€‚\n2. é€™äº›æˆåˆ†èƒ½é™ä½ç™¼ç‚æŒ‡æ¨™ï¼Œæå‡æŠ—æ°§åŒ–èƒ½åŠ›ã€‚\n3. ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…·é«”æ•ˆæœï¼",
    "image_prompt": "Create a flat design infographic explaining the experimental methods and main results of a study on the protective effects of sulforaphane and black radish juice on bronchial epithelial cells. Include simplified icons of broccoli or sulforaphane, a simplified representation of human or cell subjects, arrows or flow lines indicating experimental steps, and a section highlighting key results such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‘¼å¸é“ç–¾ç—… Respiratory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40580757/"
  },
  {
    "id": "40961586",
    "title_en": "Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.",
    "pub_date": "2025 Dec",
    "abstract_en": "Triple-negative breast cancer (TNBC) is an aggressive subtype that primarily relies on chemotherapy. Natural products like magnolol and sulforaphane, especially their synthetic hybrid, have shown promising antitumor activity. To develop more potent agents, we designed and synthesized 15 novel magnolol-sulforaphane hybrid analogues and evaluated their anticancer efficacy. Among them, compound 17a demonstrated the highest potency, exhibiting an average 7.4-fold increase in antiproliferative activity with IC<sub>50</sub> values ranging from 0.85Â Â±Â 0.04Â Î¼M to 1.34Â Â±Â 0.02Â Î¼M in TNBC cell lines compared to the parent hybrid CT1-3. In vitro, 17a significantly suppressed TNBC cell proliferation, colony formation, migration, and invasion while inducing apoptosis. In vivo, administration of 17a effectively inhibited tumor growth without apparent toxicity in an MDA-MB-231 xenograft model, as evidenced by normal organ morphology. Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-ÎºB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKÎ± and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å¯èƒ½çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰æ–¹é¢ã€‚é€™ç¨®ç™Œç—‡é¡å‹é€šå¸¸å°åŒ–ç™‚çš„ä¾è³´æ€§å¾ˆé«˜ï¼Œå› æ­¤å°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶ä¸­æåˆ°çš„å¤©ç„¶ç”¢ç‰©ï¼Œå¦‚è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šçš„åˆæˆæ··åˆç‰©ï¼Œé¡¯ç¤ºå‡ºè‰¯å¥½çš„æŠ—è…«ç˜¤æ´»æ€§ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚é¸æ“‡æä¾›æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯å°æ–¼é‚£äº›å°å‚³çµ±ç™‚æ³•åæ‡‰ä¸ä½³çš„æ‚£è€…ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼å’Œè©•ä¼°ä¸€ç³»åˆ—æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä»¥æ¢ç´¢å…¶åœ¨ä¸‰é™°æ€§ä¹³ç™Œä¸­çš„æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•é€šéåˆæˆæ–°çš„åŒ–åˆç‰©ä¾†æé«˜æŠ—ç™Œæ´»æ€§ï¼Œä¸¦å°‹æ‰¾æ›´æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ã€‚é€™äº›æ–°åŒ–åˆç‰©çš„è¨­è¨ˆå’Œåˆæˆæ˜¯åŸºæ–¼å…ˆå‰å·²çŸ¥çš„å¤©ç„¶ç”¢å“ï¼Œç›®çš„æ˜¯å¸Œæœ›èƒ½å¤ æ‰¾åˆ°æ›´å…·ç™‚æ•ˆçš„æŠ—ç™Œè—¥ç‰©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦å°å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœé€²è¡Œäº†è©•ä¼°ã€‚é€™äº›åŒ–åˆç‰©åœ¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒç³»ä¸­é€²è¡Œäº†é«”å¤–æ¸¬è©¦ï¼Œç‰¹åˆ¥é—œæ³¨å®ƒå€‘å°ç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä»¥è§€å¯Ÿé€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœåŠå…¶æ½›åœ¨çš„æ¯’æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—ç™Œæ´»æ€§æ–¹é¢è¡¨ç¾æœ€ä½³ï¼Œé¡¯ç¤ºå‡ºé¡¯è‘—çš„ç´°èƒå¢æ®–æŠ‘åˆ¶æ•ˆæœï¼Œä¸¦èƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”åœ¨å°é¼ æ¨¡å‹ä¸­æœªè¦‹æ˜é¡¯æ¯’æ€§ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œ17aèƒ½å¤ ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™äº›çµæœé¡¯ç¤º17aå¯èƒ½æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚çš„æœ‰åŠ›å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å¯èƒ½çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰æ–¹é¢ã€‚é€™ç¨®ç™Œç—‡é¡å‹é€šå¸¸å°åŒ–ç™‚çš„ä¾è³´æ€§å¾ˆé«˜ï¼Œå› æ­¤å°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶ä¸­æåˆ°çš„å¤©ç„¶ç”¢ç‰©ï¼Œå¦‚è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šçš„åˆæˆæ··åˆç‰©ï¼Œé¡¯ç¤ºå‡ºè‰¯å¥½çš„æŠ—è…«ç˜¤æ´»æ€§ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚é¸æ“‡æä¾›æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯å°æ–¼é‚£äº›å°å‚³çµ±ç™‚æ³•åæ‡‰ä¸ä½³çš„æ‚£è€…ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼å’Œè©•ä¼°ä¸€ç³»åˆ—æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä»¥æ¢ç´¢å…¶åœ¨ä¸‰é™°æ€§ä¹³ç™Œä¸­çš„æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•é€šéåˆæˆæ–°çš„åŒ–åˆç‰©ä¾†æé«˜æŠ—ç™Œæ´»æ€§ï¼Œä¸¦å°‹æ‰¾æ›´æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ã€‚é€™äº›æ–°åŒ–åˆç‰©çš„è¨­è¨ˆå’Œåˆæˆæ˜¯åŸºæ–¼å…ˆå‰å·²çŸ¥çš„å¤©ç„¶ç”¢å“ï¼Œç›®çš„æ˜¯å¸Œæœ›èƒ½å¤ æ‰¾åˆ°æ›´å…·ç™‚æ•ˆçš„æŠ—ç™Œè—¥ç‰©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†15ç¨®æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä¸¦å°å®ƒå€‘çš„æŠ—ç™Œæ•ˆæœé€²è¡Œäº†è©•ä¼°ã€‚é€™äº›åŒ–åˆç‰©åœ¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒç³»ä¸­é€²è¡Œäº†é«”å¤–æ¸¬è©¦ï¼Œç‰¹åˆ¥é—œæ³¨å®ƒå€‘å°ç´°èƒå¢æ®–ã€é›†è½å½¢æˆã€é·ç§»å’Œä¾µè¥²çš„å½±éŸ¿ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä»¥è§€å¯Ÿé€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœåŠå…¶æ½›åœ¨çš„æ¯’æ€§ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—ç™Œæ´»æ€§æ–¹é¢è¡¨ç¾æœ€ä½³ï¼Œé¡¯ç¤ºå‡ºé¡¯è‘—çš„ç´°èƒå¢æ®–æŠ‘åˆ¶æ•ˆæœï¼Œä¸¦èƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”åœ¨å°é¼ æ¨¡å‹ä¸­æœªè¦‹æ˜é¡¯æ¯’æ€§ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œ17aèƒ½å¤ ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™äº›çµæœé¡¯ç¤º17aå¯èƒ½æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œæ²»ç™‚çš„æœ‰åŠ›å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "fb_post": "ğŸŒ± è½èªªéè˜¿è””ç¡«ç´ å—ï¼Ÿé€™å¯æ˜¯ä¸€å€‹å°æŠ—ä¸‰é™°æ€§ä¹³ç™Œçš„æ½›åŠ›æ–°æ˜Ÿï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼é–‹ç™¼ä¸€ç³»åˆ—æ–°çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œç›®çš„æ˜¯è¦æ‰¾å‡ºæ›´æœ‰æ•ˆçš„æŠ—ç™Œæ–¹æ³•ã€‚é€™ç¨®ç™Œç—‡é€šå¸¸å°å‚³çµ±åŒ–ç™‚çš„åæ‡‰ä¸ä½³ï¼Œå› æ­¤ç§‘å­¸å®¶å€‘å¸Œæœ›é€éåˆæˆæ–°çš„åŒ–åˆç‰©ä¾†æé«˜æ²»ç™‚æ•ˆæœã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘åˆæˆäº†15ç¨®ä¸åŒçš„åŒ–åˆç‰©ï¼Œä¸¦åœ¨ä¸‰é™°æ€§ä¹³ç™Œç´°èƒä¸­é€²è¡Œæ¸¬è©¦ã€‚ä»–å€‘ç‰¹åˆ¥è§€å¯Ÿäº†é€™äº›åŒ–åˆç‰©å°ç´°èƒå¢æ®–å’Œè…«ç˜¤ç”Ÿé•·çš„å½±éŸ¿ã€‚æœ€çµ‚ï¼Œä»–å€‘ç™¼ç¾åŒ–åˆç‰©17açš„æŠ—ç™Œæ•ˆæœæœ€ä½³ï¼Œèƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤å¢é•·ï¼Œä¸”åœ¨å°é¼ æ¨¡å‹ä¸­æ²’æœ‰æ˜é¡¯çš„æ¯’æ€§ã€‚\n\né€™é …ç ”ç©¶çš„çµæœè®“æˆ‘å€‘å°æœªä¾†çš„æŠ—ç™Œæ²»ç™‚å……æ»¿å¸Œæœ›ï¼\n\nâœ¨ é‡è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šçš„æ··åˆç‰©å¯èƒ½æˆç‚ºæ–°å‹æŠ—ç™Œè—¥ç‰©çš„å€™é¸è€…ã€‚\n2. åŒ–åˆç‰©17aåœ¨æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·æ–¹é¢è¡¨ç¾çªå‡ºã€‚\n3. é€™äº›ç ”ç©¶ç‚ºä¸‰é™°æ€§ä¹³ç™Œæ‚£è€…æä¾›äº†æ–°çš„æ²»ç™‚æ–¹å‘ï¼",
    "image_prompt": "Create a simple and informative infographic illustrating the experimental process and main results of a study on the anti-cancer effects of a new compound combining sulforaphane and magnolol. Use a flat design style with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like human cells or mice, arrows or flow lines to indicate the steps of the experiment, and a section highlighting the main results (such as tumor growth inhibition and safety profile).",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ä¸‰é™°æ€§ä¹³ç™Œ Triple-negative Breast Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40961586/"
  },
  {
    "id": "41108925",
    "title_en": "Enhancing myocardial injury recovery: Nrf2 activation by sulforaphane regulates ferroptosis and oxidative stress in takotsubo-like models.",
    "pub_date": "2025 Dec",
    "abstract_en": "Takotsubo syndrome (TTS), once considered benign, can cause life-threatening myocardial injury. Although oxidative stress and ferroptosis are implicated in its pathogenesis, targeted therapies are not available for TTS. We demonstrate that sulforaphane (SFN), a natural Nrf2 activator, mitigates TTS-related injury in isoproterenol-induced rat models and AC16 cardiomyocytes. Isoproterenol induced ferroptosis and oxidative stress by impairing Nrf2 signaling. SFN treatment restored myocardial structure and function while enhancing antioxidant capacity, reducing mitochondrial damage, and suppressing ferroptosis markers. Additionally, similar to Fer-1 (a ferroptosis inhibitor), SFN reduced intracellular ferrous levels but uniquely activated Nrf2-driven endogenous defenses. Notably, Nrf2 inhibition abrogated the benefits of SFN in both in vitro and in vivo experiments. These findings highlight SFN as a dual-action therapeutic for TTS, simultaneously targeting oxidative stress and ferroptosis via Nrf2 activation. The therapeutic efficacy of SFN, combined with endogenous pathway modulation, underscores its translational potential for improving TTS outcomes.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›é‡è¦çš„å•Ÿç¤ºã€‚å°¤å…¶æ˜¯é‡å°å¿ƒè‡Ÿå¥åº·ï¼Œç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰æ‰€é€ æˆçš„å¿ƒè‚Œæå‚·ã€‚é€™ç¨®ç—‡å€™ç¾¤é›–ç„¶éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå»å¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‡Ÿå•é¡Œã€‚å› æ­¤ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•å°æ–¼æ”¹å–„æ‚£è€…çš„é å¾Œè‡³é—œé‡è¦ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ï¼Œç‰¹åˆ¥æ˜¯åœ¨é‡å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡æ©Ÿåˆ¶æ–¹é¢ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨Takotsuboç—‡å€™ç¾¤ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ä¾†æ¸›è¼•å› æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡æ‰€å¼•èµ·çš„å¿ƒè‚Œæå‚·ã€‚Takotsuboç—‡å€™ç¾¤æ˜¯ä¸€ç¨®å¿ƒè‡Ÿç–¾ç—…ï¼Œé€šå¸¸èˆ‡æƒ…ç·’å£“åŠ›æœ‰é—œï¼Œæœƒå°è‡´å¿ƒè‡ŸåŠŸèƒ½æ€¥åŠ‡ä¸‹é™ã€‚ç ”ç©¶çš„ç›®çš„æ˜¯æ‰¾å‡ºæœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œä»¥æ”¹å–„é€™ç¨®ç–¾ç—…çš„é å¾Œï¼Œä¸¦æ¸›å°‘å…¶å°æ‚£è€…ç”Ÿæ´»è³ªé‡çš„å½±éŸ¿ã€‚",
    "para3": "å¯¦é©—çš„è¨­è¨ˆåŒ…æ‹¬ä½¿ç”¨å¤§é¼ æ¨¡å‹å’Œå¿ƒè‡Ÿç´°èƒç³»ï¼ˆAC16ï¼‰ä¾†æ¨¡æ“¬Takotsuboç—‡å€™ç¾¤ã€‚ç ”ç©¶è€…ä½¿ç”¨ç•°ä¸™è…ä¸Šè…ºç´ ä¾†èª˜å°å¿ƒè‚Œæå‚·ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è©•ä¼°äº†å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½çš„è®ŠåŒ–ï¼Œä¸¦æ¸¬é‡äº†æŠ—æ°§åŒ–èƒ½åŠ›ã€ç·šç²’é«”æå‚·å’Œéµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å¿ƒè‡Ÿç´°èƒçš„å¥åº·ç‹€æ…‹ï¼Œä»¥åŠå…¶æ½›åœ¨çš„æ²»ç™‚æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒæ™‚æ¸›å°‘ç·šç²’é«”æå‚·å’Œéµæ­»äº¡çš„ç›¸é—œæ¨™è¨˜ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶æ¶‰åŠæ¿€æ´»Nrf2é€™ä¸€å…§æºæ€§é˜²ç¦¦ç³»çµ±ï¼Œé€™å°æ–¼æ¸›è¼•å¿ƒè‚Œæå‚·è‡³é—œé‡è¦ã€‚æ­¤å¤–ï¼ŒNrf2çš„æŠ‘åˆ¶æœƒå‰Šå¼±è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œé€™è¡¨æ˜Nrf2åœ¨é€™ä¸€éç¨‹ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚é€™äº›çµæœå¼·èª¿äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨ç™‚æ³•çš„æ½›åŠ›ï¼Œå¯èƒ½ç‚ºæ”¹å–„Takotsuboç—‡å€™ç¾¤çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›é‡è¦çš„å•Ÿç¤ºã€‚å°¤å…¶æ˜¯é‡å°å¿ƒè‡Ÿå¥åº·ï¼Œç ”ç©¶é¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰æ‰€é€ æˆçš„å¿ƒè‚Œæå‚·ã€‚é€™ç¨®ç—‡å€™ç¾¤é›–ç„¶éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå»å¯èƒ½å°è‡´å±åŠç”Ÿå‘½çš„å¿ƒè‡Ÿå•é¡Œã€‚å› æ­¤ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•å°æ–¼æ”¹å–„æ‚£è€…çš„é å¾Œè‡³é—œé‡è¦ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ï¼Œç‰¹åˆ¥æ˜¯åœ¨é‡å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡æ©Ÿåˆ¶æ–¹é¢ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨Takotsuboç—‡å€™ç¾¤ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•åˆ©ç”¨é€™ç¨®å¤©ç„¶åŒ–åˆç‰©ä¾†æ¸›è¼•å› æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡æ‰€å¼•èµ·çš„å¿ƒè‚Œæå‚·ã€‚Takotsuboç—‡å€™ç¾¤æ˜¯ä¸€ç¨®å¿ƒè‡Ÿç–¾ç—…ï¼Œé€šå¸¸èˆ‡æƒ…ç·’å£“åŠ›æœ‰é—œï¼Œæœƒå°è‡´å¿ƒè‡ŸåŠŸèƒ½æ€¥åŠ‡ä¸‹é™ã€‚ç ”ç©¶çš„ç›®çš„æ˜¯æ‰¾å‡ºæœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œä»¥æ”¹å–„é€™ç¨®ç–¾ç—…çš„é å¾Œï¼Œä¸¦æ¸›å°‘å…¶å°æ‚£è€…ç”Ÿæ´»è³ªé‡çš„å½±éŸ¿ã€‚\n\nå¯¦é©—çš„è¨­è¨ˆåŒ…æ‹¬ä½¿ç”¨å¤§é¼ æ¨¡å‹å’Œå¿ƒè‡Ÿç´°èƒç³»ï¼ˆAC16ï¼‰ä¾†æ¨¡æ“¬Takotsuboç—‡å€™ç¾¤ã€‚ç ”ç©¶è€…ä½¿ç”¨ç•°ä¸™è…ä¸Šè…ºç´ ä¾†èª˜å°å¿ƒè‚Œæå‚·ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è©•ä¼°äº†å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½çš„è®ŠåŒ–ï¼Œä¸¦æ¸¬é‡äº†æŠ—æ°§åŒ–èƒ½åŠ›ã€ç·šç²’é«”æå‚·å’Œéµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å¿ƒè‡Ÿç´°èƒçš„å¥åº·ç‹€æ…‹ï¼Œä»¥åŠå…¶æ½›åœ¨çš„æ²»ç™‚æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒæ™‚æ¸›å°‘ç·šç²’é«”æå‚·å’Œéµæ­»äº¡çš„ç›¸é—œæ¨™è¨˜ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶æ¶‰åŠæ¿€æ´»Nrf2é€™ä¸€å…§æºæ€§é˜²ç¦¦ç³»çµ±ï¼Œé€™å°æ–¼æ¸›è¼•å¿ƒè‚Œæå‚·è‡³é—œé‡è¦ã€‚æ­¤å¤–ï¼ŒNrf2çš„æŠ‘åˆ¶æœƒå‰Šå¼±è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆï¼Œé€™è¡¨æ˜Nrf2åœ¨é€™ä¸€éç¨‹ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ã€‚é€™äº›çµæœå¼·èª¿äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨ç™‚æ³•çš„æ½›åŠ›ï¼Œå¯èƒ½ç‚ºæ”¹å–„Takotsuboç—‡å€™ç¾¤çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "fb_post": "ğŸŒŸä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„ç§˜å¯†æˆåˆ†ï¼Œå¯èƒ½å°å¿ƒè‡Ÿå¥åº·æœ‰å¹«åŠ©ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ ï¼ˆé€™æ˜¯ä¸€ç¨®å¤©ç„¶åŒ–åˆç‰©ï¼‰å°Takotsuboç—‡å€™ç¾¤çš„æ½›åœ¨ç™‚æ•ˆã€‚é€™ç¨®ç—‡å€™ç¾¤é€šå¸¸èˆ‡æƒ…ç·’å£“åŠ›æœ‰é—œï¼Œæœƒè®“å¿ƒè‡Ÿçš„åŠŸèƒ½æ€¥åŠ‡ä¸‹é™ï¼Œç”šè‡³å¯èƒ½å±åŠç”Ÿå‘½ã€‚\n\nç ”ç©¶è€…å€‘ä½¿ç”¨å¤§é¼ æ¨¡å‹å’Œå¿ƒè‡Ÿç´°èƒä¾†æ¨¡æ“¬é€™ç¨®å¿ƒè‡Ÿç–¾ç—…ï¼Œä»–å€‘ç”¨ç•°ä¸™è…ä¸Šè…ºç´ ä¾†èª˜å°å¿ƒè‚Œæå‚·ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…æ”¹å–„äº†å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œé‚„å¢å¼·äº†æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘äº†ç´°èƒæå‚·çš„æ¨™è¨˜ã€‚\n\né€™é …ç ”ç©¶çš„ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°äº†è˜¿è””ç¡«ç´ åœ¨å¿ƒè‡Ÿæ²»ç™‚ä¸Šçš„æ½›åŠ›ï¼Œå°¤å…¶æ˜¯å®ƒèƒ½å¤ å•Ÿå‹•ä¸€ç¨®å…§æºæ€§é˜²ç¦¦ç³»çµ±ï¼Œå°å¿ƒè‚Œæå‚·çš„ç·©è§£éå¸¸é‡è¦ã€‚\n\nğŸ”‘ ä½ å¯ä»¥å¸¶èµ°çš„å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¿ƒè‡Ÿå¥åº·ã€‚\n2. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„å¿ƒè‡Ÿç—…æ²»ç™‚æä¾›äº†æ–°æ–¹å‘ã€‚\n3. äº†è§£å¤©ç„¶åŒ–åˆç‰©çš„æ½›åŠ›ï¼Œæˆ–è¨±èƒ½æ”¹å–„æˆ‘å€‘çš„ç”Ÿæ´»å“è³ªï¼",
    "image_prompt": "Create a flat design infographic on a light background explaining the experiment and main results of the study. Include simple icons representing sulforaphane (from broccoli or radish), experimental subjects like simplified human, animal, or cell illustrations. Use arrows or flow lines to depict the experimental steps. Add a section labeled 'Main Results' that highlights protective effects and changes observed, such as improved heart structure and function, enhanced antioxidant capacity, and reduced cell damage markers.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "Takotsuboç—‡å€™ç¾¤ Takotsubo Syndrome",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41108925/"
  },
  {
    "id": "41340527",
    "title_en": "Metabolomics and Transcriptomics Analyses Reveal the Mechanisms of Sulforaphane Conversion and Adaptive Strategies in the Absence of Glucose by <i>Lactiplantibacillus plantarum</i>.",
    "pub_date": "2025 Dec",
    "abstract_en": "Sulforaphane is a beneficial but unstable bioactive compound that can be converted from glucoraphanin by <i>Lactiplantibacillus plantarum</i>. However, the sulforaphane conversion rate is low, and the conversion mechanism of <i>L. plantarum</i> remains unclear. This research utilized the adaptive laboratory evolution technology to enhance the sulforaphane conversion rate of <i>L. plantarum</i>. The results showed that an increase in the glucose replacement ratio significantly downregulated carbohydrate metabolism and upregulated amino acid metabolism. Transcriptomic analysis showed that the ALE-adapted strain significantly upregulated carbohydrate metabolism and amino acid metabolism. In the conversion pathway, glucoraphanin is imported into <i>L. plantarum</i> cells, and its glucose moiety is phosphorylated by bglF (the phosphate group may be derived from phosphoenolpyruvate via the phosphotransferase system). Subsequently, the S-glycosidic bond of phosphorylated glucoraphanin is hydrolyzed by bglA (6-phospho-Î²-glucosidase), followed by nonenzymatic rearrangement and sulfate elimination, ultimately yielding sulforaphane. This research can contribute to revealing the interaction mechanism between microorganisms and natural active substances.",
    "para1": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œå› ç‚ºè˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰æ½›åœ¨å¥åº·ç›Šè™•çš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ã€‚å®ƒèƒ½å¤ å¾é’èŠ±æ¤°èœä¸­çš„è‘¡è„ç³–è‹·è½‰åŒ–è€Œä¾†ï¼Œé€™æ„å‘³è‘—é€éæ”¹å–„å…¶è½‰åŒ–ç‡ï¼Œå¯èƒ½èƒ½å¤ å¢åŠ æˆ‘å€‘æ”å–é€™ç¨®æœ‰ç›Šæˆåˆ†çš„æ©Ÿæœƒã€‚éš¨è‘—å°è˜¿è””ç¡«ç´ çš„ç ”ç©¶æ·±å…¥ï¼Œäº†è§£å…¶è½‰åŒ–éç¨‹å’Œæ©Ÿåˆ¶ï¼Œæˆ–è¨±èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²æä¾›æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç™Œå’ŒæŠ—ç‚ç­‰æ–¹é¢çš„æ½›åœ¨æ‡‰ç”¨ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ å…·æœ‰æ½›åœ¨çš„å¥åº·ç›Šè™•ï¼Œä½†å…¶è½‰åŒ–ç‡å»ç›¸å°è¼ƒä½ï¼Œä¸”ç›®å‰å°æ–¼ä¹³é…¸èŒå¦‚ä½•é€²è¡Œé€™ä¸€è½‰åŒ–çš„æ©Ÿåˆ¶ä»ä¸æ¸…æ¥šã€‚å› æ­¤ï¼Œç ”ç©¶çš„é‡é»åœ¨æ–¼æ­ç¤ºé€™ä¸€è½‰åŒ–éç¨‹çš„ç´°ç¯€ï¼Œä¸¦å°‹æ‰¾æé«˜è½‰åŒ–æ•ˆç‡çš„æ–¹æ³•ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·ä¹³é…¸èŒå°è˜¿è””ç¡«ç´ çš„è½‰åŒ–èƒ½åŠ›ã€‚ç ”ç©¶å°è±¡æ˜¯ç¶“éé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªï¼Œä¸¦é€éè½‰éŒ„çµ„åˆ†æä¾†è©•ä¼°å…¶ä»£è¬è®ŠåŒ–ã€‚ç ”ç©¶è€…è§€å¯Ÿåˆ°åœ¨æé«˜è‘¡è„ç³–æ›¿ä»£æ¯”ç‡çš„æƒ…æ³ä¸‹ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ï¼Œé€™äº›è®ŠåŒ–å¯èƒ½æœ‰åŠ©æ–¼æé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªåœ¨ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬æ–¹é¢çš„è¡¨ç¾æœ‰é¡¯è‘—è®ŠåŒ–ï¼Œé€™å¯èƒ½ä¿ƒé€²äº†è˜¿è””ç¡«ç´ çš„è½‰åŒ–éç¨‹ã€‚å…·é«”ä¾†èªªï¼Œè‘¡è„ç³–è‹·é€²å…¥ä¹³é…¸èŒç´°èƒå¾Œï¼Œç¶“éä¸€ç³»åˆ—çš„é…¶ä¿ƒåæ‡‰å’Œéé…¶ä¿ƒé‡çµ„ï¼Œæœ€çµ‚ç”¢ç”Ÿè˜¿è””ç¡«ç´ ã€‚é€™äº›çµæœæœ‰åŠ©æ–¼æˆ‘å€‘ç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦å¯èƒ½ç‚ºæœªä¾†çš„æ‡‰ç”¨æä¾›æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œå› ç‚ºè˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰æ½›åœ¨å¥åº·ç›Šè™•çš„ç”Ÿç‰©æ´»æ€§åŒ–åˆç‰©ã€‚å®ƒèƒ½å¤ å¾é’èŠ±æ¤°èœä¸­çš„è‘¡è„ç³–è‹·è½‰åŒ–è€Œä¾†ï¼Œé€™æ„å‘³è‘—é€éæ”¹å–„å…¶è½‰åŒ–ç‡ï¼Œå¯èƒ½èƒ½å¤ å¢åŠ æˆ‘å€‘æ”å–é€™ç¨®æœ‰ç›Šæˆåˆ†çš„æ©Ÿæœƒã€‚éš¨è‘—å°è˜¿è””ç¡«ç´ çš„ç ”ç©¶æ·±å…¥ï¼Œäº†è§£å…¶è½‰åŒ–éç¨‹å’Œæ©Ÿåˆ¶ï¼Œæˆ–è¨±èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²æä¾›æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç™Œå’ŒæŠ—ç‚ç­‰æ–¹é¢çš„æ½›åœ¨æ‡‰ç”¨ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜ä¹³é…¸èŒï¼ˆLactiplantibacillus plantarumï¼‰å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œé›–ç„¶è˜¿è””ç¡«ç´ å…·æœ‰æ½›åœ¨çš„å¥åº·ç›Šè™•ï¼Œä½†å…¶è½‰åŒ–ç‡å»ç›¸å°è¼ƒä½ï¼Œä¸”ç›®å‰å°æ–¼ä¹³é…¸èŒå¦‚ä½•é€²è¡Œé€™ä¸€è½‰åŒ–çš„æ©Ÿåˆ¶ä»ä¸æ¸…æ¥šã€‚å› æ­¤ï¼Œç ”ç©¶çš„é‡é»åœ¨æ–¼æ­ç¤ºé€™ä¸€è½‰åŒ–éç¨‹çš„ç´°ç¯€ï¼Œä¸¦å°‹æ‰¾æé«˜è½‰åŒ–æ•ˆç‡çš„æ–¹æ³•ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·ä¹³é…¸èŒå°è˜¿è””ç¡«ç´ çš„è½‰åŒ–èƒ½åŠ›ã€‚ç ”ç©¶å°è±¡æ˜¯ç¶“éé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªï¼Œä¸¦é€éè½‰éŒ„çµ„åˆ†æä¾†è©•ä¼°å…¶ä»£è¬è®ŠåŒ–ã€‚ç ”ç©¶è€…è§€å¯Ÿåˆ°åœ¨æé«˜è‘¡è„ç³–æ›¿ä»£æ¯”ç‡çš„æƒ…æ³ä¸‹ï¼Œä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ï¼Œé€™äº›è®ŠåŒ–å¯èƒ½æœ‰åŠ©æ–¼æé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éé©æ‡‰æ€§é€²åŒ–çš„ä¹³é…¸èŒæ ªåœ¨ç¢³æ°´åŒ–åˆç‰©å’Œæ°¨åŸºé…¸ä»£è¬æ–¹é¢çš„è¡¨ç¾æœ‰é¡¯è‘—è®ŠåŒ–ï¼Œé€™å¯èƒ½ä¿ƒé€²äº†è˜¿è””ç¡«ç´ çš„è½‰åŒ–éç¨‹ã€‚å…·é«”ä¾†èªªï¼Œè‘¡è„ç³–è‹·é€²å…¥ä¹³é…¸èŒç´°èƒå¾Œï¼Œç¶“éä¸€ç³»åˆ—çš„é…¶ä¿ƒåæ‡‰å’Œéé…¶ä¿ƒé‡çµ„ï¼Œæœ€çµ‚ç”¢ç”Ÿè˜¿è””ç¡«ç´ ã€‚é€™äº›çµæœæœ‰åŠ©æ–¼æˆ‘å€‘ç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„ç›¸äº’ä½œç”¨æ©Ÿåˆ¶ï¼Œä¸¦å¯èƒ½ç‚ºæœªä¾†çš„æ‡‰ç”¨æä¾›æ–°çš„æ€è·¯ã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„è…¸é“è£¡æœ‰ä¸€ç¨®å°å¹«æ‰‹ï¼Œå«ä¹³é…¸èŒï¼Œå®ƒå€‘ä¸åƒ…èƒ½å¹«åŠ©æ¶ˆåŒ–ï¼Œé‚„å¯èƒ½è®“æˆ‘å€‘çš„å¥åº·æ›´ä¸Šä¸€å±¤æ¨“ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶èšç„¦æ–¼ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„ç‰©è³ªï¼Œå®ƒä¾†è‡ªé’èŠ±æ¤°èœï¼Œè½èªªå°æŠ—ç™Œå’ŒæŠ—ç‚æœ‰æ½›åœ¨çš„å¥½è™•ã€‚ä¸éï¼Œé€™ç¨®ç‰©è³ªçš„è½‰åŒ–ç‡ä¸é«˜ï¼Œæ‰€ä»¥ç ”ç©¶è€…å€‘æƒ³çŸ¥é“å¦‚ä½•æå‡ä¹³é…¸èŒå°å®ƒçš„è½‰åŒ–èƒ½åŠ›ã€‚  \n  \né€™é …ç ”ç©¶ä½¿ç”¨äº†ä¸€ç¨®å«é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–çš„æŠ€è¡“ï¼Œä¾†å¢å¼·ä¹³é…¸èŒçš„èƒ½åŠ›ã€‚ä»–å€‘ç™¼ç¾ï¼Œç•¶ä¹³é…¸èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬ä¸‹é™ï¼Œæ°¨åŸºé…¸ä»£è¬ä¸Šå‡æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„ç”¢é‡ä¹Ÿéš¨ä¹‹å¢åŠ ã€‚é€™æ„å‘³è‘—ï¼Œé€éèª¿æ•´ä¹³é…¸èŒçš„ä»£è¬æ–¹å¼ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ï¼Œé€²ä¸€æ­¥ä¿ƒé€²å¥åº·ã€‚  \n  \né€™è£¡æœ‰å¹¾å€‹é‡é»å¯ä»¥è®“ä½ å¸¶èµ°ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½å°å¥åº·æœ‰ç›Šï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç™Œå’ŒæŠ—ç‚æ–¹é¢ã€‚  \n2. ä¹³é…¸èŒçš„è½‰åŒ–èƒ½åŠ›å¯ä»¥é€éå¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·ã€‚  \n3. ç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶ç‰©è³ªçš„é—œä¿‚ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„å¥åº·æ‡‰ç”¨é–‹å•Ÿæ–°æ–¹å‘ï¼",
    "image_prompt": "Create an infographic that explains the experimental process and main results of a study on lactic acid bacteria and its conversion of sulforaphane. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans or cells, arrows or flow lines to indicate the steps of the experiment, and a section clearly labeled 'Main Results' showing the changes in metabolism and potential health benefits.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41340527/"
  },
  {
    "id": "41341174",
    "title_en": "Sulforaphane attenuates oxidative stress, senescence, and ferroptosis induced by cigarette smoke extract <i>in vitro</i> and <i>in vivo via</i> upregulating the expression of SIRT1.",
    "pub_date": "2025 Dec",
    "abstract_en": "Cigarette smoking induces lung toxicity by triggering oxidative stress, leading to apoptosis, ferroptosis, and senescence. Sulforaphane (SFN), a potent antioxidant, activates the SIRT1 pathway, enhancing cellular stress resistance and survival. This study aimed to evaluate the protective effects of SFN against cigarette smoke extract (CSE)-induced damage in human airway epithelial cells (BEAS-2B) and in mouse lungs, focusing on its role in upregulating SIRT1 expression. BEAS-2B cells were treated with CSE and SFN, and cell viability was assessed using the MTT assay. Cellular senescence was assessed using the SA-Î²-gal assay and the expression of genes associated with senescence (p16 and p21). The expression levels of SIRT1, senescence-associated secretory phenotype (SASP) cytokines (IL-1Î², IL-6, IL-8, TNF-Î±), GPX4, and SLC7A11 were quantified using qRT-PCR. Additionally, ROS production, GSH and MDA levels, and iron content were measured. An emphysema mouse model was induced by intraperitoneal administration of CSE (7.2 mg/kg) alone or in combination with SFN (10.2 mg/kg) over 28 days, and subsequent histopathological changes were evaluated. Our findings revealed that SFN co-treatment effectively mitigated CSE-induced cytotoxicity, senescence, and SASP cytokine secretion, as well as the pronounced emphysematous changes in lung tissues. Furthermore, SFN reversed CSE-induced downregulation of SIRT1 and upregulation of NF-ÎºB. Notably, SFN also inhibited CSE-induced ferroptosis by increasing GPX4 and SLC7A11 expression while reducing iron and MDA levels. The findings of the present study demonstrated that sulforaphane offers protective effects against CSE-induced toxicity by mitigating oxidative stress, ferroptosis, and cellular senescence.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¸ç…™å°è‚ºéƒ¨é€ æˆçš„å‚·å®³æ–¹é¢ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œè€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æœ‰å®³å½±éŸ¿ã€‚é€éæå‡ç´°èƒçš„æŠ—å£“èƒ½åŠ›ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æ½›åœ¨çš„ä¿è­·åŠ‘ï¼Œå¹«åŠ©æ¸›å°‘å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·ï¼Œé€™å°æ–¼å¸ç…™è€…å’ŒäºŒæ‰‹ç…™æš´éœ²è€…ä¾†èªªï¼Œéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„å¥åº·è­°é¡Œã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¸ç…™å¦‚ä½•å°è‡´è‚ºéƒ¨ç´°èƒçš„æ°§åŒ–å£“åŠ›å’Œç´°èƒè€åŒ–ï¼Œä¸¦å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ åœ¨é€™å€‹éç¨‹ä¸­æ‰€æ‰®æ¼”çš„è§’è‰²ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶èšç„¦æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸€ç¨®åç‚ºSIRT1çš„è›‹ç™½è³ªçš„è¡¨é”ï¼Œé€™ç¨®è›‹ç™½è³ªèˆ‡ç´°èƒçš„æŠ—å£“èƒ½åŠ›æœ‰é—œã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†äº†å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„è©•ä¼°äº†ç´°èƒè€åŒ–çš„æƒ…æ³ï¼Œä¸¦é‡æ¸¬äº†èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ ï¼Œç ”ç©¶è€…å‰‡ä½¿ç”¨äº†å¸ç…™æå–ç‰©ä¾†èª˜å°è‚ºæ°£è…«æ¨¡å‹ï¼Œä¸¦è§€å¯Ÿäº†è‚ºçµ„ç¹”çš„ç—…ç†è®ŠåŒ–ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†æœ‰æ•ˆæ¸›å°‘äº†å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–å’Œç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„äº†å°é¼ è‚ºéƒ¨çš„ç—…ç†è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™æå–ç‰©å¼•èµ·çš„SIRT1ä¸‹èª¿å’ŒNF-ÎºBä¸Šèª¿ï¼Œä¸¦ä¸”é€šéå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†æŠ‘åˆ¶éµæ­»äº¡ï¼Œé™ä½äº†éµå’ŒMDAçš„æ°´å¹³ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–å…·æœ‰ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¸ç…™å°è‚ºéƒ¨é€ æˆçš„å‚·å®³æ–¹é¢ã€‚å¸ç…™æœƒå¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œå°è‡´ç´°èƒæ­»äº¡å’Œè€åŒ–ï¼Œè€Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æœ‰å®³å½±éŸ¿ã€‚é€éæå‡ç´°èƒçš„æŠ—å£“èƒ½åŠ›ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æ½›åœ¨çš„ä¿è­·åŠ‘ï¼Œå¹«åŠ©æ¸›å°‘å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·ï¼Œé€™å°æ–¼å¸ç…™è€…å’ŒäºŒæ‰‹ç…™æš´éœ²è€…ä¾†èªªï¼Œéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„å¥åº·è­°é¡Œã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°å¸ç…™å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¸ç…™å¦‚ä½•å°è‡´è‚ºéƒ¨ç´°èƒçš„æ°§åŒ–å£“åŠ›å’Œç´°èƒè€åŒ–ï¼Œä¸¦å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ åœ¨é€™å€‹éç¨‹ä¸­æ‰€æ‰®æ¼”çš„è§’è‰²ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶èšç„¦æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ä¸€ç¨®åç‚ºSIRT1çš„è›‹ç™½è³ªçš„è¡¨é”ï¼Œé€™ç¨®è›‹ç™½è³ªèˆ‡ç´°èƒçš„æŠ—å£“èƒ½åŠ›æœ‰é—œã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡æ°£é“ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰å’Œå°é¼ ä½œç‚ºç ”ç©¶å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†äº†å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„è©•ä¼°äº†ç´°èƒè€åŒ–çš„æƒ…æ³ï¼Œä¸¦é‡æ¸¬äº†èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ ï¼Œç ”ç©¶è€…å‰‡ä½¿ç”¨äº†å¸ç…™æå–ç‰©ä¾†èª˜å°è‚ºæ°£è…«æ¨¡å‹ï¼Œä¸¦è§€å¯Ÿäº†è‚ºçµ„ç¹”çš„ç—…ç†è®ŠåŒ–ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†æœ‰æ•ˆæ¸›å°‘äº†å¸ç…™æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–å’Œç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„äº†å°é¼ è‚ºéƒ¨çš„ç—…ç†è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é€†è½‰å¸ç…™æå–ç‰©å¼•èµ·çš„SIRT1ä¸‹èª¿å’ŒNF-ÎºBä¸Šèª¿ï¼Œä¸¦ä¸”é€šéå¢åŠ GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†æŠ‘åˆ¶éµæ­»äº¡ï¼Œé™ä½äº†éµå’ŒMDAçš„æ°´å¹³ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—å¸ç…™å¼•èµ·çš„æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–å…·æœ‰ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "ğŸ€ å¸ç…™å°è‚ºéƒ¨çš„å‚·å®³å¯ä¸æ˜¯å°äº‹ï¼Œæœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½èƒ½å¹«æˆ‘å€‘å°æŠ—é€™äº›å‚·å®³ï¼é€™é …ç ”ç©¶å°ˆæ³¨æ–¼å¸ç…™å¦‚ä½•å¼•ç™¼æ°§åŒ–å£“åŠ›ï¼Œä¸¦å°è‡´è‚ºéƒ¨ç´°èƒè€åŒ–ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ åœ¨é€™å€‹éç¨‹ä¸­èƒ½æ‰®æ¼”ä»€éº¼è§’è‰²ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿ä¸€ç¨®å«åšSIRT1çš„è›‹ç™½è³ªï¼Œé€™å€‹è›‹ç™½è³ªèƒ½å¹«åŠ©ç´°èƒæŠµæŠ—å£“åŠ›ã€‚  \n\nåœ¨å¯¦é©—ä¸­ï¼Œç§‘å­¸å®¶å€‘ç”¨äººé¡æ°£é“ä¸Šçš®ç´°èƒå’Œå°é¼ ä¾†é€²è¡Œæ¸¬è©¦ã€‚ä»–å€‘çµ¦ç´°èƒå’Œå°é¼ æ–½åŠ äº†å¸ç…™æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿç´°èƒçš„å­˜æ´»ç‡å’Œè€åŒ–æƒ…æ³ã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæ¸›å°‘å¸ç…™å¼•èµ·çš„ç´°èƒæ¯’æ€§å’Œè€åŒ–ï¼Œé‚„èƒ½æ”¹å–„å°é¼ çš„è‚ºéƒ¨ç—…ç†è®ŠåŒ–ã€‚æ›´é‡è¦çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½èª¿æ•´ä¸€äº›é—œéµè›‹ç™½è³ªçš„è¡¨é”ï¼Œæœ‰åŠ©æ–¼é™ä½æ°§åŒ–å£“åŠ›ã€‚  \n\nğŸ” é‡é»å›é¡§ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å¸ç…™å°è‚ºéƒ¨çš„æå‚·ã€‚  \n2. å®ƒèƒ½æ”¹å–„ç´°èƒçš„æŠ—å£“èƒ½åŠ›ï¼Œæ¸›å°‘ç´°èƒè€åŒ–ã€‚  \n3. é€™å°æ–¼å¸ç…™è€…å’ŒäºŒæ‰‹ç…™æš´éœ²è€…ä¾†èªªï¼Œéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„å¥åº·è­°é¡Œï¼",
    "image_prompt": "Create an infographic illustrating the experimental process and main findings of a study on the protective effects of sulforaphane against smoking-induced lung damage. The image should include simplified representations of broccoli or sulforaphane, human airway epithelial cells, and mice as experimental subjects. Use arrows or flow lines to indicate the experimental steps. Include a section labeled 'Main Results' highlighting protective effects, such as reduced cell toxicity and aging. The style should be flat, with a light background and soft colors, suitable for educational purposes.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºæ°£è…« Emphysema",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41341174/"
  },
  {
    "id": "41039785",
    "title_en": "Integrative Network Pharmacology and Proteomics Decipher the Immunomodulatory Mechanism of Sulforaphane Against Intrinsic Skin Aging.",
    "pub_date": "2025 Dec",
    "abstract_en": "Skin aging is characterized by declines in structural functions, contributing to age-associated frailty. Sulforaphane (SFN), a natural anti-inflammatory substance, has been widely applied in multiple types of cancer therapies. However, its role in alleviating intrinsic skin aging remains to be elucidated. Integrative network pharmacology and proteomics were utilized to investigate the underlying mechanisms of SFN in intrinsic skin aging. Fifty-one anti-aging targets of SFN were identified, highlighting its promising regulatory impact on the aging process. Based on an 18-month-old natural aging mouse model, significant alleviation in skin structure, redox homeostasis, and immune cell composition was noted after 2 months of SFN supplementation. Additionally, proteomic analysis demonstrated that SFN reversed the proteomic profile of intrinsic skin aging, with 233 differentially expressed proteins (DEPs) identified in SFN-fed aging mice. Of note, the up-regulated DEPs were highly enriched in the apelin signaling pathway (pÂ =Â 0.010). Furthermore, immune cell infiltration and whole blood cell analysis revealed that SFN rescued T cells depletion in dermal tissue, which was strongly correlated with DEPs enriched in the SFN-activated apelin signaling pathway. SFN improves skin morphology and immune functions via activating the apelin signaling pathway, suggesting new prime targets in counteracting intrinsic skin aging.",
    "para1": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šçš„çµæ§‹åŠŸèƒ½æœƒé€æ¼¸ä¸‹é™ï¼Œé€™å¯èƒ½æœƒå°è‡´èˆ‡å¹´é½¡ç›¸é—œçš„è„†å¼±æ€§å•é¡Œã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°æ–¼å…§åœ¨çš®è†šè€åŒ–çš„å½±éŸ¿ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—æ½›åœ¨çš„å•Ÿç¤ºã€‚è‹¥èƒ½æœ‰æ•ˆæ”¹å–„çš®è†šè€åŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æå‡è€å¹´äººçš„ç”Ÿæ´»å“è³ªï¼Œä¸¦æ¸›å°‘èˆ‡å¹´é½¡ç›¸é—œçš„çš®è†šå•é¡Œï¼Œé€™å°æ–¼å¸Œæœ›å»¶ç·©è¡°è€éç¨‹çš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–ä¸­çš„ä½œç”¨ã€‚é›–ç„¶è˜¿è””ç¡«ç´ åœ¨å¤šç¨®ç™Œç—‡æ²»ç™‚ä¸­å·²ç¶“è¢«å»£æ³›æ‡‰ç”¨ï¼Œä½†å…¶å°æ–¼çš®è†šè€åŒ–çš„å…·é«”å½±éŸ¿ä»ç„¶ä¸æ˜ç¢ºã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›é€šéé€™é …ç ”ç©¶ä¾†æ­ç¤ºè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šè€åŒ–çš„æ©Ÿåˆ¶ï¼Œä¸¦æ‰¾å‡ºå…¶å¯èƒ½çš„æŠ—è€åŒ–ç›®æ¨™ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¸¦å°å…¶é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆçš„è®ŠåŒ–ï¼Œä¸¦é€²è¡Œäº†è›‹ç™½è³ªçµ„å­¸åˆ†æï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ å°æ–¼å…§åœ¨çš®è†šè€åŒ–çš„å½±éŸ¿ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæ—¨åœ¨å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è€åŒ–æ•ˆæœåŠå…¶æ½›åœ¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æœ‰é¡¯è‘—æ”¹å–„ã€‚ç ”ç©¶ä¸­è­˜åˆ¥å‡º233ç¨®å·®ç•°è¡¨é”çš„è›‹ç™½è³ªï¼Œä¸¦ç™¼ç¾é€™äº›è›‹ç™½è³ªåœ¨è˜¿è””ç¡«ç´ æ¿€æ´»çš„apelinä¿¡è™Ÿé€šè·¯ä¸­é«˜åº¦å¯Œé›†ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œé€™äº›çµæœæš—ç¤ºäº†è˜¿è””ç¡«ç´ åœ¨å°æŠ—å…§åœ¨çš®è†šè€åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚",
    "explanation_zh": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šçš„çµæ§‹åŠŸèƒ½æœƒé€æ¼¸ä¸‹é™ï¼Œé€™å¯èƒ½æœƒå°è‡´èˆ‡å¹´é½¡ç›¸é—œçš„è„†å¼±æ€§å•é¡Œã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°æ–¼å…§åœ¨çš®è†šè€åŒ–çš„å½±éŸ¿ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—æ½›åœ¨çš„å•Ÿç¤ºã€‚è‹¥èƒ½æœ‰æ•ˆæ”¹å–„çš®è†šè€åŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æå‡è€å¹´äººçš„ç”Ÿæ´»å“è³ªï¼Œä¸¦æ¸›å°‘èˆ‡å¹´é½¡ç›¸é—œçš„çš®è†šå•é¡Œï¼Œé€™å°æ–¼å¸Œæœ›å»¶ç·©è¡°è€éç¨‹çš„äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–ä¸­çš„ä½œç”¨ã€‚é›–ç„¶è˜¿è””ç¡«ç´ åœ¨å¤šç¨®ç™Œç—‡æ²»ç™‚ä¸­å·²ç¶“è¢«å»£æ³›æ‡‰ç”¨ï¼Œä½†å…¶å°æ–¼çš®è†šè€åŒ–çš„å…·é«”å½±éŸ¿ä»ç„¶ä¸æ˜ç¢ºã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›é€šéé€™é …ç ”ç©¶ä¾†æ­ç¤ºè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šè€åŒ–çš„æ©Ÿåˆ¶ï¼Œä¸¦æ‰¾å‡ºå…¶å¯èƒ½çš„æŠ—è€åŒ–ç›®æ¨™ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¸¦å°å…¶é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ã€‚ç ”ç©¶è€…è§€å¯Ÿäº†çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆçš„è®ŠåŒ–ï¼Œä¸¦é€²è¡Œäº†è›‹ç™½è³ªçµ„å­¸åˆ†æï¼Œä»¥äº†è§£è˜¿è””ç¡«ç´ å°æ–¼å…§åœ¨çš®è†šè€åŒ–çš„å½±éŸ¿ã€‚é€™æ¨£çš„å¯¦é©—è¨­è¨ˆæ—¨åœ¨å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è€åŒ–æ•ˆæœåŠå…¶æ½›åœ¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½æœ‰é¡¯è‘—æ”¹å–„ã€‚ç ”ç©¶ä¸­è­˜åˆ¥å‡º233ç¨®å·®ç•°è¡¨é”çš„è›‹ç™½è³ªï¼Œä¸¦ç™¼ç¾é€™äº›è›‹ç™½è³ªåœ¨è˜¿è””ç¡«ç´ æ¿€æ´»çš„apelinä¿¡è™Ÿé€šè·¯ä¸­é«˜åº¦å¯Œé›†ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œé€™äº›çµæœæš—ç¤ºäº†è˜¿è””ç¡«ç´ åœ¨å°æŠ—å…§åœ¨çš®è†šè€åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚",
    "fb_post": "ğŸŒ± æœ€è¿‘æœ‰ä¸€å€‹æœ‰è¶£çš„ç ”ç©¶ï¼Œå°ˆé–€æ¢è¨è˜¿è””ç¡«ç´ å°çš®è†šè€åŒ–çš„å½±éŸ¿ï¼éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šå¯èƒ½æœƒè®Šå¾—è„†å¼±ï¼Œé€™å°æˆ‘å€‘çš„ç”Ÿæ´»å“è³ªæœ‰å¾ˆå¤§å½±éŸ¿ã€‚é€™é …ç ”ç©¶å¸Œæœ›èƒ½æ‰¾åˆ°æ”¹å–„çš®è†šè€åŒ–çš„æ–¹æ³•ï¼Œè®“æˆ‘å€‘èƒ½å¤ æ›´å¥½åœ°é¢å°å¹´é½¡å¸¶ä¾†çš„æŒ‘æˆ°ã€‚\n\nç ”ç©¶è€…ä½¿ç”¨äº†18å€‹æœˆå¤§çš„å°é¼ ï¼Œå°ç‰ å€‘é€²è¡Œäº†è˜¿è””ç¡«ç´ çš„è£œå……ï¼Œä¸¦è§€å¯Ÿäº†çš®è†šçµæ§‹å’Œå…ç–«ç³»çµ±çš„è®ŠåŒ–ã€‚çµæœé¡¯ç¤ºï¼Œç¶“éå…©å€‹æœˆçš„è£œå……ï¼Œå°é¼ çš„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½éƒ½æœ‰æ˜é¡¯æ”¹å–„ï¼Œç”šè‡³ç™¼ç¾äº†233ç¨®èˆ‡çš®è†šå¥åº·ç›¸é—œçš„è›‹ç™½è³ªè®ŠåŒ–ï¼é€™äº›ç™¼ç¾æš—ç¤ºè‘—è˜¿è””ç¡«ç´ åœ¨å°æŠ—çš®è†šè€åŒ–æ–¹é¢çš„æ½›åŠ›ã€‚\n\nâœ¨ ä½ å¯ä»¥å¸¶èµ°çš„å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„çš®è†šè€åŒ–å•é¡Œã€‚\n2. ç ”ç©¶ç™¼ç¾äº†233ç¨®èˆ‡çš®è†šå¥åº·ç›¸é—œçš„è›‹ç™½è³ªã€‚\n3. æ”¹å–„çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½å¯èƒ½æå‡è€å¹´äººçš„ç”Ÿæ´»å“è³ªã€‚",
    "image_prompt": "Create a flat design infographic that visually explains the experiment and main results of a study on the effects of sulforaphane on skin aging. Use a light background with soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects such as mice or cells, arrows or flow lines indicating the steps of the experiment, and a section highlighting the main results, such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41039785/"
  },
  {
    "id": "41027171",
    "title_en": "Multi-omics analysis of gut-liver axis reveals the mechanism by which sulforaphane alleviates liver injury in Cyprinus carpio exposed to triphenyltin.",
    "pub_date": "2025 Dec",
    "abstract_en": "This study investigates the protective effects of sulforaphane (SFN) against triphenyltin (TPT)-induced hepatotoxicity, immune dysfunction and gut microbiota dysbiosis in Cyprinus carpio. Cyprinus carpio were divided into three groups and exposed for 8Â weeks, including control, 10Â Î¼g/L TPT and 10Â Î¼g/L TPTÂ +Â 10Â mg/kg SFN group. This result showed that TPT exposure induced significantly (PÂ <Â 0.05) hepatotoxicity, evidenced by increasing hepatic total bile acid (TBA) and total cholesterol levels, while upregulating Hsp70/90 and downregulating lysozyme gene expression. SFN supplementation reduced TBA accumulation, normalized Hsp90 and lysozyme expression, mitigating TPT-induced lipid dysregulation and immunosuppression. Transcriptomic analysis revealed that TPT exposure activated lipid metabolism pathways (PPAR signaling and cholesterol metabolism), but suppressed immune-related pathways. SFN supplementation restored metabolic homeostasis by enriching glucose and amino acid metabolism pathways and activating AMPK signaling, while also modulating the expression of key genes (PLIN1, ME1, CPT1B). The microbiota composition were changed in SFNÂ +Â TPT, including the increased of beneficial Fusobacteriota and Cetobacterium, and the decreased of pathogenic Proteobacteria and Aeromonas. The gut transcriptome dysregulation were restored in SFNÂ +Â TPT by enhancing immune pathways in Toll-like/NOD-like receptors. The significant correlations linked were found in gut microbes (Kaistia, Vagococcus) to hepatic/intestinal gene expression in SFNÂ +Â TPT. Overall, these findings elucidate novel mechanisms underlying TPT-induced immunotoxicity in liver and intestine and demonstrate the protective role of SFN, providing a theoretical foundation for its application in toxicity mitigation strategies.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±çš„ä¿è­·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™ï¼Œé€™å°æ–¼å°‹æ‰¾æ–°çš„ä¿è­·æ€§ç‡Ÿé¤Šç´ å…·æœ‰é‡è¦æ„ç¾©ã€‚é€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„é£²é£Ÿå»ºè­°å’Œè£œå……åŠ‘çš„é–‹ç™¼æä¾›ä¾æ“šï¼Œç‰¹åˆ¥æ˜¯é‡å°é‚£äº›å¯èƒ½æ¥è§¸åˆ°ç’°å¢ƒæ¯’ç´ çš„äººç¾¤ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«èª˜å°çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½éšœç¤™åŠè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·ä½œç”¨ã€‚ä¸‰è‹¯éŒ«æ˜¯ä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œå·²çŸ¥æœƒå°ç”Ÿç‰©é«”é€ æˆå‚·å®³ï¼Œå› æ­¤äº†è§£å¦‚ä½•é€éé£²é£Ÿæˆåˆ†ä¾†æ¸›è¼•å…¶å½±éŸ¿æ˜¯éå¸¸é‡è¦çš„ã€‚é€™é …ç ”ç©¶æ—¨åœ¨æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨é€™äº›å¥åº·å•é¡Œä¸­çš„æ½›åœ¨ä½œç”¨ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†é¯‰é­šä½œç‚ºç ”ç©¶å°è±¡ï¼Œå°‡å…¶åˆ†ç‚ºä¸‰çµ„ï¼Œåˆ†åˆ¥ç‚ºå°ç…§çµ„ã€10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠ10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ ä¸Š10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ã€‚é€™äº›é­šåœ¨å¯¦é©—ä¸­æš´éœ²æ–¼é€™äº›ç‰©è³ªé”8é€±ï¼Œä»¥è§€å¯Ÿä¸åŒè™•ç†å°å…¶è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±çš„å½±éŸ¿ã€‚ç ”ç©¶è€…åˆ†æäº†è‚è‡Ÿçš„ç”ŸåŒ–æŒ‡æ¨™å’ŒåŸºå› è¡¨é”ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿçš„æ¯’æ€§åæ‡‰ï¼Œè¡¨ç¾ç‚ºè†½é¹½å’Œè†½å›ºé†‡æ°´å¹³çš„ä¸Šå‡ï¼Œä»¥åŠå…ç–«ç›¸é—œåŸºå› çš„è¡¨é”è®ŠåŒ–ã€‚è€Œè˜¿è””ç¡«ç´ çš„è£œå……å‰‡æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æ¯’æ€§å½±éŸ¿ï¼Œæ¢å¾©æ­£å¸¸çš„ä»£è¬å¹³è¡¡ï¼Œä¸¦æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œå¢åŠ æœ‰ç›ŠèŒç¾¤çš„æ¯”ä¾‹ã€‚é€™äº›çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•ç’°å¢ƒæ¯’ç´ å½±éŸ¿æ–¹é¢çš„æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ©Ÿåˆ¶å’Œæ•ˆæœã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±çš„ä¿è­·æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™ï¼Œé€™å°æ–¼å°‹æ‰¾æ–°çš„ä¿è­·æ€§ç‡Ÿé¤Šç´ å…·æœ‰é‡è¦æ„ç¾©ã€‚é€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„é£²é£Ÿå»ºè­°å’Œè£œå……åŠ‘çš„é–‹ç™¼æä¾›ä¾æ“šï¼Œç‰¹åˆ¥æ˜¯é‡å°é‚£äº›å¯èƒ½æ¥è§¸åˆ°ç’°å¢ƒæ¯’ç´ çš„äººç¾¤ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ä¸‰è‹¯éŒ«èª˜å°çš„è‚è‡Ÿæ¯’æ€§ã€å…ç–«åŠŸèƒ½éšœç¤™åŠè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„ä¿è­·ä½œç”¨ã€‚ä¸‰è‹¯éŒ«æ˜¯ä¸€ç¨®ç’°å¢ƒæ±¡æŸ“ç‰©ï¼Œå·²çŸ¥æœƒå°ç”Ÿç‰©é«”é€ æˆå‚·å®³ï¼Œå› æ­¤äº†è§£å¦‚ä½•é€éé£²é£Ÿæˆåˆ†ä¾†æ¸›è¼•å…¶å½±éŸ¿æ˜¯éå¸¸é‡è¦çš„ã€‚é€™é …ç ”ç©¶æ—¨åœ¨æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨é€™äº›å¥åº·å•é¡Œä¸­çš„æ½›åœ¨ä½œç”¨ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†é¯‰é­šä½œç‚ºç ”ç©¶å°è±¡ï¼Œå°‡å…¶åˆ†ç‚ºä¸‰çµ„ï¼Œåˆ†åˆ¥ç‚ºå°ç…§çµ„ã€10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠ10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ ä¸Š10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ã€‚é€™äº›é­šåœ¨å¯¦é©—ä¸­æš´éœ²æ–¼é€™äº›ç‰©è³ªé”8é€±ï¼Œä»¥è§€å¯Ÿä¸åŒè™•ç†å°å…¶è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±çš„å½±éŸ¿ã€‚ç ”ç©¶è€…åˆ†æäº†è‚è‡Ÿçš„ç”ŸåŒ–æŒ‡æ¨™å’ŒåŸºå› è¡¨é”ï¼Œä»¥è©•ä¼°è˜¿è””ç¡«ç´ çš„ä¿è­·æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚è‡Ÿçš„æ¯’æ€§åæ‡‰ï¼Œè¡¨ç¾ç‚ºè†½é¹½å’Œè†½å›ºé†‡æ°´å¹³çš„ä¸Šå‡ï¼Œä»¥åŠå…ç–«ç›¸é—œåŸºå› çš„è¡¨é”è®ŠåŒ–ã€‚è€Œè˜¿è””ç¡«ç´ çš„è£œå……å‰‡æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æ¯’æ€§å½±éŸ¿ï¼Œæ¢å¾©æ­£å¸¸çš„ä»£è¬å¹³è¡¡ï¼Œä¸¦æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œå¢åŠ æœ‰ç›ŠèŒç¾¤çš„æ¯”ä¾‹ã€‚é€™äº›çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨æ¸›è¼•ç’°å¢ƒæ¯’ç´ å½±éŸ¿æ–¹é¢çš„æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ©Ÿåˆ¶å’Œæ•ˆæœã€‚",
    "fb_post": "ğŸ€ æƒ³çŸ¥é“æ€éº¼åƒå¾—æ›´å¥åº·ï¼Œé‚„èƒ½æŠµæŠ—ç’°å¢ƒæ¯’ç´ å—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ï¼ˆå°±æ˜¯å¾è˜¿è””è£¡æå–çš„ç‡Ÿé¤Šæˆåˆ†ï¼‰å¯èƒ½å°è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±æœ‰ä¿è­·ä½œç”¨ï¼\n\né€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨è˜¿è””ç¡«ç´ å°ä¸€ç¨®å«ä¸‰è‹¯éŒ«çš„ç’°å¢ƒæ±¡æŸ“ç‰©é€ æˆçš„è‚è‡Ÿæ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™çš„å½±éŸ¿ã€‚ç ”ç©¶è€…ä½¿ç”¨é¯‰é­šé€²è¡Œå¯¦é©—ï¼Œå°‡å®ƒå€‘åˆ†æˆä¸‰çµ„ï¼Œåˆ†åˆ¥æš´éœ²åœ¨ä¸åŒæ¿ƒåº¦çš„ä¸‰è‹¯éŒ«å’Œè˜¿è””ç¡«ç´ ä¸‹ï¼ŒæŒçºŒè§€å¯Ÿäº†8é€±ã€‚\n\nçµæœé¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«æœƒå°è‡´è‚è‡ŸæŒ‡æ¨™ç•°å¸¸ï¼Œä½†åŠ å…¥è˜¿è””ç¡«ç´ å¾Œï¼Œé€™äº›æ¯’æ€§å½±éŸ¿æ˜é¡¯æ¸›å°‘ï¼Œä¸¦ä¸”æœ‰åŠ©æ–¼æ¢å¾©æ­£å¸¸çš„ä»£è¬å¹³è¡¡ï¼Œç”šè‡³æ”¹å–„è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼\n\nğŸ’¡ é€™è£¡æœ‰å¹¾å€‹é‡é»å¯ä»¥å¸¶èµ°ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•ç’°å¢ƒæ¯’ç´ å°è‚è‡Ÿçš„å‚·å®³ã€‚\n2. å¥åº·çš„è…¸é“å¾®ç”Ÿç‰©çµ„æˆå°æˆ‘å€‘çš„å…ç–«ç³»çµ±å¾ˆé‡è¦ã€‚\n3. é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„é£²é£Ÿå»ºè­°å’Œè£œå……åŠ‘é–‹ç™¼æä¾›äº†æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main findings of a study on the protective effects of daikon isothiocyanate against tributyltin-induced liver toxicity. Include simple icons representing daikon or broccoli, a simplified fish or animal as the experimental subject, arrows or flow lines showing the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes in liver health and gut microbiota composition.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚è‡Ÿæ¯’æ€§ Hepatotoxicity",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41027171/"
  },
  {
    "id": "40714240",
    "title_en": "Gut microbiota-related glutathione metabolism is key mechanism for sulforaphane ameliorating ulcerative colitis.",
    "pub_date": "2025 Dec",
    "abstract_en": "Gut barrier dysfunction is associated with dysbiosis of the gut microbiota and its metabolites, which is closely linked to the pathogenesis of ulcerative colitis (UC). Recent studies have demonstrated that Sulforaphane (SFN) exerts beneficial effects on UC. However, the role of the gut microbiota and microbial metabolism in the anti-UC mechanisms of SFN remains inadequately understood. In this study, we observed that SFN administration significantly improved the pathological phenotype, restored gut barrier integrity, and reduced colon inflammation in dextran sulfate sodium (DSS)-induced colitis mice. Gut microbiota analysis illustrated that SFN administration rebalances the alterations in gut microbiota composition, including genera such as Turicibacter, Lactobacillus and Bacteroides, in DSS-induced mice. Furthermore, untargeted metabolomics analysis indicated that the levels of microbial arachidonic acid metabolism, as well as the metabolism of alanine, aspartate, and glutamate, and glutathione metabolism in the gastrointestinal tract, were significantly altered in DSS-induced mice. Interestingly, SFN treatment significantly restore the alterations in glutathione metabolism and the levels of associated metabolites. Additionally, we observed that the MAPK/NF-ÎºB signaling pathway, regulated by glutathione metabolism, was inhibited in the colon of DSS-induced mice following SFN treatment. Collectively, these results suggest that SFN can alleviate DSS-induced colitis in mice by restoring dysregulated gut microbiota and glutathione metabolism, thereby modulating the MAPK/NF-ÎºB signaling pathway, enhancing intestinal barrier function and reducing colonic inflammation. Importantly, our findings elucidate a novel mechanism by which SFN improves gut barrier function, highlighting its potential to advance the development of SFN-derived therapeutics for the clinical management of colitis.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±è¡¡æœ‰é—œï¼Œé€™å¯èƒ½å°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°é€™äº›å•é¡Œæœ‰ä¸€å®šçš„æ”¹å–„æ•ˆæœï¼Œé€™è®“æˆ‘å€‘å°æœªä¾†çš„è…¸é“å¥åº·ç®¡ç†å’Œæ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æœ‰äº†æ–°çš„æ€è€ƒæ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘è…¸é“ç‚ç—‡ï¼Œé€²è€Œç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æä¾›æ–°çš„è¦‹è§£ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„çµè…¸ç‚å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ã€‚ç ”ç©¶è€…çµ¦äºˆé€™äº›å°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°ç—…ç†è¡¨ç¾çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è…¸é“å±éšœçš„å®Œæ•´æ€§å’Œçµè…¸ç‚ç—‡çš„ç¨‹åº¦ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æï¼Œä¸¦ä½¿ç”¨ä»£è¬çµ„å­¸æŠ€è¡“ä¾†è©•ä¼°å¾®ç”Ÿç‰©ä»£è¬çš„è®ŠåŒ–ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„DSSèª˜å°çš„å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘çµè…¸ç‚ç—‡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½èª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµ„æˆï¼Œä¸¦å½±éŸ¿èˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œè°·èƒ±ç”˜è‚½ä»£è¬ä¾†æ”¹å–„è…¸é“åŠŸèƒ½ï¼Œç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„è‡¨åºŠç®¡ç†æä¾›äº†æ–°çš„æ½›åœ¨æ²»ç™‚æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±è¡¡æœ‰é—œï¼Œé€™å¯èƒ½å°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°é€™äº›å•é¡Œæœ‰ä¸€å®šçš„æ”¹å–„æ•ˆæœï¼Œé€™è®“æˆ‘å€‘å°æœªä¾†çš„è…¸é“å¥åº·ç®¡ç†å’Œæ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æœ‰äº†æ–°çš„æ€è€ƒæ–¹å‘ã€‚\n\næœ¬ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå¾®ç”Ÿç‰©ä»£è¬ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘è…¸é“ç‚ç—‡ï¼Œé€²è€Œç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æä¾›æ–°çš„è¦‹è§£ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†ä»¥å³æ—‹ç³–é…ç¡«é…¸éˆ‰ï¼ˆDSSï¼‰èª˜å°çš„çµè…¸ç‚å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ã€‚ç ”ç©¶è€…çµ¦äºˆé€™äº›å°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°ç—…ç†è¡¨ç¾çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬è…¸é“å±éšœçš„å®Œæ•´æ€§å’Œçµè…¸ç‚ç—‡çš„ç¨‹åº¦ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æï¼Œä¸¦ä½¿ç”¨ä»£è¬çµ„å­¸æŠ€è¡“ä¾†è©•ä¼°å¾®ç”Ÿç‰©ä»£è¬çš„è®ŠåŒ–ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—æ”¹å–„DSSèª˜å°çš„å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘çµè…¸ç‚ç—‡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½èª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµ„æˆï¼Œä¸¦å½±éŸ¿èˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œè°·èƒ±ç”˜è‚½ä»£è¬ä¾†æ”¹å–„è…¸é“åŠŸèƒ½ï¼Œç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„è‡¨åºŠç®¡ç†æä¾›äº†æ–°çš„æ½›åœ¨æ²»ç™‚æ–¹å‘ã€‚",
    "fb_post": "ğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„ç¡«ç´ å¯èƒ½å°è…¸é“å¥åº·æœ‰æ„æƒ³ä¸åˆ°çš„å¥½è™•ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶èšç„¦æ–¼è˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚ï¼ˆUCï¼‰çš„å½±éŸ¿ï¼Œé€™æ˜¯ä¸€ç¨®å½±éŸ¿è…¸é“çš„ç–¾ç—…ã€‚ç ”ç©¶åœ˜éšŠæƒ³äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•æ”¹å–„è…¸é“çš„å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘è…¸é“ä¸­çš„ç‚ç—‡ã€‚ä»–å€‘ç”¨ä¸€ç¨®ç‰¹å®šçš„è—¥ç‰©èª˜å°å°é¼ ç”¢ç”Ÿçµè…¸ç‚ï¼Œç„¶å¾Œçµ¦äºˆå®ƒå€‘è˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿå®ƒå€‘çš„ç—…ç†è®ŠåŒ–ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ”¹å–„å°é¼ çš„è…¸é“å¥åº·ï¼Œé‚„èƒ½æ¢å¾©è…¸é“çš„å®Œæ•´æ€§ï¼Œæ¸›å°‘ç‚ç—‡ï¼Œç”šè‡³èª¿æ•´è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†æ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æœ‰äº†æ–°çš„æ€è€ƒæ–¹å‘ã€‚\n\nâœ¨å¸¶èµ°çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ã€‚\n2. å®ƒèƒ½æ¸›å°‘è…¸é“ç‚ç—‡ï¼Œå°æ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æä¾›æ–°æ€è·¯ã€‚\n3. èª¿æ•´è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„çµ„æˆä¹Ÿè¨±æ˜¯å®ƒçš„ä½œç”¨æ©Ÿåˆ¶ä¹‹ä¸€ã€‚",
    "image_prompt": "Create a flat design infographic that explains the experiment and main results of a study on the effects of sulforaphane from radishes on gut health. Include simple icons representing sulforaphane or radishes, simplified representations of experimental subjects like mice, and arrows or flow lines indicating the experimental steps. Add a section labeled 'Main Results' that highlights protective effects and changes observed in gut health.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40714240/"
  },
  {
    "id": "41291551",
    "title_en": "Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model.",
    "pub_date": "2025 Nov",
    "abstract_en": "The anticancer activity of sulforaphane (SFN) involves multiple signaling pathways, but its mechanism against Ehrlich Ascites Carcinoma (EAC) in mice remains unclear. This study evaluated the antitumor efficacy of SFN-loaded nanoliposomes (SFN-NLPs). Ninety female Swiss albino mice were allocated into six groups: (1) untreated control, (2) SFN alone (50Â mg/kg/day, orally), (3) SFN-NLPs alone (50Â mg/kg/day, orally), (4) EAC-bearing mice (2.5â€‰Ã—â€‰10â¶ cells, intraperitoneally), (5) EACâ€‰+â€‰SFN, and (6) EACâ€‰+â€‰SFN-NLPs. with treatment lasting 20 days in tumor-bearing groups. SFN-NLPs significantly reduced EAC tumor volume, viable cell count, and tumor marker levels, while prolonging survival more effectively than free SFN. SFN-NLPs modulated key molecular pathways by suppressing inflammatory gene expression (NF-ÎºB, COX-2) and shifting the balance toward apoptosis via upregulation of TP53 and Bax and concomitant downregulation of Bcl-2. Regarding liver integrity, SFN-NLPs significantly reduced DNA fragmentation and hepatic oxidative stress, while modulating systemic inflammation through reductions in total leukocyte count, TNF-Î±, and C-reactive protein. In addition, SFN-NLPs conferred superior protection against both histopathological and ultrastructural liver damage. Furthermore, molecular docking analysis suggested plausible interactions of SFN with proteins associated with antioxidant defense, inflammation regulation, and apoptosis, indicating a potential modulatory role. In conclusion, nanoformulated SFN enhances stability, augments efficacy, and facilitates sustained release and bioavailability, thereby strengthening its antitumor, anti-inflammatory, antioxidant, and pro-apoptotic effects in EAC-bearing mice. These findings highlight the potential of SFN-NLPs to suppress tumor growth by modulating inflammatory and apoptotic gene expression while preserving liver integrity.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™Œæ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½é€éèª¿ç¯€å¤šç¨®åˆ†å­é€”å¾‘ä¾†å°æŠ—ç™Œç—‡ï¼Œé€™å°æ–¼æœªä¾†é–‹ç™¼æ–°çš„ç™Œç—‡æ²»ç™‚æ–¹æ³•å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™é …ç ”ç©¶å¼·èª¿äº†ä½¿ç”¨ç´ç±³æŠ€è¡“ä¾†å¢å¼·è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œé€™å¯èƒ½æœƒæ”¹å–„ç™Œç—‡æ‚£è€…çš„æ²»ç™‚çµæœï¼Œä¸¦æ¸›å°‘å‰¯ä½œç”¨ï¼Œè®“æ›´å¤šäººå—ç›Šæ–¼é€™ç¨®å¤©ç„¶åŒ–åˆç‰©çš„æŠ—ç™Œç‰¹æ€§ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ ä¸­å°Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œç™¼å±•ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„æŠ—ç™Œç‰¹æ€§ï¼Œä¸¦å°‹æ‰¾æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ä¾†å°æŠ—é€™ç¨®ç™Œç—‡ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†ç‚ºå…­çµ„é€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›è™•ç†åŒ…æ‹¬ä¸æ²»ç™‚çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„ã€ä»¥åŠå¸¶æœ‰EACçš„é¼ é¡ã€‚å¯¦é©—æŒçºŒäº†20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡ä»¥åŠè‚è‡Ÿå¥åº·ç­‰å¤šå€‹æŒ‡æ¨™ï¼Œä»¥è©•ä¼°ä¸åŒè™•ç†å°è…«ç˜¤çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³é…æ–¹é‚„æ”¹å–„äº†å°é¼ çš„ç”Ÿå­˜ç‡ï¼Œä¸¦æ¸›å°‘äº†è‚è‡Ÿçš„æ°§åŒ–å£“åŠ›å’Œç‚ç—‡åæ‡‰ã€‚ç ”ç©¶çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½é€éèª¿ç¯€ç‚ç—‡å’Œå‡‹äº¡åŸºå› çš„è¡¨é”ä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼ŒåŒæ™‚ä¿è­·è‚è‡Ÿçš„å¥åº·ï¼Œé€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™Œæ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å¯èƒ½é€éèª¿ç¯€å¤šç¨®åˆ†å­é€”å¾‘ä¾†å°æŠ—ç™Œç—‡ï¼Œé€™å°æ–¼æœªä¾†é–‹ç™¼æ–°çš„ç™Œç—‡æ²»ç™‚æ–¹æ³•å…·æœ‰æ½›åœ¨çš„æ„ç¾©ã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™é …ç ”ç©¶å¼·èª¿äº†ä½¿ç”¨ç´ç±³æŠ€è¡“ä¾†å¢å¼·è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œé€™å¯èƒ½æœƒæ”¹å–„ç™Œç—‡æ‚£è€…çš„æ²»ç™‚çµæœï¼Œä¸¦æ¸›å°‘å‰¯ä½œç”¨ï¼Œè®“æ›´å¤šäººå—ç›Šæ–¼é€™ç¨®å¤©ç„¶åŒ–åˆç‰©çš„æŠ—ç™Œç‰¹æ€§ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ ä¸­å°Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·å’Œç™¼å±•ã€‚é€éé€™é …ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„æŠ—ç™Œç‰¹æ€§ï¼Œä¸¦å°‹æ‰¾æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ä¾†å°æŠ—é€™ç¨®ç™Œç—‡ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†ç‚ºå…­çµ„é€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›è™•ç†åŒ…æ‹¬ä¸æ²»ç™‚çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„ã€ä»¥åŠå¸¶æœ‰EACçš„é¼ é¡ã€‚å¯¦é©—æŒçºŒäº†20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤é«”ç©ã€å­˜æ´»ç‡ä»¥åŠè‚è‡Ÿå¥åº·ç­‰å¤šå€‹æŒ‡æ¨™ï¼Œä»¥è©•ä¼°ä¸åŒè™•ç†å°è…«ç˜¤çš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚æ­¤å¤–ï¼Œé€™ç¨®ç´ç±³é…æ–¹é‚„æ”¹å–„äº†å°é¼ çš„ç”Ÿå­˜ç‡ï¼Œä¸¦æ¸›å°‘äº†è‚è‡Ÿçš„æ°§åŒ–å£“åŠ›å’Œç‚ç—‡åæ‡‰ã€‚ç ”ç©¶çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”å¯èƒ½é€éèª¿ç¯€ç‚ç—‡å’Œå‡‹äº¡åŸºå› çš„è¡¨é”ä¾†æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼ŒåŒæ™‚ä¿è­·è‚è‡Ÿçš„å¥åº·ï¼Œé€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "ğŸŒ±ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¯èƒ½åœ¨æŠ—ç™Œæ–¹é¢æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼æœ€è¿‘ä¸€é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°å°é¼ Ehrlichè…¹æ°´ç™Œçš„å½±éŸ¿ï¼Œç ”ç©¶è€…å€‘æƒ³çŸ¥é“å®ƒæ˜¯å¦‚ä½•å½±éŸ¿è…«ç˜¤ç”Ÿé•·çš„ã€‚  \n\nä»–å€‘ä½¿ç”¨äº†90éš»å°é¼ ï¼Œåˆ†æˆä¸åŒçµ„åˆ¥é€²è¡Œå¯¦é©—ï¼Œè§€å¯Ÿä¸æ²»ç™‚ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ã€ä»¥åŠä½¿ç”¨è˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„æ•ˆæœï¼Œå¯¦é©—æŒçºŒäº†20å¤©ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”åœ¨æ¸›å°‘è…«ç˜¤é«”ç©å’Œæ´»ç´°èƒæ•¸é‡æ–¹é¢ï¼Œæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆï¼Œé‚„æé«˜äº†å°é¼ çš„ç”Ÿå­˜ç‡ï¼  \n\né€™æ„å‘³è‘—ï¼Œå°‡è˜¿è””ç¡«ç´ èˆ‡ç´ç±³æŠ€è¡“çµåˆï¼Œå¯èƒ½æœƒç‚ºç™Œç—‡æ²»ç™‚é–‹å•Ÿæ–°çš„å¤§é–€ï¼Œä¸¦æ¸›å°‘å‰¯ä½œç”¨ã€‚  \n\nâœ¨ ä½ å¯ä»¥å¾é€™ç¯‡ç ”ç©¶ä¸­å¸¶èµ°é€™äº›é‡é»ï¼š  \n1ï¸âƒ£ è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æŠ—ç™Œï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ã€‚  \n2ï¸âƒ£ ç´ç±³æŠ€è¡“èƒ½å¢å¼·è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œæ”¹å–„æ²»ç™‚çµæœã€‚  \n3ï¸âƒ£ é€™äº›ç™¼ç¾ç‚ºæœªä¾†ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a simple and informative infographic that explains the experiment and main results of a study on sulforaphane's effects on Ehrlich ascites carcinoma in mice. Use a flat design style with a white or light-colored background and soft color palette. Include symbols for broccoli or sulforaphane, simplified illustrations of experimental subjects (like mice or cells), arrows or flow lines to represent the experimental steps, and a section clearly labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è…¹æ°´ç™Œ Ehrlich Ascites Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41291551/"
  },
  {
    "id": "41135276",
    "title_en": "Sulforaphane targets STAT3-CKMT2-AS1 to suppress gastric cancer via PSMB8 downregulation and AIMP1 stabilization.",
    "pub_date": "2025 Nov",
    "abstract_en": "Gastric cancer (GC) remains one of the most formidable threats to human health with limited therapeutic options. Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear. To investigate the mechanism of action of SFN in gastric cancer. The antitumor effects of SFN were comprehensively assessed in vitro and in vivo, followed by sequencing analysis to identify the targeted lncRNA. Subsequently, the mechanical verification experiments were carried out to determine the upstream and downstream regulatory components involved in the STAT3-CKMT2-AS1 regulatory axis. We demonstrated that SFN strongly inhibits GC. SFN downregulated the expression of the lncRNA CKMT2-AS1. Elevated expression levels of CKMT2-AS1 in human GC tissues are correlated with poor patient survival rates. Knockdown of CKMT2-AS1 significantly inhibited GC proliferation and migration both in vivo and in vitro, whereas CKMT2-AS1 overexpression enhanced malignant phenotypes. Mechanistically, we identified STAT3 as the transcriptional activator driving CKMT2-AS1 expression, with SFN directly binding to, and inhibiting, STAT3 phosphorylation to decrease its transcriptional activity. Interestingly, cytoplasmic CKMT2-AS1 competitively adsorbs miR-451a, leading to the expression of PSMB8, ultimately promoting the progression of the malignant phenotype of GC. Moreover, we discovered that CKMT2-AS1 directly binds to the RNA-binding protein (RBP) AIMP1, promoting ubiquitination-mediated degradation of AIMP1 protein via the proteasomal pathway. The highly expressed AIMP1 protein, in turn, inhibits the phosphorylation of the PI3K/AKT signaling pathway, which is hyperactivated in virtually all solid tumors. Our findings not only elucidate a novel SFN-mediated tumor-suppressive mechanism via the STAT3/CKMT2-AS1 regulatory axis, but also validate CKMT2-AS1 as a promising therapeutic target for GC intervention.",
    "para1": "èƒƒç™Œæ˜¯ä¸€ç¨®å°äººé¡å¥åº·æ§‹æˆé‡å¤§å¨è„…çš„ç–¾ç—…ï¼Œç›®å‰å¯ç”¨çš„æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œé¡¯ç¤ºå‡ºå®ƒå¯èƒ½å…·æœ‰æŠ—è…«ç˜¤çš„æ½›åŠ›ã€‚é€™æ„å‘³è‘—ï¼Œé€éé€²ä¸€æ­¥çš„ç ”ç©¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†é é˜²æˆ–æ²»ç™‚èƒƒç™Œï¼Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡å’Œç”Ÿæ´»å“è³ªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œä¸¦è©¦åœ–æ­ç¤ºå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ï¼Œä»¥ä¾¿ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›ç§‘å­¸ä¾æ“šã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é«”å¤–å’Œé«”å…§çš„æ¨¡å‹ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœï¼Œä¸¦é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æä»¥è­˜åˆ¥ç›®æ¨™é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œä»–å€‘é€²è¡Œäº†æ©Ÿæ¢°é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸ç›¸é—œçš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿ç¯€çµ„ä»¶ï¼Œå¾è€Œæ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥çµåˆä¸¦æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œå¾è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ã€‚",
    "explanation_zh": "èƒƒç™Œæ˜¯ä¸€ç¨®å°äººé¡å¥åº·æ§‹æˆé‡å¤§å¨è„…çš„ç–¾ç—…ï¼Œç›®å‰å¯ç”¨çš„æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œé¡¯ç¤ºå‡ºå®ƒå¯èƒ½å…·æœ‰æŠ—è…«ç˜¤çš„æ½›åŠ›ã€‚é€™æ„å‘³è‘—ï¼Œé€éé€²ä¸€æ­¥çš„ç ”ç©¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†é é˜²æˆ–æ²»ç™‚èƒƒç™Œï¼Œæ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡å’Œç”Ÿæ´»å“è³ªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œä¸¦è©¦åœ–æ­ç¤ºå…¶èƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ï¼Œä»¥ä¾¿ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›ç§‘å­¸ä¾æ“šã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é«”å¤–å’Œé«”å…§çš„æ¨¡å‹ä¾†è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœï¼Œä¸¦é€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æä»¥è­˜åˆ¥ç›®æ¨™é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œä»–å€‘é€²è¡Œäº†æ©Ÿæ¢°é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸ç›¸é—œçš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿ç¯€çµ„ä»¶ï¼Œå¾è€Œæ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦é™ä½CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§ç‰¹å¾µã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥çµåˆä¸¦æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œå¾è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ã€‚",
    "fb_post": "ğŸ€ å¤§å®¶çŸ¥é“å—ï¼Ÿæœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾è˜¿è””ç¡«ç´ å¯èƒ½å°èƒƒç™Œæœ‰æŠ—è…«ç˜¤çš„æ½›åŠ›ï¼é€™å€‹æ¶ˆæ¯å¯çœŸè®“äººæŒ¯å¥®ï¼Œå› ç‚ºèƒƒç™Œçš„æ²»ç™‚é¸æ“‡ä¸€ç›´éƒ½å¾ˆæœ‰é™ã€‚  \n  \né€™é …ç ”ç©¶ä¸»è¦æ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£çš„ã€‚ç ”ç©¶è€…å€‘ä½¿ç”¨äº†é«”å¤–å’Œé«”å…§çš„æ¨¡å‹ï¼Œä¸¦é€²è¡Œäº†ä¸€äº›åŸºå› åˆ†æï¼Œæƒ³è¦æ‰¾å‡ºèƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚  \n  \nä»–å€‘çš„å¯¦é©—é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦ä¸”é™ä½äº†ä¸€ç¨®å«CKMT2-AS1çš„åˆ†å­çš„è¡¨é”ã€‚é€™å€‹åˆ†å­åœ¨èƒƒç™Œæ‚£è€…ä¸­é€šå¸¸è¡¨é”è¼ƒé«˜ï¼Œèˆ‡è¼ƒä½çš„ç”Ÿå­˜ç‡æœ‰é—œã€‚ç•¶ç ”ç©¶è€…æŠ‘åˆ¶é€™å€‹åˆ†å­çš„æ™‚å€™ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»æ˜é¡¯æ¸›å°‘ï¼Œé€™ä»£è¡¨è‘—è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„èƒƒç™Œçš„æƒ…æ³ï¼  \n  \nğŸ” è®“æˆ‘å€‘ä¾†çœ‹çœ‹é€™é …ç ”ç©¶çš„å¹¾å€‹é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½å°èƒƒç™Œç´°èƒæœ‰æŠ—è…«ç˜¤ä½œç”¨ã€‚  \n2. CKMT2-AS1çš„é«˜è¡¨é”èˆ‡èƒƒç™Œæ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½æœ‰é—œã€‚  \n3. æŠ‘åˆ¶CKMT2-AS1èƒ½æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚  \n  \né€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›äº†æ–°çš„ç§‘å­¸ä¾æ“šï¼Œæˆ‘å€‘æœŸå¾…æ›´å¤šç ”ç©¶èƒ½è®“æˆ‘å€‘æ›´äº†è§£é€™å€‹ç¥å¥‡çš„æˆåˆ†ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of the study on the effects of sulforaphane on gastric cancer. Use a simple and clear design with a flat illustration style and a light background. Include symbols representing broccoli or sulforaphane, simplified icons of experimental subjects like humans, animals, or cells, and arrows or flow lines to indicate the experimental steps. Include a section that clearly states the main results, such as protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41135276/"
  },
  {
    "id": "41275316",
    "title_en": "Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.",
    "pub_date": "2025 Nov",
    "abstract_en": "Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has emerged as a promising dietary supplement for autism spectrum disorder (ASD). However, its therapeutic efficacy remains controversial, and the pharmacological mechanisms are not fully elucidated. Eligible randomized controlled trials were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Review Manager 5.4 was used for meta-analysis and bias risk assessment. Network pharmacology, Mendelian randomization, GEO data analyses, molecular docking, and molecular dynamics simulation were employed to explore the mechanisms of sulforaphane in ASD. Six trials involving 333 participants were included in the meta-analysis. Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. No significant difference was observed in the incidence of adverse events. Network pharmacology identified 10 core targets of sulforaphane in ASD, including AKT1, EGFR, HSP90AA1, SRC, CASP3, STAT1, MAPK1, MMP9, MAPK8, and JAK2. These targets were implicated in the PI3K-Akt signaling pathway, MAPK signaling pathway, Chemokine signaling pathway, Chemical carcinogenesis - reactive oxygen species, TNF signaling pathway, Th17 cell differentiation, mTOR signaling pathway, and IL-17 signaling pathway. Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk. GEO transcriptomic data provided independent validation for the network pharmacology predictions. The binding energies between sulforaphane and the top 10 core targets are all â‰¤ -4.0Â kcal/mol. Molecular dynamics simulations further validated the stable interaction between MMP-9 and sulforaphane. Sulforaphane may serve as an efficacious and safe adjunctive therapy for ASD, mediated by its anti-oxidant and anti-inflammatory effects along with the modulation of autophagy. CRD42025635045.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæœ€è¿‘è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é›–ç„¶æœ‰äº›ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½æœ‰ç›Šï¼Œä½†å…¶ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä¸”å…·é«”çš„è—¥ç†æ©Ÿåˆ¶å°šæœªå®Œå…¨æ˜ç­ã€‚å› æ­¤ï¼Œäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶å’Œæ•ˆæœï¼Œå°æ–¼å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²å…·æœ‰é‡è¦æ„ç¾©ï¼Œå°¤å…¶æ˜¯åœ¨è‡ªé–‰ç—‡çš„ç®¡ç†ä¸Šï¼Œå¯èƒ½ç‚ºæ‚£è€…æä¾›æ–°çš„è¼”åŠ©ç™‚æ³•é¸æ“‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ASDæ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä¸¦ä¸”å¸Œæœ›é€éç³»çµ±æ€§çš„æ–‡ç»å›é¡§å’Œæ•¸æ“šåˆ†æï¼Œä¾†è©•ä¼°å…¶ç™‚æ•ˆåŠæ½›åœ¨çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™ä¸åƒ…æ¶‰åŠè‡¨åºŠè©¦é©—çš„çµæœï¼Œé‚„åŒ…æ‹¬åˆ†å­å±¤é¢çš„æ©Ÿåˆ¶æ¢è¨ï¼Œæ—¨åœ¨æä¾›æ›´å…¨é¢çš„ç†è§£ã€‚",
    "para3": "ç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—é€²è¡Œçµ±åˆåˆ†æã€‚ç ”ç©¶ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€åŸºå› è¡¨é”æ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œä¾†æ¢ç´¢è˜¿è””ç¡«ç´ åœ¨ASDä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ›´æ·±å…¥åœ°äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ASDçš„ç›¸é—œç”Ÿç‰©é€”å¾‘ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼ŒASDæ‚£è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œèˆ‡å®‰æ…°åŠ‘çµ„ç›¸æ¯”æœ‰æ˜é¡¯æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„ä¸è‰¯äº‹ä»¶ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†ææŒ‡å‡ºè˜¿è””ç¡«ç´ åœ¨ASDä¸­çš„åå€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»èˆ‡å¤šæ¢ä¿¡è™Ÿé€šè·¯æœ‰é—œï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ï¼Œå°ASDæ‚£è€…ç”¢ç”Ÿè¼”åŠ©ç™‚æ•ˆï¼Œä¸¦ä¸”é€™äº›çµæœå¾—åˆ°äº†å…¶ä»–æ•¸æ“šçš„æ”¯æŒã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦å­˜åœ¨æ–¼åå­—èŠ±ç§‘è”¬èœä¸­ï¼Œæœ€è¿‘è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ã€‚é›–ç„¶æœ‰äº›ç ”ç©¶é¡¯ç¤ºå®ƒå¯èƒ½æœ‰ç›Šï¼Œä½†å…¶ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œä¸”å…·é«”çš„è—¥ç†æ©Ÿåˆ¶å°šæœªå®Œå…¨æ˜ç­ã€‚å› æ­¤ï¼Œäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶å’Œæ•ˆæœï¼Œå°æ–¼å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²å…·æœ‰é‡è¦æ„ç¾©ï¼Œå°¤å…¶æ˜¯åœ¨è‡ªé–‰ç—‡çš„ç®¡ç†ä¸Šï¼Œå¯èƒ½ç‚ºæ‚£è€…æä¾›æ–°çš„è¼”åŠ©ç™‚æ³•é¸æ“‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ASDæ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä¸¦ä¸”å¸Œæœ›é€éç³»çµ±æ€§çš„æ–‡ç»å›é¡§å’Œæ•¸æ“šåˆ†æï¼Œä¾†è©•ä¼°å…¶ç™‚æ•ˆåŠæ½›åœ¨çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™ä¸åƒ…æ¶‰åŠè‡¨åºŠè©¦é©—çš„çµæœï¼Œé‚„åŒ…æ‹¬åˆ†å­å±¤é¢çš„æ©Ÿåˆ¶æ¢è¨ï¼Œæ—¨åœ¨æä¾›æ›´å…¨é¢çš„ç†è§£ã€‚\n\nç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—é€²è¡Œçµ±åˆåˆ†æã€‚ç ”ç©¶ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€åŸºå› è¡¨é”æ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œä¾†æ¢ç´¢è˜¿è””ç¡«ç´ åœ¨ASDä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ›´æ·±å…¥åœ°äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ASDçš„ç›¸é—œç”Ÿç‰©é€”å¾‘ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼ŒASDæ‚£è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œèˆ‡å®‰æ…°åŠ‘çµ„ç›¸æ¯”æœ‰æ˜é¡¯æ”¹å–„ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„ä¸è‰¯äº‹ä»¶ç™¼ç”Ÿç‡ã€‚ç¶²çµ¡è—¥ç†å­¸åˆ†ææŒ‡å‡ºè˜¿è””ç¡«ç´ åœ¨ASDä¸­çš„åå€‹æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»èˆ‡å¤šæ¢ä¿¡è™Ÿé€šè·¯æœ‰é—œï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ï¼Œå°ASDæ‚£è€…ç”¢ç”Ÿè¼”åŠ©ç™‚æ•ˆï¼Œä¸¦ä¸”é€™äº›çµæœå¾—åˆ°äº†å…¶ä»–æ•¸æ“šçš„æ”¯æŒã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æˆåˆ†ï¼Œå¯èƒ½å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ç ”ç©¶æ¢è¨äº†å®ƒåœ¨æ”¹å–„ç¤¾äº¤åæ‡‰æ–¹é¢çš„æ½›åŠ›ã€‚ ç ”ç©¶è€…å€‘å¾å¤šå€‹è³‡æ–™åº«ä¸­æ‰¾åˆ°äº†å…­é …éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±æ¶‰åŠ333ååƒèˆ‡è€…ï¼Œé€²è¡Œäº†ç¶œåˆåˆ†æã€‚ä»–å€‘ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†æ¢ç´¢è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæƒ³è¦äº†è§£å®ƒå¦‚ä½•å½±éŸ¿ASDçš„ç›¸é—œç”Ÿç‰©é€”å¾‘ã€‚ çµæœé¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……ï¼ŒASDæ‚£è€…åœ¨ç¤¾äº¤åæ‡‰é‡è¡¨ä¸Šçš„å¾—åˆ†é¡¯è‘—é™ä½ï¼Œèˆ‡å®‰æ…°åŠ‘çµ„ç›¸æ¯”æœ‰æ˜é¡¯æ”¹å–„ï¼è€Œä¸”ï¼Œç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„ä¸è‰¯äº‹ä»¶ç™¼ç”Ÿç‡ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ç®¡ç†ä¸Šçš„æ½›åŠ›å……æ»¿æœŸå¾…ï¼\n\nğŸ” ä½ å¯ä»¥å¸¶èµ°çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰ã€‚\n2. ç ”ç©¶é¡¯ç¤ºï¼Œè£œå……è˜¿è””ç¡«ç´ å¾Œçš„æ”¹å–„æ˜¯é¡¯è‘—çš„ã€‚\n3. æ­¤ç ”ç©¶æœªç™¼ç¾æ˜é¡¯çš„ä¸è‰¯äº‹ä»¶ï¼Œé¡¯ç¤ºå‡ºå®ƒçš„å®‰å…¨æ€§ã€‚",
    "image_prompt": "Create an infographic that explains the experimental methodology and main results of the study on sulforaphane and autism spectrum disorder (ASD). Use a flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like humans or cells), arrows or flow lines to show experimental steps, and a section that highlights the main results (such as improvement in social response scores).",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé–‰ç—‡è­œç³»éšœç¤™ Autism Spectrum Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41275316/"
  },
  {
    "id": "41265122",
    "title_en": "Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying.",
    "pub_date": "2025 Nov",
    "abstract_en": "This study investigated methionine-sucrose stress treatments on glucoraphanin biosynthesis in broccoli sprouts and the impact of vacuum freeze-drying (VFD) on sprout powder quality. Results showed that sucrose treatment elevated glucoraphanin content by 316.30Â % in 4-day sprouts compared to the control (9.72Â mg/g), accompanied by increases of 42.65Â % in total isothiocyanates (ITCs) and 70.00Â % in anthocyanins. The treatment enhanced myrosinase activity and upregulated osmotic regulators. PCA confirmed that sucrose stress optimized the nutritional quality of broccoli sprouts and exhibited potential in sulforaphane enrichment. The VFD broccoli sprout powder exhibited high retention of sulforaphane (6.00Â mg/g dw) and total ITCs (7.00Â mg/g dw), with optimal water-holding capacity, oil-holding capacity, and swelling capacity. The sulforaphane extract exhibited significant antimicrobial activity against E. coli (16.00Â mm inhibition zone) and Staphylococcus aureus (10.02Â mm). The synergistic application of sucrose stress and VFD presents a promising approach for developing functional foods.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚é’èŠ±æ¤°èœä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥é¡¯è‘—æå‡é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šæˆåˆ†ï¼Œé€™å°æ–¼å¸Œæœ›æ”¹å–„é£²é£Ÿå’Œå¢å¼·å…ç–«åŠ›çš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹æœ‰è¶£çš„é¸æ“‡ã€‚é€™äº›ç™¼ç¾ä¹Ÿå¯èƒ½å°æ–¼é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æœ‰é‡è¦çš„åƒè€ƒåƒ¹å€¼ï¼Œè®“æˆ‘å€‘èƒ½å¤ æ›´å¥½åœ°åˆ©ç”¨é’èŠ±æ¤°èœçš„å¥åº·æ½›åŠ›ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„ç”Ÿç‰©åˆæˆå½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•é€éç‰¹å®šçš„è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚é€™å°æ–¼å¸Œæœ›æé«˜é’èŠ±æ¤°èœç‡Ÿé¤Šåƒ¹å€¼çš„è¾²æ¥­å’Œé£Ÿå“ç§‘å­¸é ˜åŸŸä¾†èªªï¼Œå…·æœ‰é‡è¦çš„æ„ç¾©ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†4å¤©å¤§çš„é’èŠ±æ¤°èœèŠ½ï¼Œä¸¦æ¸¬é‡äº†å…¶è˜¿è””ç¡«ç´ åŠå…¶ä»–ç‡Ÿé¤Šæˆåˆ†çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†çœŸç©ºå†·å‡ä¹¾ç‡¥å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªå½±éŸ¿ï¼ŒåŒ…æ‹¬æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ç­‰æŒ‡æ¨™ã€‚é€™äº›æ–¹æ³•çš„çµåˆä½¿å¾—ç ”ç©¶èƒ½å¤ å…¨é¢äº†è§£è™•ç†å°é’èŠ±æ¤°èœèŠ½ç‡Ÿé¤Šæˆåˆ†çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†ä½¿é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·å«é‡æé«˜äº†316.30%ï¼Œä¸¦ä¸”ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—å¢åŠ ã€‚æ­¤å¤–ï¼ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½çš„ä¿ç•™ä¸Šè¡¨ç¾è‰¯å¥½ï¼Œä¸¦å±•ç¾å‡ºå„ªè¶Šçš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æå–ç‰©å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒå…·æœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„çµåˆå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€å€‹æœ‰å‰æ™¯çš„æ–¹æ³•ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼æ–¹é¢ã€‚é’èŠ±æ¤°èœä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥é¡¯è‘—æå‡é’èŠ±æ¤°èœçš„ç‡Ÿé¤Šæˆåˆ†ï¼Œé€™å°æ–¼å¸Œæœ›æ”¹å–„é£²é£Ÿå’Œå¢å¼·å…ç–«åŠ›çš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹æœ‰è¶£çš„é¸æ“‡ã€‚é€™äº›ç™¼ç¾ä¹Ÿå¯èƒ½å°æ–¼é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æœ‰é‡è¦çš„åƒè€ƒåƒ¹å€¼ï¼Œè®“æˆ‘å€‘èƒ½å¤ æ›´å¥½åœ°åˆ©ç”¨é’èŠ±æ¤°èœçš„å¥åº·æ½›åŠ›ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·çš„ç”Ÿç‰©åˆæˆå½±éŸ¿ï¼Œä»¥åŠçœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶é—œå¿ƒçš„å•é¡Œæ˜¯å¦‚ä½•é€éç‰¹å®šçš„è™•ç†æ–¹æ³•ä¾†æå‡é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ çš„å«é‡ã€‚é€™å°æ–¼å¸Œæœ›æé«˜é’èŠ±æ¤°èœç‡Ÿé¤Šåƒ¹å€¼çš„è¾²æ¥­å’Œé£Ÿå“ç§‘å­¸é ˜åŸŸä¾†èªªï¼Œå…·æœ‰é‡è¦çš„æ„ç¾©ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†ï¼Œä¸¦è§€å¯Ÿå…¶å°è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†4å¤©å¤§çš„é’èŠ±æ¤°èœèŠ½ï¼Œä¸¦æ¸¬é‡äº†å…¶è˜¿è””ç¡«ç´ åŠå…¶ä»–ç‡Ÿé¤Šæˆåˆ†çš„è®ŠåŒ–ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†çœŸç©ºå†·å‡ä¹¾ç‡¥å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªå½±éŸ¿ï¼ŒåŒ…æ‹¬æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ç­‰æŒ‡æ¨™ã€‚é€™äº›æ–¹æ³•çš„çµåˆä½¿å¾—ç ”ç©¶èƒ½å¤ å…¨é¢äº†è§£è™•ç†å°é’èŠ±æ¤°èœèŠ½ç‡Ÿé¤Šæˆåˆ†çš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†ä½¿é’èŠ±æ¤°èœèŠ½ä¸­çš„è‘¡è„ç³–è‹·å«é‡æé«˜äº†316.30%ï¼Œä¸¦ä¸”ç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰é¡¯è‘—å¢åŠ ã€‚æ­¤å¤–ï¼ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„é’èŠ±æ¤°èœèŠ½ç²‰åœ¨è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½çš„ä¿ç•™ä¸Šè¡¨ç¾è‰¯å¥½ï¼Œä¸¦å±•ç¾å‡ºå„ªè¶Šçš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æå–ç‰©å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒå…·æœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„çµåˆå¯èƒ½ç‚ºé–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æä¾›äº†ä¸€å€‹æœ‰å‰æ™¯çš„æ–¹æ³•ã€‚",
    "fb_post": "ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ æœ‰å¤šå²å®³å—ï¼Ÿé€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼Œé€éä¸€äº›ç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œé’èŠ±æ¤°èœçš„ç‡Ÿé¤Šåƒ¹å€¼å¯ä»¥å¤§å¹…æå‡ï¼ç ”ç©¶ä¸»è¦æ¢è¨äº†ç”²ç¡«æ°¨é…¸å’Œè”—ç³–çš„å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–è‹·åˆæˆçš„å½±éŸ¿ï¼Œé‚„æœ‰çœŸç©ºå†·å‡ä¹¾ç‡¥å°èŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚ç ”ç©¶åœ˜éšŠå°4å¤©å¤§çš„é’èŠ±æ¤°èœèŠ½é€²è¡Œäº†å¯¦é©—ï¼Œç™¼ç¾è”—ç³–è™•ç†ä½¿è‘¡è„ç³–è‹·å«é‡æé«˜äº†316.30%ï¼Œè€Œä¸”è˜¿è””ç¡«ç´ å’Œå…¶ä»–ç‡Ÿé¤Šæˆåˆ†ä¹Ÿé¡¯è‘—å¢åŠ ï¼é€™ä¸åƒ…è®“é’èŠ±æ¤°èœæ›´ç‡Ÿé¤Šï¼Œé‚„å¯èƒ½å°é–‹ç™¼å¥åº·é£Ÿå“æœ‰å¹«åŠ©å“¦ï¼\n\nâœ¨ ä½ å¯ä»¥å¸¶èµ°çš„é‡é»ï¼š\n1. è”—ç³–è™•ç†å¤§å¹…æå‡é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ã€‚\n2. çœŸç©ºå†·å‡ä¹¾ç‡¥ä¿æŒäº†é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªã€‚\n3. è˜¿è””ç¡«ç´ å°æŸäº›ç´°èŒæœ‰æŠ—èŒæ•ˆæœï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·å…ç–«åŠ›ï¼",
    "image_prompt": "Create a flat design infographic with a light background. Include simplified illustrations of broccoli and sulforaphane, as well as a representation of the experimental subjects like humans or cells. Use arrows or flow lines to indicate the steps of the experiment, showing the pressure treatment with methionine and sucrose, and vacuum freeze-drying. Incorporate a section highlighting the main results, such as increased glucosinolate content and antibacterial effects.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41265122/"
  },
  {
    "id": "41159773",
    "title_en": "Sulforaphane-Loaded Hydrogel Prolongs Fully MHC-Mismatched Skin Allograft Survival.",
    "pub_date": "2025 Nov",
    "abstract_en": "Despite immunosuppression, acute rejection (AR) is still a common setback among transplantation patients and is a risk factor for graft survival. Sulforaphane (SFN), a phytochemical present in crucifers, has been shown to have anti-inflammatory and immunoregulatory properties, yet its influences on immune cell activation as well as in graft survival are still unknown. Thus, the aim was to evaluate SFN's effect, and to improve efficacy, efficiency, and availability, it was incorporated into thermosensitive polymeric hydrogels, to prevent AR in skin transplant (Tx) model mice. A thermosensitive hydrogel containing SFN (0.1%) and hyaluronic acid (HA) (0.5%) dispersed in a poloxamer matrix (PL407 at 20% w/v) was developed (GS-PL407 20%, HA and SFN) and characterized as a liquid-viscous hydrogel. The fully MHC-incompatible skin Tx procedure was performed by using donor skin Balb/c mice, transplanted into C57BL/6 recipient mice. The cytotoxicity test of GS was performed using in vitro assays with bone marrow-derived dendritic cells (BMDC). Treatment of BMDC with GS for 24 h presents no cytotoxicity. Untreated allograft mice present 100% of graft loss at day 9 post Tx. Remarkably, subcutaneous GS injection every 3 days promoted 80% of allograft survival for more than 14 days when compared with untreated recipients (<i>p</i> < 0.001). Histological analysis showed a lower level of inflammatory cells in the skin Tx of GS-treated mice. Flow cytometry analysis of draining lymph nodes at day 5 post Tx revealed that GS treatment reduced the frequency of DC and subtypes and function of the CD4<sup>+</sup> T cells. In vitro GS-treated lipopolysaccharide-activated BMDC present less activation of costimulatory markers. Taken together, GS treatment reduced immune cell activation, postponing AR onset and prolonging allograft survival in Tx animals. This strategy highlights the role of SFN as a promising candidate for further studies in organ transplantation experiments and being tested combined with current immunosuppression protocols.",
    "para1": "åœ¨å™¨å®˜ç§»æ¤çš„éç¨‹ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™å¯èƒ½æœƒå½±éŸ¿ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°å…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œä¸¦ä¸”å¸Œæœ›èƒ½æ‰¾åˆ°æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰çš„æ–¹æ³•ã€‚é€™å°æ–¼æ”¹å–„å™¨å®˜ç§»æ¤çš„æˆåŠŸç‡å’Œç—…äººçš„å¥åº·ç‹€æ³å…·æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨å¦‚ä½•åˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†å¢å¼·å…ç–«èª¿ç¯€æ–¹é¢ï¼Œæä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ çš„æŠ—ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§ä¾†æé«˜ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ï¼Œä¸¦ä¸”å¸Œæœ›èƒ½æ‰¾åˆ°ä¸€ç¨®æœ‰æ•ˆçš„æ–¹å¼ä¾†æ¸›å°‘æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ ä½œç‚ºæ¨¡å‹ï¼Œå°‡è˜¿è””ç¡«ç´ èˆ‡é€æ˜è³ªé…¸è£½æˆç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä¸¦é€²è¡Œäº†çš®è†šç§»æ¤æ‰‹è¡“ã€‚ç ”ç©¶è€…å°‡é€™ç¨®æ°´å‡è† æ³¨å°„åˆ°æ¥å—ç§»æ¤çš„å°é¼ èº«ä¸Šï¼Œä¸¦è§€å¯Ÿå…¶å°ç§»æ¤çš®è†šçš„å½±éŸ¿ã€‚å¯¦é©—ä¸­é‚„é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿æ°´å‡è† å°å…ç–«ç´°èƒä¸æœƒé€ æˆå‚·å®³ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ æ²»ç™‚çš„å°é¼ åœ¨ç§»æ¤å¾Œçš„çš®è†šå­˜æ´»ç‡é¡¯è‘—æé«˜ï¼Œèˆ‡æœªæ²»ç™‚çš„å°é¼ ç›¸æ¯”ï¼Œå­˜æ´»ç‡é”åˆ°80%ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰æ•ˆæ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ä¸­çš„æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ã€‚",
    "explanation_zh": "åœ¨å™¨å®˜ç§»æ¤çš„éç¨‹ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™å¯èƒ½æœƒå½±éŸ¿ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°å…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œä¸¦ä¸”å¸Œæœ›èƒ½æ‰¾åˆ°æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰çš„æ–¹æ³•ã€‚é€™å°æ–¼æ”¹å–„å™¨å®˜ç§»æ¤çš„æˆåŠŸç‡å’Œç—…äººçš„å¥åº·ç‹€æ³å…·æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨å¦‚ä½•åˆ©ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†å¢å¼·å…ç–«èª¿ç¯€æ–¹é¢ï¼Œæä¾›äº†æ–°çš„æ€è·¯ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è©•ä¼°è˜¿è””ç¡«ç´ åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å®ƒå°æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ çš„æŠ—ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§ä¾†æé«˜ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ï¼Œä¸¦ä¸”å¸Œæœ›èƒ½æ‰¾åˆ°ä¸€ç¨®æœ‰æ•ˆçš„æ–¹å¼ä¾†æ¸›å°‘æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ ä½œç‚ºæ¨¡å‹ï¼Œå°‡è˜¿è””ç¡«ç´ èˆ‡é€æ˜è³ªé…¸è£½æˆç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä¸¦é€²è¡Œäº†çš®è†šç§»æ¤æ‰‹è¡“ã€‚ç ”ç©¶è€…å°‡é€™ç¨®æ°´å‡è† æ³¨å°„åˆ°æ¥å—ç§»æ¤çš„å°é¼ èº«ä¸Šï¼Œä¸¦è§€å¯Ÿå…¶å°ç§»æ¤çš®è†šçš„å½±éŸ¿ã€‚å¯¦é©—ä¸­é‚„é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿æ°´å‡è† å°å…ç–«ç´°èƒä¸æœƒé€ æˆå‚·å®³ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ æ²»ç™‚çš„å°é¼ åœ¨ç§»æ¤å¾Œçš„çš®è†šå­˜æ´»ç‡é¡¯è‘—æé«˜ï¼Œèˆ‡æœªæ²»ç™‚çš„å°é¼ ç›¸æ¯”ï¼Œå­˜æ´»ç‡é”åˆ°80%ã€‚æ­¤å¤–ï¼Œçµ„ç¹”å­¸åˆ†æé¡¯ç¤ºï¼Œæ¥å—æ²»ç™‚çš„å°é¼ çš®è†šä¸­çš„ç‚ç—‡ç´°èƒæ•¸é‡è¼ƒå°‘ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰æ•ˆæ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚é€™äº›çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ åœ¨å™¨å®˜ç§»æ¤ä¸­çš„æ½›åŠ›ï¼Œå€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿå™¨å®˜ç§»æ¤å¾Œï¼Œæ€¥æ€§æ’æ–¥åæ‡‰å¸¸å¸¸æˆç‚ºç—…äººåº·å¾©çš„çµ†è…³çŸ³ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶è®“æˆ‘å€‘çœ‹åˆ°äº†ä¸€çµ²å¸Œæœ›ï¼Œé‚£å°±æ˜¯è˜¿è””ç¡«ç´ ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å°å…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤çš„æƒ…å¢ƒä¸­ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›èƒ½åˆ©ç”¨è˜¿è””ç¡«ç´ çš„æŠ—ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§ï¼Œä¾†æé«˜ç§»æ¤å™¨å®˜çš„å­˜æ´»ç‡ã€‚ä»–å€‘ç”¨å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå°‡è˜¿è””ç¡«ç´ èˆ‡é€æ˜è³ªé…¸è£½æˆæ°´å‡è† ï¼Œä¸¦é€²è¡Œäº†çš®è†šç§»æ¤æ‰‹è¡“ï¼Œè§€å¯Ÿå…¶æ•ˆæœã€‚\n\nçµæœé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ æ²»ç™‚çš„å°é¼ åœ¨ç§»æ¤å¾Œçš„çš®è†šå­˜æ´»ç‡é”åˆ°äº†80%ï¼è€Œä¸”ï¼Œé€™äº›å°é¼ çš„çš®è†šä¸­ç‚ç—‡ç´°èƒçš„æ•¸é‡ä¹Ÿè¼ƒå°‘ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰æ•ˆæ¸›å°‘å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿã€‚\n\né€™äº›ç™¼ç¾ä¸åƒ…è®“æˆ‘å€‘å°å™¨å®˜ç§»æ¤çš„æœªä¾†å……æ»¿æœŸå¾…ï¼Œä¹Ÿç‚ºå¤©ç„¶åŒ–åˆç‰©åœ¨é†«ç™‚ä¸Šçš„æ‡‰ç”¨æä¾›äº†æ–°çš„æ€è·¯ï¼\n\nğŸ” ä½ å¯ä»¥å¸¶èµ°çš„å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ æˆ–è¨±èƒ½å¹«åŠ©æé«˜å™¨å®˜ç§»æ¤çš„æˆåŠŸç‡ã€‚\n2. æ¸›å°‘ç‚ç—‡ç´°èƒçš„æ´»åŒ–å¯èƒ½æ˜¯å»¶ç·©æ’æ–¥åæ‡‰çš„é—œéµã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„å…ç–«èª¿ç¯€ç™‚æ³•æä¾›äº†æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experimental process and main findings of a study on the effects of sulforaphane on skin grafts. Include symbols representing broccoli or sulforaphane, simplified representations of experimental subjects like mice, and arrows or flow lines to indicate the steps of the experiment. Add a section clearly labeled 'Main Findings' highlighting key results, such as increased skin graft survival rates and reduced inflammation cell counts.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§æ’æ–¥åæ‡‰ Acute Rejection",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41159773/"
  },
  {
    "id": "41196460",
    "title_en": "Sulforaphane: a natural organosulfur having potential to modulate apoptosis and survival signalling in cancer.",
    "pub_date": "2025 Nov",
    "abstract_en": "Owing to its ever-growing range of pharmacological advantages, sulforaphane, an isothiocyanate from cruciferous vegetables such as broccoli, is becoming increasingly popular. This review aims to provide a thorough understanding and a current update on the application of sulforaphane in cancer treatment. Sulforaphane interacts with many signaling molecules that control various pathways in malignant cells, including angiogenesis, apoptosis, cell cycle arrest, metastasis, and inflammation pathways. This review examines the effects of this isothiocyanate on inflammatory mediators, caspases, MMPs, cytokines, and the proteins Bax and Bcl-2. Furthermore, the advantages of nanotechnology and synergistic effects in sulforaphane applications are also reviewed. As per evidence, sulforaphane is a shining example of how ethno-pharmacological expertise can be used to create modern medications.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°æ–¼è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥ç†è§£ï¼Œä¸¦ä¸”å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚é€éäº†è§£é€™ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ä¿¡è™Ÿé€šè·¯ï¼Œæœªä¾†æˆ–è¨±èƒ½é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œå¹«åŠ©äººå€‘æ›´å¥½åœ°æŠµæŠ—ç™Œç—‡åŠå…¶ä»–ç›¸é—œç–¾ç—…ã€‚",
    "para2": "é€™ç¯‡ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒå…§çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·ã€æ­»äº¡åŠè½‰ç§»ç­‰éç¨‹ã€‚é€™äº›ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œé‚„èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯å’Œæ–¹æ³•ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ å°æ–¼å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç™¼ç‚ä»‹è³ªã€å‡‹äº¡ç›¸é—œè›‹ç™½ã€ç´°èƒé€±æœŸèª¿æ§å› å­ç­‰ã€‚ç ”ç©¶æ–¹æ³•ä¸»è¦æ˜¯é€šéæ–‡ç»å›é¡§ï¼Œåˆ†æè˜¿è””ç¡«ç´ åœ¨ä¸åŒå¯¦é©—æ¢ä»¶ä¸‹çš„æ•ˆæœï¼Œä¸¦æ¢è¨å…¶èˆ‡ç´ç±³æŠ€è¡“çš„çµåˆåŠå”åŒæ•ˆæ‡‰ï¼Œå¾è€Œå…¨é¢äº†è§£å…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©éç¨‹ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ç™¼ç‚ã€ä¿ƒé€²ç´°èƒå‡‹äº¡åŠæŠ‘åˆ¶è…«ç˜¤è½‰ç§»æ–¹é¢ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ å…·æœ‰è‰¯å¥½çš„æ‡‰ç”¨æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ï¼Œä»¥ä¾¿åœ¨è‡¨åºŠä¸Šæ›´æœ‰æ•ˆåœ°æ‡‰ç”¨æ–¼ç™Œç—‡æ²»ç™‚ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°æ–¼è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥ç†è§£ï¼Œä¸¦ä¸”å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºã€‚é€éäº†è§£é€™ç¨®åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„å¤šç¨®ä¿¡è™Ÿé€šè·¯ï¼Œæœªä¾†æˆ–è¨±èƒ½é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ï¼Œå¹«åŠ©äººå€‘æ›´å¥½åœ°æŠµæŠ—ç™Œç—‡åŠå…¶ä»–ç›¸é—œç–¾ç—…ã€‚\n\né€™ç¯‡ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒå…§çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·ã€æ­»äº¡åŠè½‰ç§»ç­‰éç¨‹ã€‚é€™äº›ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œé‚„èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯å’Œæ–¹æ³•ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å›é¡§äº†è˜¿è””ç¡«ç´ å°æ–¼å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç™¼ç‚ä»‹è³ªã€å‡‹äº¡ç›¸é—œè›‹ç™½ã€ç´°èƒé€±æœŸèª¿æ§å› å­ç­‰ã€‚ç ”ç©¶æ–¹æ³•ä¸»è¦æ˜¯é€šéæ–‡ç»å›é¡§ï¼Œåˆ†æè˜¿è””ç¡«ç´ åœ¨ä¸åŒå¯¦é©—æ¢ä»¶ä¸‹çš„æ•ˆæœï¼Œä¸¦æ¢è¨å…¶èˆ‡ç´ç±³æŠ€è¡“çš„çµåˆåŠå”åŒæ•ˆæ‡‰ï¼Œå¾è€Œå…¨é¢äº†è§£å…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©éç¨‹ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ç™¼ç‚ã€ä¿ƒé€²ç´°èƒå‡‹äº¡åŠæŠ‘åˆ¶è…«ç˜¤è½‰ç§»æ–¹é¢ã€‚é›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ å…·æœ‰è‰¯å¥½çš„æ‡‰ç”¨æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ï¼Œä»¥ä¾¿åœ¨è‡¨åºŠä¸Šæ›´æœ‰æ•ˆåœ°æ‡‰ç”¨æ–¼ç™Œç—‡æ²»ç™‚ã€‚",
    "fb_post": "ğŸŒ± ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½åœ¨ç™Œç—‡æ²»ç™‚ä¸Šæœ‰å¤§å¤§çš„æ½›åŠ›ï¼é€™ç¯‡ç ”ç©¶è®“æˆ‘å€‘æ›´æ·±å…¥äº†è§£é€™å€‹ç¥å¥‡çš„åŒ–åˆç‰©æ˜¯å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ã€‚ç ”ç©¶è€…å€‘ä¸»è¦æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒå…§çš„ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œå½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·èˆ‡è½‰ç§»ã€‚ä»–å€‘å›é¡§äº†è˜¿è””ç¡«ç´ å°å¤šç¨®ç”Ÿç‰©æ¨™è¨˜çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ç™¼ç‚ã€ç´°èƒå‡‹äº¡ï¼ˆç´°èƒæ­»äº¡ï¼‰åŠç´°èƒé€±æœŸèª¿æ§ç­‰ï¼Œä¸¦åˆ†æäº†å…¶èˆ‡ç´ç±³æŠ€è¡“çµåˆçš„æ½›åŠ›ã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å°æŠ—ç™¼ç‚ã€ä¿ƒé€²ç´°èƒå‡‹äº¡ä»¥åŠæŠ‘åˆ¶è…«ç˜¤è½‰ç§»æ–¹é¢ï¼Œæ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼ä¸éï¼Œé›–ç„¶ç›®å‰çš„è­‰æ“šé¡¯ç¤ºå®ƒæœ‰è‰¯å¥½çš„æ‡‰ç”¨æ½›åŠ›ï¼Œä½†ä»éœ€æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå®ƒçš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚ ä½ å¯ä»¥è¨˜ä½é€™å¹¾é»ï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœã€‚\n2. å®ƒå¯èƒ½å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œè½‰ç§»ã€‚\n3. ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå®ƒçš„ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚",
    "image_prompt": "Create a flat design infographic explaining the study on sulforaphane. Include symbols of broccoli and sulforaphane, simplified representations of experimental subjects like humans or cells, arrows or flow lines indicating the experimental steps, and a section highlighting the main results such as protective effects or changes observed. Use a light-colored background with soft color palettes, focusing on a scientific and educational style.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41196460/"
  },
  {
    "id": "41184790",
    "title_en": "Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.",
    "pub_date": "2025 Nov",
    "abstract_en": "Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; pâ€‰=â€‰0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; pâ€‰=â€‰0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RRâ€‰=â€‰0.68; 95% CI: 0.49 to 0.95; pâ€‰=â€‰0.02). The study provides initial insights into sulforaphane's potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†é—œæ–¼è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥å¥åº·æ–¹é¢çš„æ½›åœ¨å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥åˆ†è£‚ç—‡çš„æ²»ç™‚ä¸Šã€‚é›–ç„¶ç ”ç©¶çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ å°æ–¼æ”¹å–„æŸäº›ç—‡ç‹€æœ‰ä¸€å®šçš„æ•ˆæœï¼Œä½†é€™äº›æ•ˆæœä¸¦ä¸æ˜é¡¯ï¼Œä¸”åœ¨é•·æœŸè·Ÿè¹¤ä¸­æœªèƒ½æŒçºŒã€‚å› æ­¤ï¼Œå°æ–¼å¸Œæœ›é€éé£²é£Ÿä¾†æ”¹å–„å¿ƒç†å¥åº·çš„äººä¾†èªªï¼Œé€™é …ç ”ç©¶æé†’æˆ‘å€‘ï¼Œé›–ç„¶æŸäº›å¤©ç„¶æˆåˆ†å¯èƒ½æœ‰åŠ©æ–¼å¥åº·ï¼Œä½†ä»éœ€è¬¹æ…çœ‹å¾…å…¶ç™‚æ•ˆï¼Œä¸¦ä¸æ‡‰è©²å®Œå…¨ä¾è³´é€™äº›æˆåˆ†ä½œç‚ºæ²»ç™‚æ‰‹æ®µã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚ç²¾ç¥åˆ†è£‚ç—‡æ˜¯ä¸€ç¨®è¤‡é›œçš„ç²¾ç¥ç–¾ç—…ï¼Œå½±éŸ¿æ‚£è€…çš„æ€ç¶­ã€æƒ…æ„Ÿå’Œè¡Œç‚ºã€‚ç ”ç©¶è€…å¸Œæœ›é€šéç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œäº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„é€™äº›æ‚£è€…çš„ç—‡ç‹€ï¼Œç‰¹åˆ¥æ˜¯æ­£å‘å’Œè² å‘ç—‡ç‹€çš„è®ŠåŒ–ã€‚é€™æ˜¯é¦–æ¬¡é‡å°è˜¿è””ç¡«ç´ åœ¨æ­¤ç–¾ç—…ä¸­çš„æ½›åœ¨ç™‚æ•ˆé€²è¡Œçš„ç³»çµ±æ€§ç ”ç©¶ï¼Œå°æ–¼æœªä¾†çš„ç ”ç©¶å’Œè‡¨åºŠæ‡‰ç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠå¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œæ–‡ç»ï¼Œä¸¦ç´å…¥äº†éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTsï¼‰ï¼Œé€™äº›è©¦é©—è©•ä¼°äº†è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚æœ€çµ‚ï¼Œç ”ç©¶ç´å…¥äº†å››é …RCTï¼Œå…±æœ‰369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…åƒèˆ‡ã€‚ä¸»è¦çš„è©•ä¼°æŒ‡æ¨™æ˜¯æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰çš„ç¸½åˆ†åŠå…¶å­é‡è¡¨ï¼Œæ­¤å¤–é‚„è©•ä¼°äº†èªçŸ¥åŠŸèƒ½ã€ä»£è¬æŒ‡æ¨™åŠå®‰å…¨æ€§ç­‰æ¬¡è¦çµæœã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶èƒ½å¤ å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„PANSSç¸½åˆ†å’Œæ­£å‘ç—‡ç‹€æ–¹é¢ä¸¦æœªé¡¯è‘—æœ‰æ•ˆï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œå°æ–¼è² å‘ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿæœ‰é¡¯è‘—æ”¹å–„ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨æŸäº›æ–¹é¢å¯èƒ½æœ‰ç›Šã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ å°æ–¼é™ä½ä»£è¬æŒ‡æ¨™ï¼Œå¦‚ä½å¯†åº¦è„‚è›‹ç™½ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ç­‰ï¼Œé¡¯ç¤ºå‡ºå…¶æ½›åœ¨çš„å¥åº·ç›Šè™•ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ çµ„çš„ä¸­æ­¢ç‡è¼ƒä½ï¼Œé€™å¯èƒ½åæ˜ å‡ºå…¶è¼ƒå¥½çš„è€å—æ€§ã€‚ç„¶è€Œï¼Œç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œé€™äº›çµæœéœ€è¦è¬¹æ…è§£è®€ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†é—œæ–¼è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥å¥åº·æ–¹é¢çš„æ½›åœ¨å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥åˆ†è£‚ç—‡çš„æ²»ç™‚ä¸Šã€‚é›–ç„¶ç ”ç©¶çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ å°æ–¼æ”¹å–„æŸäº›ç—‡ç‹€æœ‰ä¸€å®šçš„æ•ˆæœï¼Œä½†é€™äº›æ•ˆæœä¸¦ä¸æ˜é¡¯ï¼Œä¸”åœ¨é•·æœŸè·Ÿè¹¤ä¸­æœªèƒ½æŒçºŒã€‚å› æ­¤ï¼Œå°æ–¼å¸Œæœ›é€éé£²é£Ÿä¾†æ”¹å–„å¿ƒç†å¥åº·çš„äººä¾†èªªï¼Œé€™é …ç ”ç©¶æé†’æˆ‘å€‘ï¼Œé›–ç„¶æŸäº›å¤©ç„¶æˆåˆ†å¯èƒ½æœ‰åŠ©æ–¼å¥åº·ï¼Œä½†ä»éœ€è¬¹æ…çœ‹å¾…å…¶ç™‚æ•ˆï¼Œä¸¦ä¸æ‡‰è©²å®Œå…¨ä¾è³´é€™äº›æˆåˆ†ä½œç‚ºæ²»ç™‚æ‰‹æ®µã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚ç²¾ç¥åˆ†è£‚ç—‡æ˜¯ä¸€ç¨®è¤‡é›œçš„ç²¾ç¥ç–¾ç—…ï¼Œå½±éŸ¿æ‚£è€…çš„æ€ç¶­ã€æƒ…æ„Ÿå’Œè¡Œç‚ºã€‚ç ”ç©¶è€…å¸Œæœ›é€šéç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œäº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„é€™äº›æ‚£è€…çš„ç—‡ç‹€ï¼Œç‰¹åˆ¥æ˜¯æ­£å‘å’Œè² å‘ç—‡ç‹€çš„è®ŠåŒ–ã€‚é€™æ˜¯é¦–æ¬¡é‡å°è˜¿è””ç¡«ç´ åœ¨æ­¤ç–¾ç—…ä¸­çš„æ½›åœ¨ç™‚æ•ˆé€²è¡Œçš„ç³»çµ±æ€§ç ”ç©¶ï¼Œå°æ–¼æœªä¾†çš„ç ”ç©¶å’Œè‡¨åºŠæ‡‰ç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nç ”ç©¶åœ˜éšŠå¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œæ–‡ç»ï¼Œä¸¦ç´å…¥äº†éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTsï¼‰ï¼Œé€™äº›è©¦é©—è©•ä¼°äº†è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚æœ€çµ‚ï¼Œç ”ç©¶ç´å…¥äº†å››é …RCTï¼Œå…±æœ‰369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…åƒèˆ‡ã€‚ä¸»è¦çš„è©•ä¼°æŒ‡æ¨™æ˜¯æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰çš„ç¸½åˆ†åŠå…¶å­é‡è¡¨ï¼Œæ­¤å¤–é‚„è©•ä¼°äº†èªçŸ¥åŠŸèƒ½ã€ä»£è¬æŒ‡æ¨™åŠå®‰å…¨æ€§ç­‰æ¬¡è¦çµæœã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶èƒ½å¤ å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ•ˆæœã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„PANSSç¸½åˆ†å’Œæ­£å‘ç—‡ç‹€æ–¹é¢ä¸¦æœªé¡¯è‘—æœ‰æ•ˆï¼Œä½†åœ¨12é€±çš„æ™‚é–“é»ä¸Šï¼Œå°æ–¼è² å‘ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚ä¸€èˆ¬ç²¾ç¥ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿæœ‰é¡¯è‘—æ”¹å–„ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨æŸäº›æ–¹é¢å¯èƒ½æœ‰ç›Šã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ å°æ–¼é™ä½ä»£è¬æŒ‡æ¨™ï¼Œå¦‚ä½å¯†åº¦è„‚è›‹ç™½ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ç­‰ï¼Œé¡¯ç¤ºå‡ºå…¶æ½›åœ¨çš„å¥åº·ç›Šè™•ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ çµ„çš„ä¸­æ­¢ç‡è¼ƒä½ï¼Œé€™å¯èƒ½åæ˜ å‡ºå…¶è¼ƒå¥½çš„è€å—æ€§ã€‚ç„¶è€Œï¼Œç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œé€™äº›çµæœéœ€è¦è¬¹æ…è§£è®€ã€‚",
    "fb_post": "ğŸŒ± ä½ çŸ¥é“è˜¿è””ç¡«ç´ å¯èƒ½å°å¿ƒç†å¥åº·æœ‰ä»€éº¼å½±éŸ¿å—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨äº†å®ƒåœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„æ½›åœ¨ç™‚æ•ˆã€‚\n\né€™é …ç ”ç©¶çš„ç›®çš„æ˜¯æƒ³çœ‹çœ‹è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç—‡ç‹€ï¼Œå°¤å…¶æ˜¯ä»–å€‘çš„æ€ç¶­å’Œæƒ…æ„Ÿã€‚ç ”ç©¶åœ˜éšŠå¾å¤šå€‹è³‡æ–™åº«ä¸­æ‰¾åˆ°äº†å››é …éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œç¸½å…±æœ‰369ååƒèˆ‡è€…ã€‚é€™äº›è©¦é©—ä¸»è¦è©•ä¼°äº†æ‚£è€…çš„ç—‡ç‹€è®ŠåŒ–ï¼Œé‚„æœ‰èªçŸ¥åŠŸèƒ½å’Œå¥åº·æŒ‡æ¨™ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„æŸäº›ç—‡ç‹€æ–¹é¢çš„æ•ˆæœä¸¦ä¸æ˜é¡¯ï¼Œä½†åœ¨è² å‘ç—‡ç‹€ä¸Šæœ‰è¼•å¾®çš„æ”¹å–„ã€‚æ­¤å¤–ï¼Œå®ƒé‚„é¡¯ç¤ºå‡ºå°é™ä½ä¸€äº›ä»£è¬æŒ‡æ¨™ï¼ˆå¦‚è†½å›ºé†‡ï¼‰çš„æ½›åœ¨å¥½è™•ï¼Œä¸¦ä¸”åƒèˆ‡è€…å°é€™å€‹æˆåˆ†çš„è€å—æ€§ä¹Ÿä¸éŒ¯ã€‚\n\nä¸éï¼Œé€™äº›çµæœé‚„éœ€è¦è¬¹æ…è§£è®€ï¼Œå› ç‚ºæ•¸æ“šæœ‰é™ï¼Œä¸”å­˜åœ¨ä¸€äº›è®Šç•°ã€‚å¸Œæœ›é€™é …ç ”ç©¶èƒ½ç‚ºæœªä¾†çš„ç ”ç©¶æä¾›ä¸€äº›å•Ÿç¤ºï¼\n\nğŸ”‘ è®€å®Œé€™è£¡ï¼Œä½ å¯ä»¥å¸¶èµ°é€™å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡çš„ç™‚æ•ˆå°šéœ€é€²ä¸€æ­¥ç ”ç©¶ã€‚\n2. åœ¨æŸäº›æ–¹é¢ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æœ‰è¼•å¾®çš„æ”¹å–„æ•ˆæœã€‚\n3. å¥åº·çš„é£²é£Ÿæˆåˆ†ä¸èƒ½æ›¿ä»£å°ˆæ¥­æ²»ç™‚ï¼Œä»éœ€è¬¹æ…çœ‹å¾…ã€‚",
    "image_prompt": "Create a flat design infographic with a light background that explains the experiment method and main results of a study on sulforaphane in schizophrenia. Include simplified icons of broccoli or sulforaphane, simplified representations of human subjects, arrows or flow lines indicating the experimental steps, and a section clearly labeled 'Main Results' highlighting any protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç²¾ç¥åˆ†è£‚ç—‡ Schizophrenia",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41184790/"
  },
  {
    "id": "40992247",
    "title_en": "Assessing the transplacental passage and breastmilk levels of broccoli sprout-derived sulforaphane.",
    "pub_date": "2025 Nov",
    "abstract_en": "Preeclampsia is characterised by hypertension with maternal end-organ dysfunction and/or fetal growth restriction. Sulforaphane, an antioxidant found in broccoli sprouts, has potential as a future therapeutic. With its ability to attenuate the injurious impacts of endothelial dysfunction in vitro, sulforaphane is uniquely positioned to protect against the harmful effects of preeclampsia. However, the transferability of sulforaphane from mother to fetus/baby remains unknown in humans. Uncomplicated pregnant patients (nÂ =Â 8) scheduled for elective caesarean sections (>37 weeks gestation) provided written and informed consent. A single oral dose of EnduraCell, a broccoli sprout extract (equivalent to 21Â mg of sulforaphane), was administered prior to caesarean section. Baseline blood pressure, blood and urine were collected and again at time of operation, alongside umbilical cord blood (vein and artery) and placental samples. 2-4 days post-delivery, a second dose was administered. Two hours later, maternal bloods and breast milk were collected. Samples were processed and analysed by liquid-chromatography mass-spectrometry to measure sulforaphane. Besides an increase in peripheral diastolic blood pressure on the day of caesarean section (pÂ =Â 0.028), there were no changes in maternal blood pressure or heart rate after ingestion of EnduraCell. Sulforaphane was found in maternal serum (70.10Â ng/mlÂ Â±Â 11.90), umbilical cord blood (vein: 25.18Â ng/mLÂ Â±Â 3.11, artery: 18.81Â ng/mLÂ Â±Â 2.36), urine (5726.00Â ng/mLÂ Â±Â 1175.00), placental tissue (10.99Â ng/mgÂ Â±Â 2.11) and breast milk (1.33Â ng/mLÂ Â±Â 2.29). Sulforaphane is present in the umbilical cord and breast milk, providing the world's first evidence of sulforaphane maternal-fetal transfer in humans, and opening avenues for future research into relevant fetal implications.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¦Šå¨ æœŸé«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰æ–¹é¢ã€‚å­ç™²å‰ç—‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“çš„ä½µç™¼ç—‡ï¼Œå¯èƒ½å°æ¯è¦ªå’Œèƒå…’é€ æˆåš´é‡å½±éŸ¿ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„æŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„æå®³ï¼Œå¾è€Œå°æŠ—å­ç™²å‰ç—‡çš„æœ‰å®³å½±éŸ¿ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨å¦Šå¨ æœŸé–“ä½¿ç”¨è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æ–°çš„æ²»ç™‚é¸æ“‡ï¼Œå¹«åŠ©æ”¹å–„æ¯é«”å’Œèƒå…’çš„å¥åº·ç‹€æ³ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ æœŸé«˜è¡€å£“ç—‡æ‚£è€…ä¸­çš„æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å¾æ¯é«”è½‰ç§»åˆ°èƒå…’æˆ–å¬°å…’ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ å®‰å…¨æœ‰æ•ˆåœ°é€²å…¥æ¯é«”çš„è¡€æ¶²å¾ªç’°ï¼Œä¸¦æœ€çµ‚åˆ°é”èƒå…’ï¼Œé€™å°æ–¼æœªä¾†çš„æ²»ç™‚ç­–ç•¥è‡³é—œé‡è¦ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯ç‚ºäº†æä¾›æœ‰é—œè˜¿è””ç¡«ç´ åœ¨å¦Šå¨ æœŸé–“çš„è½‰ç§»æ€§å’Œæ½›åœ¨ç›Šè™•çš„åˆæ­¥è­‰æ“šã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ‹›å‹Ÿäº†8åå¥åº·çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚å®‰æ’é€²è¡Œå‰–è…¹ç”¢ã€‚æ‰€æœ‰åƒèˆ‡è€…éƒ½ç°½ç½²äº†çŸ¥æƒ…åŒæ„æ›¸ã€‚ç ”ç©¶è€…åœ¨å‰–è…¹ç”¢å‰çµ¦äºˆåƒèˆ‡è€…ä¸€åŠ‘å£æœçš„é’èŠ±æ¤°èœèƒå–ç‰©ï¼ˆEnduraCellï¼‰ï¼Œé€™ç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶åœ˜éšŠåœ¨æ‰‹è¡“å‰æ”¶é›†äº†åŸºç·šçš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“æ™‚æ”¶é›†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚ç”¢å¾Œ2è‡³4å¤©ï¼Œåƒèˆ‡è€…å†æ¬¡æœç”¨è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œæ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æª¢æ¸¬åˆ°äº†è˜¿è””ç¡«ç´ çš„å­˜åœ¨ï¼Œé€™æ˜¯å…¨çƒé¦–å€‹è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯ä»¥å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œæ¯é«”çš„èˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†åœ¨æœç”¨è˜¿è””ç¡«ç´ å¾Œï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„æ½›åœ¨å½±éŸ¿æä¾›äº†æ–°çš„æ–¹å‘ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨å¦Šå¨ æœŸé–“çš„æ‡‰ç”¨æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¦Šå¨ æœŸé«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰æ–¹é¢ã€‚å­ç™²å‰ç—‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“çš„ä½µç™¼ç—‡ï¼Œå¯èƒ½å°æ¯è¦ªå’Œèƒå…’é€ æˆåš´é‡å½±éŸ¿ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„æŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„æå®³ï¼Œå¾è€Œå°æŠ—å­ç™²å‰ç—‡çš„æœ‰å®³å½±éŸ¿ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨å¦Šå¨ æœŸé–“ä½¿ç”¨è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æ–°çš„æ²»ç™‚é¸æ“‡ï¼Œå¹«åŠ©æ”¹å–„æ¯é«”å’Œèƒå…’çš„å¥åº·ç‹€æ³ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ æœŸé«˜è¡€å£“ç—‡æ‚£è€…ä¸­çš„æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å¾æ¯é«”è½‰ç§»åˆ°èƒå…’æˆ–å¬°å…’ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ å®‰å…¨æœ‰æ•ˆåœ°é€²å…¥æ¯é«”çš„è¡€æ¶²å¾ªç’°ï¼Œä¸¦æœ€çµ‚åˆ°é”èƒå…’ï¼Œé€™å°æ–¼æœªä¾†çš„æ²»ç™‚ç­–ç•¥è‡³é—œé‡è¦ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯ç‚ºäº†æä¾›æœ‰é—œè˜¿è””ç¡«ç´ åœ¨å¦Šå¨ æœŸé–“çš„è½‰ç§»æ€§å’Œæ½›åœ¨ç›Šè™•çš„åˆæ­¥è­‰æ“šã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…æ‹›å‹Ÿäº†8åå¥åº·çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨æ‡·å­•è¶…é37é€±æ™‚å®‰æ’é€²è¡Œå‰–è…¹ç”¢ã€‚æ‰€æœ‰åƒèˆ‡è€…éƒ½ç°½ç½²äº†çŸ¥æƒ…åŒæ„æ›¸ã€‚ç ”ç©¶è€…åœ¨å‰–è…¹ç”¢å‰çµ¦äºˆåƒèˆ‡è€…ä¸€åŠ‘å£æœçš„é’èŠ±æ¤°èœèƒå–ç‰©ï¼ˆEnduraCellï¼‰ï¼Œé€™ç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶åœ˜éšŠåœ¨æ‰‹è¡“å‰æ”¶é›†äº†åŸºç·šçš„è¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä¸¦åœ¨æ‰‹è¡“æ™‚æ”¶é›†è‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚ç”¢å¾Œ2è‡³4å¤©ï¼Œåƒèˆ‡è€…å†æ¬¡æœç”¨è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œæ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æª¢æ¸¬åˆ°äº†è˜¿è””ç¡«ç´ çš„å­˜åœ¨ï¼Œé€™æ˜¯å…¨çƒé¦–å€‹è­‰æ“šé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯ä»¥å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©ï¼Œæ¯é«”çš„èˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†åœ¨æœç”¨è˜¿è””ç¡«ç´ å¾Œï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„æ½›åœ¨å½±éŸ¿æä¾›äº†æ–°çš„æ–¹å‘ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨å¦Šå¨ æœŸé–“çš„æ‡‰ç”¨æ½›åŠ›ã€‚",
    "fb_post": "ğŸ‘¶ğŸŒ±ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡çš„è˜¿è””ç¡«ç´ ï¼Œå¯èƒ½å°å­•å©¦çš„å¥åº·æœ‰æ„æƒ³ä¸åˆ°çš„å¥½è™•ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼å¦Šå¨ æœŸé«˜è¡€å£“ç—‡ï¼ˆå­ç™²å‰ç—‡ï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®å¯èƒ½å°æ¯è¦ªå’Œèƒå…’é€ æˆåš´é‡å½±éŸ¿çš„å¦Šå¨ ä½µç™¼ç—‡ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®æŠ—æ°§åŒ–åŠ‘ï¼Œæˆ–è¨±å¯ä»¥æ¸›è¼•é€™ç¨®ç–¾ç—…å°å…§çš®åŠŸèƒ½çš„æå®³ï¼Œå¹«åŠ©æ”¹å–„æ¯é«”å’Œèƒå…’çš„å¥åº·ã€‚\n\né€™é …ç ”ç©¶æ‹›å‹Ÿäº†8ä½å¥åº·çš„å­•å©¦ï¼Œä¸¦åœ¨å‰–è…¹ç”¢å‰çµ¦å¥¹å€‘æœç”¨é’èŠ±æ¤°èœèƒå–ç‰©ï¼Œé€™ç›¸ç•¶æ–¼21æ¯«å…‹çš„è˜¿è””ç¡«ç´ ã€‚çµæœé¡¯ç¤ºï¼Œæ¯é«”çš„è¡€æ¶²ã€è‡å¸¶è¡€ã€å°¿æ¶²ç­‰æ¨£æœ¬ä¸­éƒ½æª¢æ¸¬åˆ°è˜¿è””ç¡«ç´ çš„å­˜åœ¨ï¼Œé€™æ„å‘³è‘—å®ƒå¯ä»¥å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ï¼é›–ç„¶åœ¨æ‰‹è¡“ç•¶å¤©æ¯é«”çš„è¡€å£“ç•¥æœ‰ä¸Šå‡ï¼Œä½†æ•´é«”ä¾†èªªï¼Œè¡€å£“å’Œå¿ƒç‡ä¸¦æœªæœ‰é¡¯è‘—è®ŠåŒ–ã€‚\n\né€™äº›ç™¼ç¾ç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„æ½›åœ¨å½±éŸ¿æä¾›äº†æ–°çš„æ–¹å‘ï¼Œé¡¯ç¤ºå‡ºå®ƒåœ¨å¦Šå¨ æœŸé–“çš„æ‡‰ç”¨æ½›åŠ›ã€‚\n\nâœ¨é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•å¦Šå¨ æœŸé«˜è¡€å£“ç—‡çš„å½±éŸ¿ã€‚\n2. ç ”ç©¶è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ å¾æ¯é«”è½‰ç§»åˆ°èƒå…’ã€‚\n3. æœªä¾†æˆ–è¨±èƒ½æˆç‚ºæ”¹å–„å­•å©¦å¥åº·çš„æ–°é¸æ“‡ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental process and main results of a study on sulforaphane. Include simple icons representing broccoli and sulforaphane, as well as simplified figures of human subjects. Use arrows or flow lines to indicate the steps of the experiment. Include a section labeled 'Main Results' highlighting that sulforaphane was detected in maternal blood, cord blood, urine, and breast milk, indicating its transfer from mother to fetus. Use a light background with soft colors for a scientific and educational feel.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¦Šå¨ æœŸé«˜è¡€å£“ç—‡ Preeclampsia",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40992247/"
  },
  {
    "id": "40633511",
    "title_en": "Synthesis and biological evaluation of Sulforaphane derivatives with dual functions: Ischemia-reperfusion injury protection and antitumor effects.",
    "pub_date": "2025 Nov",
    "abstract_en": "Reperfusion therapy for the treatment of acute myocardial infarction (AMI) often leads to ischemia-reperfusion (I/R) injuries, characterized by excessive ROS. Sulforaphane (SFN) homologous, known for their anti-inflammatory and antioxidant properties, activate the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway and reduce mitochondrial ROS but are limited by poor stability and short half-life. SFN derivatives were synthesized through structural modifications of the dithiocarbamate and thiourea moieties at the isothiocyanate group, aiming to enhance stability and maintain therapeutic efficacy. Compound 3g emerged as a promising candidate, demonstrating superior protection against hypoxia-reoxygenation (H/R) injury in cardiac microvascular endothelial cells (CMECs) and exhibiting good antitumor activity. Specifically, 3g reduced ROS levels by 24.5Â % (compared to nifedipine at 17.8Â %), increased NO production to 48.0Â Î¼M (vs. 44.0Â Î¼M), lowered TNF-Î± secretion to 22.6Â pg/mL (vs. 23.9Â pg/mL). Concurrently, 3g showed potent antiproliferative activity (IC<sub>50</sub>Â =Â 7.5Â Î¼M), with 3.8-fold greater potency than 5-fluorouracil (IC<sub>50</sub>Â =Â 28.2Â Î¼M). Stability studies showed enhanced resistance in both protic and aprotic solvents. Density functional theory (DFT) was applied to characterize the molecular properties of the optimal compounds. Molecular docking and ADMET analysis revealed that aromatic substitution and sulfur oxidation significantly improved Nrf2/Keap1 pathway targeting, highlighting the derivative's potential for stability and therapeutic efficacy. These findings suggest that 3g is a promising candidate for treating I/R-induced injury and oxidative stress-related cardiovascular conditions.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡ï¼ˆAMIï¼‰æ‚£è€…åœ¨æ¥å—å†çŒæ³¨æ²»ç™‚å¾Œï¼Œå¸¸å¸¸æœƒå‡ºç¾ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æå‚·èˆ‡éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰æœ‰é—œã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼Œå› å…¶æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æå‚·ï¼Œå¾è€Œæ”¹å–„å¿ƒè‡Ÿå¥åº·ã€‚é€™æ„å‘³è‘—ï¼Œé€éæ”¹å–„é€™äº›åŒ–åˆç‰©çš„ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œæœªä¾†å¯èƒ½æœƒæœ‰æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ä¾†æ‡‰å°å¿ƒè¡€ç®¡ç–¾ç—…çš„æŒ‘æˆ°ã€‚",
    "para2": "æœ¬ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯å¦‚ä½•æ”¹å–„è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©çš„ç©©å®šæ€§ï¼Œä»¥ä¾¿æ›´æœ‰æ•ˆåœ°æ²»ç™‚å› ç¼ºè¡€å†çŒæ³¨å¼•èµ·çš„å¿ƒè‡Ÿæå‚·ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›é€éçµæ§‹æ”¹è‰¯ï¼Œå¢å¼·é€™äº›åŒ–åˆç‰©çš„ç™‚æ•ˆï¼Œç‰¹åˆ¥æ˜¯åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­çš„æ‡‰ç”¨ã€‚é€™é …ç ”ç©¶ä¸åƒ…æ¢è¨äº†é€™äº›åŒ–åˆç‰©çš„æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œé‚„é—œæ³¨å®ƒå€‘åœ¨å¿ƒè¡€ç®¡ç–¾ç—…ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œå°¤å…¶æ˜¯åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„æ²»ç™‚æ•ˆæœã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¤šç¨®è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œä¸¦é¸æ“‡äº†å…¶ä¸­çš„3gåŒ–åˆç‰©é€²è¡Œæ·±å…¥ç ”ç©¶ã€‚é€™äº›åŒ–åˆç‰©çš„åˆæˆæ˜¯åŸºæ–¼å°äºŒç¡«æ°¨åŸºé…¸å’Œç¡«è„²åŸºåœ˜çš„çµæ§‹æ”¹è‰¯ï¼Œç›®çš„æ˜¯æé«˜å…¶ç©©å®šæ€§å’Œç™‚æ•ˆã€‚ç ”ç©¶è€…ä½¿ç”¨äº†å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¾†æ¸¬è©¦é€™äº›åŒ–åˆç‰©å°ç¼ºæ°§å†çŒæ³¨æå‚·çš„ä¿è­·æ•ˆæœï¼Œä¸¦é€²è¡Œäº†æŠ—è…«ç˜¤æ´»æ€§æ¸¬è©¦ï¼Œä»¥è©•ä¼°å…¶åœ¨å¿ƒè¡€ç®¡ç–¾ç—…å’Œç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œ3gåŒ–åˆç‰©åœ¨æ¸›å°‘æ´»æ€§æ°§æ°´å¹³å’Œä¿ƒé€²ä¸€æ°§åŒ–æ°®ç”¢ç”Ÿæ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œä¸¦ä¸”å…¶æŠ—å¢æ®–æ´»æ€§é¡¯è‘—é«˜æ–¼å‚³çµ±çš„åŒ–ç™‚è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶ã€‚å…·é«”ä¾†èªªï¼Œ3gèƒ½å°‡æ´»æ€§æ°§æ°´å¹³é™ä½24.5%ï¼Œä¸¦æé«˜ä¸€æ°§åŒ–æ°®çš„ç”¢ç”Ÿè‡³48.0Î¼Mã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ3gåŒ–åˆç‰©åœ¨æ²»ç™‚ç¼ºè¡€å†çŒæ³¨å¼•èµ·çš„æå‚·å’Œèˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„å¿ƒè¡€ç®¡ç–¾ç—…æ–¹é¢ï¼Œå…·æœ‰è‰¯å¥½çš„æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºã€‚æ€¥æ€§å¿ƒè‚Œæ¢—å¡ï¼ˆAMIï¼‰æ‚£è€…åœ¨æ¥å—å†çŒæ³¨æ²»ç™‚å¾Œï¼Œå¸¸å¸¸æœƒå‡ºç¾ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™ç¨®æå‚·èˆ‡éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰æœ‰é—œã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼Œå› å…¶æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æå‚·ï¼Œå¾è€Œæ”¹å–„å¿ƒè‡Ÿå¥åº·ã€‚é€™æ„å‘³è‘—ï¼Œé€éæ”¹å–„é€™äº›åŒ–åˆç‰©çš„ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œæœªä¾†å¯èƒ½æœƒæœ‰æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ä¾†æ‡‰å°å¿ƒè¡€ç®¡ç–¾ç—…çš„æŒ‘æˆ°ã€‚\n\næœ¬ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯å¦‚ä½•æ”¹å–„è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©çš„ç©©å®šæ€§ï¼Œä»¥ä¾¿æ›´æœ‰æ•ˆåœ°æ²»ç™‚å› ç¼ºè¡€å†çŒæ³¨å¼•èµ·çš„å¿ƒè‡Ÿæå‚·ã€‚ç ”ç©¶è€…å€‘å¸Œæœ›é€éçµæ§‹æ”¹è‰¯ï¼Œå¢å¼·é€™äº›åŒ–åˆç‰©çš„ç™‚æ•ˆï¼Œç‰¹åˆ¥æ˜¯åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­çš„æ‡‰ç”¨ã€‚é€™é …ç ”ç©¶ä¸åƒ…æ¢è¨äº†é€™äº›åŒ–åˆç‰©çš„æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œé‚„é—œæ³¨å®ƒå€‘åœ¨å¿ƒè¡€ç®¡ç–¾ç—…ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œå°¤å…¶æ˜¯åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„æ²»ç™‚æ•ˆæœã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¤šç¨®è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œä¸¦é¸æ“‡äº†å…¶ä¸­çš„3gåŒ–åˆç‰©é€²è¡Œæ·±å…¥ç ”ç©¶ã€‚é€™äº›åŒ–åˆç‰©çš„åˆæˆæ˜¯åŸºæ–¼å°äºŒç¡«æ°¨åŸºé…¸å’Œç¡«è„²åŸºåœ˜çš„çµæ§‹æ”¹è‰¯ï¼Œç›®çš„æ˜¯æé«˜å…¶ç©©å®šæ€§å’Œç™‚æ•ˆã€‚ç ”ç©¶è€…ä½¿ç”¨äº†å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¾†æ¸¬è©¦é€™äº›åŒ–åˆç‰©å°ç¼ºæ°§å†çŒæ³¨æå‚·çš„ä¿è­·æ•ˆæœï¼Œä¸¦é€²è¡Œäº†æŠ—è…«ç˜¤æ´»æ€§æ¸¬è©¦ï¼Œä»¥è©•ä¼°å…¶åœ¨å¿ƒè¡€ç®¡ç–¾ç—…å’Œç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œ3gåŒ–åˆç‰©åœ¨æ¸›å°‘æ´»æ€§æ°§æ°´å¹³å’Œä¿ƒé€²ä¸€æ°§åŒ–æ°®ç”¢ç”Ÿæ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œä¸¦ä¸”å…¶æŠ—å¢æ®–æ´»æ€§é¡¯è‘—é«˜æ–¼å‚³çµ±çš„åŒ–ç™‚è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶ã€‚å…·é«”ä¾†èªªï¼Œ3gèƒ½å°‡æ´»æ€§æ°§æ°´å¹³é™ä½24.5%ï¼Œä¸¦æé«˜ä¸€æ°§åŒ–æ°®çš„ç”¢ç”Ÿè‡³48.0Î¼Mã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ3gåŒ–åˆç‰©åœ¨æ²»ç™‚ç¼ºè¡€å†çŒæ³¨å¼•èµ·çš„æå‚·å’Œèˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„å¿ƒè¡€ç®¡ç–¾ç—…æ–¹é¢ï¼Œå…·æœ‰è‰¯å¥½çš„æ½›åŠ›ï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "fb_post": "ğŸ‰ è½èªªéè˜¿è””ç¡«ç´ å—ï¼Ÿå®ƒä¸åƒ…èƒ½å¢æ·»èœé¤šé¢¨å‘³ï¼Œé‚„å¯èƒ½å°å¿ƒè‡Ÿå¥åº·æœ‰å¹«åŠ©å–”ï¼é€™ç¯‡ç ”ç©¶è®“æˆ‘å€‘å°å¿ƒè¡€ç®¡å¥åº·æœ‰äº†æ–°å•Ÿç¤ºã€‚  \n  \nç ”ç©¶ç™¼ç¾ï¼Œæ€¥æ€§å¿ƒè‚Œæ¢—å¡ï¼ˆAMIï¼‰æ‚£è€…åœ¨æ¥å—å†çŒæ³¨æ²»ç™‚å¾Œï¼Œå¸¸æœƒå‡ºç¾ç¼ºè¡€å†çŒæ³¨æå‚·ï¼Œé€™èˆ‡éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰æœ‰é—œã€‚è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©å› ç‚ºå…·å‚™æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æå‚·ï¼Œæ”¹å–„å¿ƒè‡Ÿå¥åº·ã€‚  \n  \né€™é …ç ”ç©¶ä¸»è¦å°ˆæ³¨æ–¼å¦‚ä½•æå‡è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©çš„ç©©å®šæ€§ï¼Œè®“å®ƒå€‘åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­ç™¼æ®æ›´å¥½çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…åˆæˆäº†å¤šç¨®è¡ç”Ÿç‰©ï¼Œä¸¦é¸æ“‡äº†3gåŒ–åˆç‰©é€²è¡Œæ·±å…¥ç ”ç©¶ï¼Œç™¼ç¾å®ƒèƒ½æœ‰æ•ˆæ¸›å°‘æ´»æ€§æ°§çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²ä¸€æ°§åŒ–æ°®çš„ç”Ÿæˆã€‚  \n  \nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»è®“ä½ å¸¶èµ°ï¼š  \n1ï¸âƒ£ 3gåŒ–åˆç‰©èƒ½å°‡æ´»æ€§æ°§æ°´å¹³é™ä½24.5%ï¼  \n2ï¸âƒ£ å®ƒä¿ƒé€²ä¸€æ°§åŒ–æ°®çš„ç”¢ç”Ÿè‡³48.0Î¼Mï¼Œå°å¿ƒè¡€ç®¡å¥åº·æœ‰æ½›åœ¨å¹«åŠ©ã€‚  \n3ï¸âƒ£ é›–ç„¶çµæœä»¤äººæŒ¯å¥®ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå®ƒçš„ç™‚æ•ˆï¼  \n  \nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æœªä¾†çš„ç™¼å±•å§ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main results of a study on sulforaphane. Include simple icons representing broccoli or sulforaphane, simplified illustrations of experimental subjects such as humans, animals, or cells. Use arrows or flow lines to indicate the steps of the experiment. Include a section labeled 'Main Results' that highlights protective effects or changes observed, such as reduction in reactive oxygen species and increase in nitric oxide production.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¿ƒè‚Œæ¢—å¡ Myocardial Infarction",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40633511/"
  },
  {
    "id": "40617372",
    "title_en": "Antioxidant effect of esculin and sulforaphane in zebrafish larvae: A comparative study.",
    "pub_date": "2025 Nov",
    "abstract_en": "Antioxidants are crucial for maintaining cellular redox homeostasis by neutralizing free radicals, including reactive oxygen species (ROS). Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor that activates various cytoprotective genes to counteract oxidative damage. The present study aimed to compare the antioxidant potential of natural phytochemicals, esculin (ESC), and sulforaphane (SFN) in zebrafish larvae, focusing on Nrf2 activation. Zebrafish larvae were treated with ESC (100Â Î¼M) and SFN (40Â Î¼M) along with control for 6Â h. The levels of ROS, lipid peroxidation (LPO), nitric oxide (NO), glutathione S-transferase (GST), glutathione peroxidase (GPx), catalase (CAT), and reduced glutathione (GSH) were measured. Further, RT-PCR and Western blotting methods were employed to determine the antioxidant genes and protein levels, respectively. In addition, Nrf2 localization within the cell was assessed using nuclear/cytosolic fractionation assay and wholemount immunohistochemistry method. Our results demonstrate that ESC treatment significantly increased antioxidant enzyme activities (GST, GPx, CAT), similar to the effects observed with SFN. Further, ESC enhanced the mRNA levels of antioxidant genes expression, such as nrf2, gstp1, hmox1a, prdx1, nqo1, gss, gsr, sqstm1, hsp90aa1.2 than SFN. Antioxidant proteins Nrf2, Gstp1, Cat, and Sod2 were upregulated in the ESC-treated groups. Subsequently, nuclear localization of Nrf2 was detected in both SFN- and ESC-treated groups, confirming Nrf2 translocation into the nucleus. Our findings suggest that ESC possesses potent antioxidant activity as SFN in 72-hpf zebrafish larvae through the Keap1-Nrf2 signaling pathway.",
    "para1": "æŠ—æ°§åŒ–åŠ‘å°æ–¼ç¶­æŒç´°èƒçš„å¥åº·éå¸¸é‡è¦ï¼Œå› ç‚ºå®ƒå€‘èƒ½ä¸­å’Œè‡ªç”±åŸºï¼Œç‰¹åˆ¥æ˜¯åæ‡‰æ€§æ°§ç‰©è³ªï¼ˆROSï¼‰ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨æŠ—æ°§åŒ–åŠ‘çš„ä½¿ç”¨ä¸Šã€‚é€éäº†è§£ä¸åŒå¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†ä¿è­·ç´°èƒå…å—æ°§åŒ–æå‚·ï¼Œé€²è€Œä¿ƒé€²å¥åº·ï¼Œæ¸›å°‘ç–¾ç—…é¢¨éšªã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å°æ¯”äº†å…©ç¨®åŒ–åˆç‰©ï¼šè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å’Œå¦ä¸€ç¨®åç‚ºesculinï¼ˆESCï¼‰çš„åŒ–åˆç‰©ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ä¸€ç¨®åç‚ºNrf2çš„è½‰éŒ„å› å­ï¼Œé€™å€‹å› å­åœ¨ç´°èƒçš„æŠ—æ°§åŒ–é˜²ç¦¦ä¸­æ‰®æ¼”é‡è¦è§’è‰²ï¼Œèƒ½å•Ÿå‹•å¤šç¨®ä¿è­·åŸºå› ä»¥å°æŠ—æ°§åŒ–æå‚·ã€‚",
    "para3": "å¯¦é©—ä½¿ç”¨äº†æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºç ”ç©¶å°è±¡ï¼Œé€™æ˜¯ä¸€ç¨®å¸¸ç”¨æ–¼ç”Ÿç‰©é†«å­¸ç ”ç©¶çš„æ¨¡å¼ç”Ÿç‰©ã€‚ç ”ç©¶åœ˜éšŠå°‡æ–‘é¦¬é­šå¹¼é«”åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥è™•ç†100Î¼Mçš„esculinå’Œ40Î¼Mçš„è˜¿è””ç¡«ç´ ï¼Œä¸¦æŒçºŒ6å°æ™‚ã€‚éš¨å¾Œï¼Œç ”ç©¶äººå“¡æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬è‡ªç”±åŸºæ°´å¹³ã€è„‚è³ªéæ°§åŒ–ã€æ°®æ°§åŒ–ç‰©ã€ä»¥åŠå¹¾ç¨®æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œä¸¦ä½¿ç”¨RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†åˆ†ææŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨ç¾ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œesculinçš„è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„å¢å¼·äº†å¤šç¨®æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”æ°´å¹³ï¼Œé¡¯ç¤ºå‡ºå…¶å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ã€‚ç ”ç©¶ä¸­ä¹Ÿè§€å¯Ÿåˆ°Nrf2åœ¨ç´°èƒå…§çš„å®šä½è®ŠåŒ–ï¼Œè­‰å¯¦äº†Nrf2é€²å…¥ç´°èƒæ ¸çš„éç¨‹ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œesculinåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­å…·æœ‰èˆ‡è˜¿è””ç¡«ç´ ç›¸ç•¶çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä¸¦é€éKeap1-Nrf2ä¿¡è™Ÿé€šè·¯ç™¼æ®ä½œç”¨ã€‚",
    "explanation_zh": "æŠ—æ°§åŒ–åŠ‘å°æ–¼ç¶­æŒç´°èƒçš„å¥åº·éå¸¸é‡è¦ï¼Œå› ç‚ºå®ƒå€‘èƒ½ä¸­å’Œè‡ªç”±åŸºï¼Œç‰¹åˆ¥æ˜¯åæ‡‰æ€§æ°§ç‰©è³ªï¼ˆROSï¼‰ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨æŠ—æ°§åŒ–åŠ‘çš„ä½¿ç”¨ä¸Šã€‚é€éäº†è§£ä¸åŒå¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†ä¿è­·ç´°èƒå…å—æ°§åŒ–æå‚·ï¼Œé€²è€Œä¿ƒé€²å¥åº·ï¼Œæ¸›å°‘ç–¾ç—…é¢¨éšªã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å°æ¯”äº†å…©ç¨®åŒ–åˆç‰©ï¼šè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å’Œå¦ä¸€ç¨®åç‚ºesculinï¼ˆESCï¼‰çš„åŒ–åˆç‰©ã€‚ç ”ç©¶çš„é‡é»åœ¨æ–¼é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ä¸€ç¨®åç‚ºNrf2çš„è½‰éŒ„å› å­ï¼Œé€™å€‹å› å­åœ¨ç´°èƒçš„æŠ—æ°§åŒ–é˜²ç¦¦ä¸­æ‰®æ¼”é‡è¦è§’è‰²ï¼Œèƒ½å•Ÿå‹•å¤šç¨®ä¿è­·åŸºå› ä»¥å°æŠ—æ°§åŒ–æå‚·ã€‚\n\nå¯¦é©—ä½¿ç”¨äº†æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºç ”ç©¶å°è±¡ï¼Œé€™æ˜¯ä¸€ç¨®å¸¸ç”¨æ–¼ç”Ÿç‰©é†«å­¸ç ”ç©¶çš„æ¨¡å¼ç”Ÿç‰©ã€‚ç ”ç©¶åœ˜éšŠå°‡æ–‘é¦¬é­šå¹¼é«”åˆ†ç‚ºä¸åŒçµ„åˆ¥ï¼Œåˆ†åˆ¥è™•ç†100Î¼Mçš„esculinå’Œ40Î¼Mçš„è˜¿è””ç¡«ç´ ï¼Œä¸¦æŒçºŒ6å°æ™‚ã€‚éš¨å¾Œï¼Œç ”ç©¶äººå“¡æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬è‡ªç”±åŸºæ°´å¹³ã€è„‚è³ªéæ°§åŒ–ã€æ°®æ°§åŒ–ç‰©ã€ä»¥åŠå¹¾ç¨®æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œä¸¦ä½¿ç”¨RT-PCRå’Œè¥¿æ–¹å°è·¡æ³•ä¾†åˆ†ææŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨ç¾ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œesculinçš„è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„å¢å¼·äº†å¤šç¨®æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”æ°´å¹³ï¼Œé¡¯ç¤ºå‡ºå…¶å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ã€‚ç ”ç©¶ä¸­ä¹Ÿè§€å¯Ÿåˆ°Nrf2åœ¨ç´°èƒå…§çš„å®šä½è®ŠåŒ–ï¼Œè­‰å¯¦äº†Nrf2é€²å…¥ç´°èƒæ ¸çš„éç¨‹ã€‚é€™äº›ç™¼ç¾è¡¨æ˜ï¼Œesculinåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­å…·æœ‰èˆ‡è˜¿è””ç¡«ç´ ç›¸ç•¶çš„æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œä¸¦é€éKeap1-Nrf2ä¿¡è™Ÿé€šè·¯ç™¼æ®ä½œç”¨ã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„èº«é«”è£¡æœ‰ä¸€ç¨®å«åšæŠ—æ°§åŒ–åŠ‘çš„å¥½æœ‹å‹ï¼Œèƒ½å¹«åŠ©æˆ‘å€‘æŠµæŠ—è‡ªç”±åŸºçš„æ”»æ“Šï¼Œç¶­æŒç´°èƒå¥åº·ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ï¼Œå°ˆæ³¨æ–¼å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰å’Œesculinï¼ˆESCï¼‰ã€‚é€™äº›åŒ–åˆç‰©èƒ½å½±éŸ¿ä¸€ç¨®åç‚ºNrf2çš„è½‰éŒ„å› å­ï¼Œé€™å€‹å› å­å°±åƒç´°èƒçš„å®ˆè­·è€…ï¼Œå•Ÿå‹•å¤šç¨®ä¿è­·åŸºå› ï¼Œå°æŠ—æ°§åŒ–æå‚·ã€‚  \n\nç ”ç©¶åœ˜éšŠä½¿ç”¨æ–‘é¦¬é­šå¹¼é«”é€²è¡Œå¯¦é©—ï¼Œå°‡å®ƒå€‘åˆ†æˆå…©çµ„ï¼Œåˆ†åˆ¥è™•ç†esculinå’Œè˜¿è””ç¡«ç´ ï¼Œç„¶å¾Œè§€å¯Ÿäº†è‡ªç”±åŸºæ°´å¹³ã€è„‚è³ªéæ°§åŒ–ç­‰æŒ‡æ¨™ã€‚çµæœç™¼ç¾ï¼Œesculinçš„æŠ—æ°§åŒ–æ•ˆæœèˆ‡è˜¿è””ç¡«ç´ ç›¸ç•¶ï¼Œç”šè‡³é‚„å¢å¼·äº†æŠ—æ°§åŒ–åŸºå› çš„è¡¨é”ï¼é€™äº›ç™¼ç¾ä¸åƒ…è®“æˆ‘å€‘æ›´äº†è§£é€™äº›åŒ–åˆç‰©çš„æ½›åŠ›ï¼Œä¹Ÿç‚ºæœªä¾†çš„å¥åº·ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ã€‚  \n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. æŠ—æ°§åŒ–åŠ‘èƒ½å¹«åŠ©æˆ‘å€‘æŠµæŠ—ç´°èƒæå‚·ã€‚  \n2. è˜¿è””ç¡«ç´ å’Œesculinéƒ½æ˜¯å¼·å¤§çš„å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ã€‚  \n3. Nrf2åœ¨ç´°èƒçš„æŠ—æ°§åŒ–é˜²ç¦¦ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚",
    "image_prompt": "Create an infographic that explains the experimental method and main results of a study on antioxidants. Use a flat design style with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of zebrafish or cells as experimental subjects, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40617372/"
  },
  {
    "id": "40533430",
    "title_en": "Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF-Ä¸B signalling pathway.",
    "pub_date": "2025 Nov",
    "abstract_en": "Sulforaphane (SFN) has notable health benefits but faces challenges due to its poor solubility and delivery. This study investigates SFN-glycoconjugates effects on lipopolysaccharide (LPS)-induced inflammation in dendritic cells (DCs). With the aiming to enhance their therapeutic potential against inflammatory diseases. Novel monovalent SFN-glycoconjugates with mannose (Man) and fucose (0Fuc) were developed and tested for their anti-inflammatory and immune-modulatory properties in DCs from healthy donors under chronic LPS exposure. By leveraging therapeutic strategies, SFN-glycoconjugates significantly improved the solubility and bioavailability of SFN, thereby overcoming the limitations of traditional delivery methods. Monocyte-derived DCs were treated with SFN-glycoconjugates and subsequently exposed to a chronic inflammatory environment induced by LPS. Our results showed that SFN-glycoconjugates enhance effectiveness in suppressing inflammation by targeting the p65 NF-ÎºB pathway, without affecting MAPK signalling. SFN-glycoconjugates induce a tolerogenic immune response, characterized by increased IL-10 production and enhanced regulatory T- and B-cell proliferation. These effects surpass those of p65 NF-ÎºB inhibition alone, highlighting a distinct and potent regulatory mechanism independent of MAPK pathways. The integration of food therapeutic strategies not only enhances the stability and delivery of bioactive compounds but also broadens their potential applications in functional foods and therapeutic approaches. In particular, SFN-glycoconjugates represent a promising option as biologically active compounds for inflammatory diseases, offering enhanced anti-inflammatory and immunomodulatory effects through optimized delivery systems and the activation of specific molecular pathways.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£æ€§å·®å’Œå‚³éå›°é›£ï¼Œé™åˆ¶äº†å®ƒçš„æ‡‰ç”¨ã€‚é€™é …ç ”ç©¶å°ˆæ³¨æ–¼æ”¹å–„è˜¿è””ç¡«ç´ çš„å‚³éæ–¹å¼ï¼Œä»¥æœŸå¢å¼·å…¶åœ¨æŠ—ç™¼ç‚ç–¾ç—…ä¸­çš„ç™‚æ•ˆï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ç®¡ç†å’Œç–¾ç—…é é˜²å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ç³–è‹·çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç™¼ç‚åæ‡‰ä¸­ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›æ–°å‹çš„è˜¿è””ç¡«ç´ ç³–è‹·å¦‚ä½•å½±éŸ¿æ¨¹çªç´°èƒçš„å…ç–«åæ‡‰ï¼Œä¸¦é€²ä¸€æ­¥æå‡å…¶åœ¨æŠ—ç™¼ç‚ç–¾ç—…ä¸­çš„æ²»ç™‚æ½›åŠ›ã€‚é€™é …ç ”ç©¶é—œæ³¨çš„æ ¸å¿ƒå•é¡Œæ˜¯å¦‚ä½•å…‹æœè˜¿è””ç¡«ç´ çš„å‚³éæŒ‘æˆ°ï¼Œä¸¦å¢å¼·å…¶ç”Ÿç‰©æ´»æ€§ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªå¥åº·æè´ˆè€…çš„å–®æ ¸ç´°èƒè¡ç”Ÿæ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§LPSç’°å¢ƒä¸­ï¼Œä»¥æ¨¡æ“¬ç™¼ç‚ç‹€æ…‹ã€‚ç ”ç©¶åœ˜éšŠé–‹ç™¼äº†æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ ç³–è‹·ï¼Œä¸¦æ¸¬è©¦å…¶åœ¨é€™äº›æ¨¹çªç´°èƒä¸­çš„æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨è©•ä¼°é€™äº›ç³–è‹·åœ¨æ”¹å–„è˜¿è””ç¡«ç´ çš„æº¶è§£æ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦æ–¹é¢çš„æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç³–è‹·èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™¼ç‚ï¼Œä¸¦ä¸”é€šéé‡å°p65 NF-ÎºBé€”å¾‘ä¾†å¢å¼·å…¶æ•ˆæœï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿå‚³éã€‚é€™äº›ç³–è‹·ä¿ƒé€²äº†è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ äº†IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²äº†èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…è¶Šäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„ä½œç”¨ï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·æ•ˆçš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œé€™ç‚ºæœªä¾†åœ¨åŠŸèƒ½æ€§é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•ä¸­çš„æ‡‰ç”¨æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£æ€§å·®å’Œå‚³éå›°é›£ï¼Œé™åˆ¶äº†å®ƒçš„æ‡‰ç”¨ã€‚é€™é …ç ”ç©¶å°ˆæ³¨æ–¼æ”¹å–„è˜¿è””ç¡«ç´ çš„å‚³éæ–¹å¼ï¼Œä»¥æœŸå¢å¼·å…¶åœ¨æŠ—ç™¼ç‚ç–¾ç—…ä¸­çš„ç™‚æ•ˆï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·ç®¡ç†å’Œç–¾ç—…é é˜²å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ç³–è‹·çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç™¼ç‚åæ‡‰ä¸­ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›æ–°å‹çš„è˜¿è””ç¡«ç´ ç³–è‹·å¦‚ä½•å½±éŸ¿æ¨¹çªç´°èƒçš„å…ç–«åæ‡‰ï¼Œä¸¦é€²ä¸€æ­¥æå‡å…¶åœ¨æŠ—ç™¼ç‚ç–¾ç—…ä¸­çš„æ²»ç™‚æ½›åŠ›ã€‚é€™é …ç ”ç©¶é—œæ³¨çš„æ ¸å¿ƒå•é¡Œæ˜¯å¦‚ä½•å…‹æœè˜¿è””ç¡«ç´ çš„å‚³éæŒ‘æˆ°ï¼Œä¸¦å¢å¼·å…¶ç”Ÿç‰©æ´»æ€§ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªå¥åº·æè´ˆè€…çš„å–®æ ¸ç´°èƒè¡ç”Ÿæ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§LPSç’°å¢ƒä¸­ï¼Œä»¥æ¨¡æ“¬ç™¼ç‚ç‹€æ…‹ã€‚ç ”ç©¶åœ˜éšŠé–‹ç™¼äº†æ–°å‹çš„å–®åƒ¹è˜¿è””ç¡«ç´ ç³–è‹·ï¼Œä¸¦æ¸¬è©¦å…¶åœ¨é€™äº›æ¨¹çªç´°èƒä¸­çš„æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€ç‰¹æ€§ã€‚é€™æ¨£çš„è¨­è¨ˆæ—¨åœ¨è©•ä¼°é€™äº›ç³–è‹·åœ¨æ”¹å–„è˜¿è””ç¡«ç´ çš„æº¶è§£æ€§å’Œç”Ÿç‰©åˆ©ç”¨åº¦æ–¹é¢çš„æ•ˆæœã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç³–è‹·èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™¼ç‚ï¼Œä¸¦ä¸”é€šéé‡å°p65 NF-ÎºBé€”å¾‘ä¾†å¢å¼·å…¶æ•ˆæœï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿå‚³éã€‚é€™äº›ç³–è‹·ä¿ƒé€²äº†è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ äº†IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²äº†èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…è¶Šäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„ä½œç”¨ï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·æ•ˆçš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œé€™ç‚ºæœªä¾†åœ¨åŠŸèƒ½æ€§é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•ä¸­çš„æ‡‰ç”¨æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "ğŸŒ± è˜¿è””ç¡«ç´ ï¼šæŠ—ç™¼ç‚çš„æ½›åŠ›æ–°æ˜Ÿï¼ä½ çŸ¥é“å—ï¼Ÿé€™ç¨®åŒ–åˆç‰©åœ¨å¥åº·å’Œç–¾ç—…é é˜²æ–¹é¢å¯èƒ½æœ‰é©šäººçš„æ•ˆæœï¼ä¸éï¼Œç”±æ–¼å®ƒçš„æº¶è§£æ€§å·®ï¼Œè®“å®ƒçš„æ‡‰ç”¨å—åˆ°é™åˆ¶ã€‚æœ€è¿‘çš„ç ”ç©¶å°ˆæ³¨æ–¼æ”¹å–„è˜¿è””ç¡«ç´ çš„å‚³éæ–¹å¼ï¼Œå¸Œæœ›èƒ½è®“å®ƒåœ¨æŠ—ç™¼ç‚ç–¾ç—…ä¸­ç™¼æ®æ›´å¤§çš„ä½œç”¨ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨äº†ä¸€ç¨®æ–°å‹çš„è˜¿è””ç¡«ç´ ç³–è‹·ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç™¼ç‚åæ‡‰ä¸­ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›ç³–è‹·å¦‚ä½•å½±éŸ¿å…ç–«ç³»çµ±ï¼Œä¸¦æå‡å®ƒå€‘çš„æŠ—ç™¼ç‚æ½›åŠ›ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¾†è‡ªå¥åº·æè´ˆè€…çš„æ¨¹çªç´°èƒï¼Œæ¨¡æ“¬ç™¼ç‚ç‹€æ…‹ï¼Œä¸¦æ¸¬è©¦é€™äº›æ–°å‹ç³–è‹·çš„æ•ˆæœã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç³–è‹·èƒ½æœ‰æ•ˆæŠ‘åˆ¶ç™¼ç‚ï¼Œä¸¦é€šéç‰¹å®šé€”å¾‘å¢å¼·æ•ˆæœï¼Œé‚„ä¿ƒé€²äº†å…ç–«ç³»çµ±çš„è€å—æ€§åæ‡‰ã€‚\n\nğŸ” ä¸»è¦æ”¶ç©«ï¼š\n1. è˜¿è””ç¡«ç´ ç³–è‹·å…·æœ‰è‰¯å¥½çš„æŠ—ç™¼ç‚æ•ˆæœã€‚\n2. é€™äº›ç³–è‹·èƒ½ä¿ƒé€²IL-10çš„ç”¢ç”Ÿï¼Œæœ‰åŠ©æ–¼å…ç–«èª¿ç¯€ã€‚\n3. ç ”ç©¶ç‚ºæœªä¾†çš„åŠŸèƒ½æ€§é£Ÿå“å’Œæ²»ç™‚æ–¹æ³•æä¾›äº†æ–°æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic on a light background that explains the experimental method and main findings of a study on sulforaphane glycosides. Include symbols representing broccoli or sulforaphane, simplified illustrations of human cells or immune cells, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Findings' highlighting protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™¼ç‚ç–¾ç—… Inflammatory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40533430/"
  },
  {
    "id": "41171476",
    "title_en": "Online solid-phase extraction of glucoraphanin and sulforaphane from non-edible plants based on amino acid-functionalized covalent organic frameworks.",
    "pub_date": "2025 Oct",
    "abstract_en": "Glucoraphanin (GR) and sulforaphane (SFN) are sulfur-containing compounds with diverse medicinal applications. However, cruciferous vegetables are a single source of GR and SFN, which limits development and utilization in natural resources. Herein, amino acid covalent organic framework (COF-Cys) was synthesized via click reactions and employed as an adsorbent in online solid-phase extraction (online SPE) to determine GR and SFN in non-edible plant samples. The adsorption mechanism was analyzed using density functional theory, revealing that adsorption occurred via electrostatic interaction and hydrogen bonding. Under the optimum conditions, good linearity (4-2500Â ng/mL; R<sup>2</sup>â€‰=â€‰0.9922 and 0.9968) and lower limits of detection (1.0Â ng/mL and 0.6Â ng/mL) were observed. GR and SFN were found in 18 non-edible plant samples, and recoveries of spiked samples were 89.1-109.3% with RSDâ€‰â‰¤â€‰6.9%. The COF-Cys-online SPE-UPLC-MS/MS approach displays great potential for application to detect GR and SFN in non-edible plants and provide valuable support for the development of functional products.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ å’Œå…¶å‰é©…ç‰©è³ªçš„æ½›åœ¨æ‡‰ç”¨ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœä¸­çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®è—¥ç”¨æ•ˆæœã€‚é€™äº›åŒ–åˆç‰©çš„æª¢æ¸¬å’Œåˆ©ç”¨ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„å¥åº·ç”¢å“ï¼Œé€²ä¸€æ­¥ä¿ƒé€²äººå€‘çš„å¥åº·å’Œç–¾ç—…é é˜²ã€‚ç„¶è€Œï¼Œé€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†è‡ªé’èŠ±æ¤°èœï¼Œé€™é™åˆ¶äº†å…¶åœ¨è‡ªç„¶è³‡æºä¸­çš„é–‹ç™¼å’Œæ‡‰ç”¨ï¼Œå› æ­¤å°‹æ‰¾å…¶ä»–ä¾†æºé¡¯å¾—å°¤ç‚ºé‡è¦ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æœ‰æ•ˆæª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©ä¸­çš„è˜¿è””ç¡«ç´ å’Œå…¶å‰é©…ç‰©è³ªâ€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•åˆ©ç”¨æ–°åˆæˆçš„ææ–™ä¾†æé«˜é€™äº›åŒ–åˆç‰©çš„æª¢æ¸¬æ•ˆç‡ï¼Œä¸¦å¸Œæœ›èƒ½å¤ æ“´å±•å…¶æ‡‰ç”¨ç¯„åœã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£é€™äº›åŒ–åˆç‰©çš„åˆ†ä½ˆï¼Œé‚„å¯èƒ½ä¿ƒé€²æœªä¾†åŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼ï¼Œå¾è€Œæå‡äººå€‘çš„å¥åº·æ°´å¹³ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–ï¼ˆonline SPEï¼‰çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…ä½¿ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€šééœé›»ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œå¯¦é©—é¡¯ç¤ºå‡ºè‰¯å¥½çš„ç·šæ€§ç¯„åœå’Œè¼ƒä½çš„æª¢æ¸¬é™ï¼Œé€™è¡¨æ˜è©²æ–¹æ³•å…·æœ‰å¾ˆå¥½çš„æª¢æ¸¬èƒ½åŠ›ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼Œåœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æª¢æ¸¬åˆ°äº†è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä¸”åœ¨æ·»åŠ æ¨£æœ¬çš„å›æ”¶ç‡é”åˆ°89.1%è‡³109.3%ä¹‹é–“ï¼Œæ¨™æº–åå·®ä¹Ÿä¿æŒåœ¨6.9%ä»¥ä¸‹ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–çµåˆè¶…é«˜æ•ˆæ¶²ç›¸è‰²è­œ-è³ªè­œè¯ç”¨ï¼ˆUPLC-MS/MSï¼‰çš„æ–¹æ³•åœ¨æª¢æ¸¬é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œç‚ºæœªä¾†åŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›äº†æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è˜¿è””ç¡«ç´ å’Œå…¶å‰é©…ç‰©è³ªçš„æ½›åœ¨æ‡‰ç”¨ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœä¸­çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å…·æœ‰å¤šç¨®è—¥ç”¨æ•ˆæœã€‚é€™äº›åŒ–åˆç‰©çš„æª¢æ¸¬å’Œåˆ©ç”¨ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é–‹ç™¼æ–°çš„å¥åº·ç”¢å“ï¼Œé€²ä¸€æ­¥ä¿ƒé€²äººå€‘çš„å¥åº·å’Œç–¾ç—…é é˜²ã€‚ç„¶è€Œï¼Œé€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†è‡ªé’èŠ±æ¤°èœï¼Œé€™é™åˆ¶äº†å…¶åœ¨è‡ªç„¶è³‡æºä¸­çš„é–‹ç™¼å’Œæ‡‰ç”¨ï¼Œå› æ­¤å°‹æ‰¾å…¶ä»–ä¾†æºé¡¯å¾—å°¤ç‚ºé‡è¦ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æœ‰æ•ˆæª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©ä¸­çš„è˜¿è””ç¡«ç´ å’Œå…¶å‰é©…ç‰©è³ªâ€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•åˆ©ç”¨æ–°åˆæˆçš„ææ–™ä¾†æé«˜é€™äº›åŒ–åˆç‰©çš„æª¢æ¸¬æ•ˆç‡ï¼Œä¸¦å¸Œæœ›èƒ½å¤ æ“´å±•å…¶æ‡‰ç”¨ç¯„åœã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£é€™äº›åŒ–åˆç‰©çš„åˆ†ä½ˆï¼Œé‚„å¯èƒ½ä¿ƒé€²æœªä¾†åŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼ï¼Œå¾è€Œæå‡äººå€‘çš„å¥åº·æ°´å¹³ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–ï¼ˆonline SPEï¼‰çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ã€‚ç ”ç©¶è€…ä½¿ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€šééœé›»ä½œç”¨å’Œæ°«éµé€²è¡Œçš„ã€‚åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œå¯¦é©—é¡¯ç¤ºå‡ºè‰¯å¥½çš„ç·šæ€§ç¯„åœå’Œè¼ƒä½çš„æª¢æ¸¬é™ï¼Œé€™è¡¨æ˜è©²æ–¹æ³•å…·æœ‰å¾ˆå¥½çš„æª¢æ¸¬èƒ½åŠ›ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼Œåœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æª¢æ¸¬åˆ°äº†è‘¡è„ç³–è˜¿è””ç¡«ç´ å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä¸”åœ¨æ·»åŠ æ¨£æœ¬çš„å›æ”¶ç‡é”åˆ°89.1%è‡³109.3%ä¹‹é–“ï¼Œæ¨™æº–åå·®ä¹Ÿä¿æŒåœ¨6.9%ä»¥ä¸‹ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–çµåˆè¶…é«˜æ•ˆæ¶²ç›¸è‰²è­œ-è³ªè­œè¯ç”¨ï¼ˆUPLC-MS/MSï¼‰çš„æ–¹æ³•åœ¨æª¢æ¸¬é€™äº›åŒ–åˆç‰©æ–¹é¢å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œç‚ºæœªä¾†åŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›äº†æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "fb_post": "ğŸ½ï¸ è˜¿è””ç¡«ç´ ï¼Œé€™å€‹è½èµ·ä¾†æœ‰é»é™Œç”Ÿçš„åå­—ï¼Œå…¶å¯¦è·Ÿæˆ‘å€‘çš„å¥åº·æ¯æ¯ç›¸é—œï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å’Œå®ƒçš„å‰é©…ç‰©â€”â€”è‘¡è„ç³–è˜¿è””ç¡«ç´ ï¼Œé€™äº›æˆåˆ†ä¸»è¦ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœï¼Œå°å¥åº·æœ‰è¨±å¤šæ½›åœ¨çš„å¥½è™•ã€‚ç ”ç©¶è€…å€‘é—œå¿ƒçš„æ˜¯å¦‚ä½•åœ¨éå¯é£Ÿç”¨æ¤ç‰©ä¸­æª¢æ¸¬é€™äº›åŒ–åˆç‰©ï¼Œä¸¦å¸Œæœ›èƒ½æé«˜æª¢æ¸¬æ•ˆç‡ï¼Œè®“é€™äº›å¥åº·æˆåˆ†çš„æ‡‰ç”¨æ›´å»£æ³›ã€‚  \n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘åˆæˆäº†ä¸€ç¨®æ–°ææ–™ï¼Œä¸¦æˆåŠŸç”¨å®ƒä¾†æª¢æ¸¬ä¸åŒæ¤ç‰©æ¨£æœ¬ä¸­çš„è˜¿è””ç¡«ç´ ã€‚ä»–å€‘ç™¼ç¾é€™ç¨®æ–¹æ³•ä¸åƒ…éˆæ•åº¦é«˜ï¼Œé‚„èƒ½æº–ç¢ºåœ°æª¢æ¸¬åˆ°é€™äº›åŒ–åˆç‰©çš„å­˜åœ¨ã€‚æœ€çµ‚çš„çµæœé¡¯ç¤ºï¼Œåœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©ä¸­éƒ½æ‰¾åˆ°äº†é€™äº›å¥åº·æˆåˆ†ï¼Œé€™ç‚ºæœªä¾†é–‹ç™¼åŠŸèƒ½æ€§ç”¢å“æä¾›äº†é‡è¦çš„æ”¯æŒï¼  \n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»å¯ä»¥å¸¶èµ°ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å¥åº·ï¼Œä¸»è¦ä¾†è‡ªé’èŠ±æ¤°èœç­‰è”¬èœã€‚  \n2. ç ”ç©¶è€…å€‘ç™¼å±•äº†æ–°æ–¹æ³•ï¼Œå¯ä»¥æœ‰æ•ˆæª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©ä¸­çš„è˜¿è””ç¡«ç´ ã€‚  \n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†å¥åº·ç”¢å“çš„é–‹ç™¼æä¾›äº†æ–°æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of a study on glucoraphanin and its derivative, sulforaphane. Use a light background with soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans or cells, and arrows or flow lines indicating the experimental steps. Include a section labeled 'Main Results' that summarizes the findings, such as detection of these compounds in non-edible plants and their potential health benefits.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41171476/"
  },
  {
    "id": "41246347",
    "title_en": "Sulforaphane in cancer precision medicine: from biosynthetic origins to multiscale mechanisms and clinical translation.",
    "pub_date": "2025",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from glucoraphanin in cruciferous vegetables, has evolved from a dietary antioxidant to a sophisticated multi-target agent in oncology. While its roles in nuclear factor erythroid 2-related factor 2 (Nrf2) activation and histone deacetylase (HDAC) inhibition are well-established, this review provides a novel synthesis by integrating disparate research scales-a multiscale perspective that spans from the genetic and epigenetic regulation of glucoraphanin biosynthesis in plants to SFN's recently elucidated effects on ferroptosis, cancer stem cells (CSCs), and the tumor immune microenvironment in humans. We critically evaluate how key host factors, such as gut microbiota composition and glutathione S-transferase (GST) polymorphisms, dictate SFN bioavailability and efficacy, thereby framing a precision nutrition paradigm for its application. Furthermore, we move beyond generic claims of synergy to detail SFN's specific mechanisms in enhancing conventional therapies, including the modulation of drug transporters and immune checkpoints. By integrating advances from plant biochemistry to molecular oncology, this review establishes an updated and mechanism-oriented framework for realizing SFN's compelling potential in cancer prevention and therapy through a precision medicine approach.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºä¸åƒ…åƒ…æ˜¯ä¸€ç¨®é£²é£ŸæŠ—æ°§åŒ–åŠ‘ï¼Œè€Œæ˜¯å°æŠ—ç™Œç—‡çš„å¤šé‡é¶å‘è—¥ç‰©ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„ç™Œç—‡é é˜²å’Œæ²»ç™‚æ–¹æ³•ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶æŒ‡å‡ºè˜¿è””ç¡«ç´ åœ¨èª¿ç¯€è…«ç˜¤å…ç–«å¾®ç’°å¢ƒå’Œç™Œç—‡å¹¹ç´°èƒæ–¹é¢çš„æ½›åŠ›ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ çš„å¤šé‡ä½œç”¨åŠå…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚ç ”ç©¶è€…å€‘æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·ã€è…«ç˜¤å¾®ç’°å¢ƒä»¥åŠç›¸é—œçš„åŸºå› å’Œè¡¨è§€éºå‚³èª¿æ§ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦åŠå…¶åœ¨ä¸åŒäººç¾¤ä¸­çš„æ•ˆæœï¼Œä¸¦ç‚ºå€‹æ€§åŒ–ç‡Ÿé¤Šæä¾›ä¾æ“šã€‚",
    "para3": "ç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘æ¡ç”¨äº†å¤šç¨®ç ”ç©¶æ–¹æ³•ï¼Œå¾æ¤ç‰©çš„åŸºå› å’Œè¡¨è§€éºå‚³èª¿æ§é–‹å§‹ï¼Œé€æ­¥æ¢è¨è˜¿è””ç¡«ç´ å°äººé«”çš„å½±éŸ¿ã€‚ä»–å€‘åˆ†æäº†è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆä»¥åŠå€‹é«”åŸºå› å¤šæ¨£æ€§å¦‚ä½•å½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦å’Œç™‚æ•ˆã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†è˜¿è””ç¡«ç´ å¦‚ä½•å¢å¼·å‚³çµ±æ²»ç™‚çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»çš„èª¿ç¯€æ–¹é¢ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸åƒ…é™æ–¼æŠ—æ°§åŒ–ï¼Œé‚„åŒ…æ‹¬èª¿ç¯€è…«ç˜¤å¾®ç’°å¢ƒå’Œå½±éŸ¿ç™Œç—‡å¹¹ç´°èƒçš„è¡Œç‚ºã€‚é›–ç„¶é€™äº›çµæœé¡¯ç¤ºäº†è˜¿è””ç¡«ç´ çš„å¤šé‡æ©Ÿåˆ¶ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä»¥ç¢ºå®šå…¶åœ¨è‡¨åºŠæ‡‰ç”¨ä¸­çš„å…·é«”æ•ˆæœå’Œå®‰å…¨æ€§ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºä¸åƒ…åƒ…æ˜¯ä¸€ç¨®é£²é£ŸæŠ—æ°§åŒ–åŠ‘ï¼Œè€Œæ˜¯å°æŠ—ç™Œç—‡çš„å¤šé‡é¶å‘è—¥ç‰©ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„ç™Œç—‡é é˜²å’Œæ²»ç™‚æ–¹æ³•ã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶æŒ‡å‡ºè˜¿è””ç¡«ç´ åœ¨èª¿ç¯€è…«ç˜¤å…ç–«å¾®ç’°å¢ƒå’Œç™Œç—‡å¹¹ç´°èƒæ–¹é¢çš„æ½›åŠ›ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ çš„å¤šé‡ä½œç”¨åŠå…¶åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚ç ”ç©¶è€…å€‘æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·ã€è…«ç˜¤å¾®ç’°å¢ƒä»¥åŠç›¸é—œçš„åŸºå› å’Œè¡¨è§€éºå‚³èª¿æ§ã€‚é€éé€™äº›ç ”ç©¶ï¼Œç§‘å­¸å®¶å¸Œæœ›èƒ½å¤ æ›´æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦åŠå…¶åœ¨ä¸åŒäººç¾¤ä¸­çš„æ•ˆæœï¼Œä¸¦ç‚ºå€‹æ€§åŒ–ç‡Ÿé¤Šæä¾›ä¾æ“šã€‚\n\nç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘æ¡ç”¨äº†å¤šç¨®ç ”ç©¶æ–¹æ³•ï¼Œå¾æ¤ç‰©çš„åŸºå› å’Œè¡¨è§€éºå‚³èª¿æ§é–‹å§‹ï¼Œé€æ­¥æ¢è¨è˜¿è””ç¡«ç´ å°äººé«”çš„å½±éŸ¿ã€‚ä»–å€‘åˆ†æäº†è…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆä»¥åŠå€‹é«”åŸºå› å¤šæ¨£æ€§å¦‚ä½•å½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦å’Œç™‚æ•ˆã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„è©•ä¼°äº†è˜¿è””ç¡«ç´ å¦‚ä½•å¢å¼·å‚³çµ±æ²»ç™‚çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»çš„èª¿ç¯€æ–¹é¢ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨ä¸åƒ…é™æ–¼æŠ—æ°§åŒ–ï¼Œé‚„åŒ…æ‹¬èª¿ç¯€è…«ç˜¤å¾®ç’°å¢ƒå’Œå½±éŸ¿ç™Œç—‡å¹¹ç´°èƒçš„è¡Œç‚ºã€‚é›–ç„¶é€™äº›çµæœé¡¯ç¤ºäº†è˜¿è””ç¡«ç´ çš„å¤šé‡æ©Ÿåˆ¶ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä»¥ç¢ºå®šå…¶åœ¨è‡¨åºŠæ‡‰ç”¨ä¸­çš„å…·é«”æ•ˆæœå’Œå®‰å…¨æ€§ã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é¤ç›¤ä¸Šç«Ÿç„¶éš±è—è‘—å°æŠ—ç™Œç—‡çš„æ½›åŠ›ï¼æœ€è¿‘ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œä¾†è‡ªåå­—èŠ±ç§‘è”¬èœçš„è˜¿è””ç¡«ç´ ä¸åƒ…æ˜¯å€‹æŠ—æ°§åŒ–åŠ‘ï¼Œé‚„å¯èƒ½æˆç‚ºå°æŠ—ç™Œç—‡çš„å¤šé‡é¶å‘è—¥ç‰©ã€‚ç ”ç©¶è€…æ·±å…¥æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·åŠè…«ç˜¤å¾®ç’°å¢ƒï¼Œç”šè‡³é‚„åˆ†æäº†è…¸é“å¾®ç”Ÿç‰©çµ„çš„å½±éŸ¿ã€‚é€™äº›ç ”ç©¶ä¸åƒ…è®“æˆ‘å€‘æ›´äº†è§£è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©åˆ©ç”¨åº¦ï¼Œé‚„ç‚ºå€‹æ€§åŒ–ç‡Ÿé¤Šæä¾›äº†æ–°çš„æ€è·¯ã€‚  \n\nç§‘å­¸å®¶å€‘ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†ç ”ç©¶è˜¿è””ç¡«ç´ çš„å½±éŸ¿ï¼Œä¸¦è§€å¯Ÿåˆ°å®ƒå¯èƒ½å¢å¼·å‚³çµ±æ²»ç™‚çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨èª¿ç¯€å…ç–«ç³»çµ±æ–¹é¢ã€‚é›–ç„¶é€™äº›çµæœä»¤äººæŒ¯å¥®ï¼Œä½†ä»éœ€æ›´å¤šç ”ç©¶ä¾†ç¢ºå®šå®ƒçš„å…·é«”æ•ˆæœå’Œå®‰å…¨æ€§ã€‚  \n\nğŸ” è®€è€…å¯ä»¥å¸¶èµ°çš„é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå…·æœ‰æŠ—ç™Œæ½›åŠ›ã€‚  \n2. å®ƒèƒ½èª¿ç¯€è…«ç˜¤å¾®ç’°å¢ƒï¼Œå½±éŸ¿ç™Œç´°èƒçš„è¡Œç‚ºã€‚  \n3. é€²ä¸€æ­¥ç ”ç©¶å°‡å¹«åŠ©æˆ‘å€‘äº†è§£å…¶è‡¨åºŠæ‡‰ç”¨çš„æ•ˆæœå’Œå®‰å…¨æ€§ã€‚",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main findings of a study on sulforaphane from cruciferous vegetables. Include symbols representing broccoli and sulforaphane, simplified illustrations of experimental subjects like humans or cells, arrows or flow lines indicating the steps of the experiment, and a section highlighting the main results, such as protective effects or changes observed. Use a light background with soft colors to keep it visually appealing and easy to understand.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41246347/"
  },
  {
    "id": "41056875",
    "title_en": "Sulforaphane inhibits gastric cancer progression by regulating the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis.",
    "pub_date": "2025 Oct",
    "abstract_en": "Sulforaphane (SFN) plays a vital role in many types of cancer as a natural extract from plants. However, whether SFN can inhibit gastric carcinogenesis by regulating the lncRNA-miRNA-mRNA axis is unclear. In the current work, the significantly differentially expressed lncRNA PSMB8AS1 was obtained by performing high-throughput sequencing of gastric cancer cells treated with SFN. The qRT-PCR assay results confirmed the inhibitory effect of SFN on PSM8AS1. Subsequently, using gastric cancer data from TCGA and 11 pairs of clinical samples from gastric and paracancerous tissues, we found that PSMB8-AS1 was upregulated in gastric cancer, and high expression of PSMB8-AS1 was associated with low survival of patients with gastric cancer. MTT, cell colony formation, scratch healing, flow cytometry, and qRT-PCR assays showed that the knockdown of PSMB8-AS1 significantly reduced the proliferation and migration of gastric cancer cells as well as promoted apoptosis. Dual luciferase reporter gene and RNA immunoprecipitation (RIP) assay confirmed that PSMB8-AS1 can function as the molecular sponge for miR-888-5p. Meanwhile, bioinformatics analysis and dual-luciferase reporter gene assay showed that miR-888-5p regulates SLC4A7. Overexpression of miR-888-5p or knockdown of SLC4A7 reduced the proliferation and migration of gastric cancer cells. In addition, rescue experiments confirmed that the inhibitory effects of the knockdown of PSMB8-AS1 or the knockdown of SLC4A7 on the proliferation and migration of gastric cancer cells could be reversed by miR-888-5p inhibitor treatment. Subcutaneous tumor formation experiments in nude mice demonstrated that the tumor volume of nude mice transplanted with PSMB8-AS1-knockdown gastric cancer cells was significantly reduced compared with that of the control group. Transcription factors can usually bind to the promoter regions of lncRNAs and regulate the transcription of lncRNAs. We demonstrated through website prediction and experiments that SFN can inhibit the level of PSMB8-AS1 by regulating the transcription factor YY1. These results suggest that SFN inhibits gastric cancer growth through the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis. Therefore, SFN might be a promising therapeutical agent for GC prevention and therapy.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é˜²æ²»æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åŸºå› å’Œåˆ†å­è·¯å¾‘ï¼Œä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½èƒƒç™Œçš„é¢¨éšªï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚é›–ç„¶é€™äº›çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªè˜¿è””ç¡«ç´ åœ¨è‡¨åºŠä¸Šçš„å¯¦éš›æ•ˆæœã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½é€éèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰-å¾®å°RNAï¼ˆmiRNAï¼‰-ä¿¡ä½¿RNAï¼ˆmRNAï¼‰è»¸ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼ç”Ÿã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯ä¸€ç¨®åç‚ºPSMB8-AS1çš„lncRNAï¼Œä¸¦è©¦åœ–äº†è§£å…¶åœ¨èƒƒç™Œç´°èƒä¸­çš„è¡¨ç¾åŠå…¶å°ç™Œç´°èƒå¢æ®–å’Œè½‰ç§»çš„å½±éŸ¿ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨èƒƒç™Œé˜²æ²»ä¸­çš„æ½›åœ¨æ©Ÿåˆ¶ã€‚",
    "para3": "ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨é«˜é€šé‡æ¸¬åºæŠ€è¡“åˆ†æäº†ç¶“éè˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒï¼Œç™¼ç¾PSMB8-AS1çš„è¡¨é”é¡¯è‘—ä¸åŒã€‚æ¥è‘—ï¼Œç ”ç©¶è€…åˆ©ç”¨qRT-PCRç­‰æ–¹æ³•ç¢ºèªäº†è˜¿è””ç¡«ç´ å°PSMB8-AS1çš„æŠ‘åˆ¶ä½œç”¨ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åˆ†æäº†ä¾†è‡ªTCGAçš„èƒƒç™Œæ•¸æ“šåŠ11å°è‡¨åºŠæ¨£æœ¬ï¼Œæ¢è¨PSMB8-AS1åœ¨èƒƒç™Œä¸­çš„è¡¨ç¾åŠå…¶èˆ‡æ‚£è€…ç”Ÿå­˜ç‡çš„é—œè¯ã€‚é€™äº›å¯¦é©—è¨­è¨ˆæ—¨åœ¨æ·±å…¥äº†è§£PSMB8-AS1åœ¨èƒƒç™Œä¸­çš„è§’è‰²ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒPSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸”å…¶é«˜è¡¨é”èˆ‡æ‚£è€…çš„ä½ç”Ÿå­˜ç‡ç›¸é—œã€‚é€²ä¸€æ­¥çš„å¯¦é©—çµæœé¡¯ç¤ºï¼ŒæŠ‘åˆ¶PSMB8-AS1èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒPSMB8-AS1å¯ä»¥ä½œç‚ºmiR-888-5pçš„åˆ†å­æµ·ç¶¿ï¼Œä¸¦ä¸”miR-888-5pèƒ½èª¿ç¯€SLC4A7çš„è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éYY1/PSMB8-AS1/miR-888-5p/SLC4A7é€™ä¸€è»¸ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºæ½›åœ¨æ²»ç™‚åŠ‘çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é˜²æ²»æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åŸºå› å’Œåˆ†å­è·¯å¾‘ï¼Œä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é’èŠ±æ¤°èœç­‰å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½èƒƒç™Œçš„é¢¨éšªï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚é›–ç„¶é€™äº›çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªè˜¿è””ç¡«ç´ åœ¨è‡¨åºŠä¸Šçš„å¯¦éš›æ•ˆæœã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½é€éèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰-å¾®å°RNAï¼ˆmiRNAï¼‰-ä¿¡ä½¿RNAï¼ˆmRNAï¼‰è»¸ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼ç”Ÿã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯ä¸€ç¨®åç‚ºPSMB8-AS1çš„lncRNAï¼Œä¸¦è©¦åœ–äº†è§£å…¶åœ¨èƒƒç™Œç´°èƒä¸­çš„è¡¨ç¾åŠå…¶å°ç™Œç´°èƒå¢æ®–å’Œè½‰ç§»çš„å½±éŸ¿ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨èƒƒç™Œé˜²æ²»ä¸­çš„æ½›åœ¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨é«˜é€šé‡æ¸¬åºæŠ€è¡“åˆ†æäº†ç¶“éè˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒï¼Œç™¼ç¾PSMB8-AS1çš„è¡¨é”é¡¯è‘—ä¸åŒã€‚æ¥è‘—ï¼Œç ”ç©¶è€…åˆ©ç”¨qRT-PCRç­‰æ–¹æ³•ç¢ºèªäº†è˜¿è””ç¡«ç´ å°PSMB8-AS1çš„æŠ‘åˆ¶ä½œç”¨ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åˆ†æäº†ä¾†è‡ªTCGAçš„èƒƒç™Œæ•¸æ“šåŠ11å°è‡¨åºŠæ¨£æœ¬ï¼Œæ¢è¨PSMB8-AS1åœ¨èƒƒç™Œä¸­çš„è¡¨ç¾åŠå…¶èˆ‡æ‚£è€…ç”Ÿå­˜ç‡çš„é—œè¯ã€‚é€™äº›å¯¦é©—è¨­è¨ˆæ—¨åœ¨æ·±å…¥äº†è§£PSMB8-AS1åœ¨èƒƒç™Œä¸­çš„è§’è‰²ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒPSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸”å…¶é«˜è¡¨é”èˆ‡æ‚£è€…çš„ä½ç”Ÿå­˜ç‡ç›¸é—œã€‚é€²ä¸€æ­¥çš„å¯¦é©—çµæœé¡¯ç¤ºï¼ŒæŠ‘åˆ¶PSMB8-AS1èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒPSMB8-AS1å¯ä»¥ä½œç‚ºmiR-888-5pçš„åˆ†å­æµ·ç¶¿ï¼Œä¸¦ä¸”miR-888-5pèƒ½èª¿ç¯€SLC4A7çš„è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éYY1/PSMB8-AS1/miR-888-5p/SLC4A7é€™ä¸€è»¸ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºæ½›åœ¨æ²»ç™‚åŠ‘çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "ğŸ½ï¸ å¤§å®¶çŸ¥é“å—ï¼Ÿåƒé’èŠ±æ¤°èœä¸åƒ…å¥½åƒï¼Œé‚„å¯èƒ½å°æŠ—èƒƒç™Œï¼é€™é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œç™¼ç¾å®ƒå¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åŸºå› ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚ç ”ç©¶è€…å°ˆæ³¨æ–¼ä¸€ç¨®åç‚ºPSMB8-AS1çš„é•·éˆéç·¨ç¢¼RNAï¼Œè©¦åœ–äº†è§£å®ƒåœ¨èƒƒç™Œç´°èƒä¸­çš„è¡¨ç¾åŠå°ç™Œç´°èƒçš„å½±éŸ¿ã€‚  \n\nç ”ç©¶ä¸­ï¼Œç§‘å­¸å®¶å€‘ä½¿ç”¨é«˜é€šé‡æ¸¬åºæŠ€è¡“åˆ†æäº†ç¶“éè˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒï¼Œç™¼ç¾PSMB8-AS1çš„è¡¨é”æœ‰é¡¯è‘—è®ŠåŒ–ï¼Œä¸¦ç¢ºèªäº†è˜¿è””ç¡«ç´ å°å…¶çš„æŠ‘åˆ¶ä½œç”¨ã€‚é€²ä¸€æ­¥çš„å¯¦é©—çµæœé¡¯ç¤ºï¼ŒPSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸”é«˜è¡¨é”èˆ‡æ‚£è€…çš„ä½ç”Ÿå­˜ç‡ç›¸é—œã€‚  \n\næ‰€ä»¥ï¼Œé€™è£¡æœ‰å¹¾å€‹é‡é»å¯ä»¥å¸¶èµ°ï¼š  \n1ï¸âƒ£ å¢åŠ å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼ˆåƒæ˜¯é’èŠ±æ¤°èœï¼‰å¯èƒ½æœ‰åŠ©æ–¼é™ä½èƒƒç™Œé¢¨éšªã€‚  \n2ï¸âƒ£ PSMB8-AS1åœ¨èƒƒç™Œç´°èƒä¸­çš„è¡¨ç¾å¯èƒ½å½±éŸ¿ç™Œç´°èƒçš„å¢æ®–å’Œè½‰ç§»ã€‚  \n3ï¸âƒ£ è˜¿è””ç¡«ç´ çš„æ½›åœ¨æ©Ÿåˆ¶å€¼å¾—é€²ä¸€æ­¥ç ”ç©¶ï¼Œæœªä¾†æˆ–è¨±èƒ½æˆç‚ºèƒƒç™Œçš„æ²»ç™‚æ–°æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic on a light background that explains the experimental methods and main results of a study on sulforaphane and its effects on gastric cancer. Include symbols for broccoli or sulforaphane, simplified representations of experimental subjects like cells or humans, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting protective effects or changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41056875/"
  },
  {
    "id": "41235157",
    "title_en": "Novel magnolol-sulforaphane hybrids as potent antitumor agents: synthesis and biological characterization.",
    "pub_date": "2025 Oct",
    "abstract_en": "The natural product-based hybrid strategy is a promising approach for innovative drug discovery. Leveraging the privileged architecture of sulforaphane-a prominent anticancer natural product-we engineered a novel library of magnolol-sulforaphane molecular hybrids for antitumor evaluation through a concise synthetic strategy for the pharmacophore of sulforaphane (SFN), culminating in the identification of CTNPC8 as a promising anticancer compound. Notably, CTNPC8 not only displays exceptional broad-spectrum anticancer activity with potency surpassing both parent compounds and cisplatin, but also exhibits potent <i>in vitro</i> efficacy against the challenging nasopharyngeal carcinoma (NPC) cell model. Mechanistic studies in nasopharyngeal carcinoma models reveal that CTNPC8 triggers mitochondrial-mediated apoptosis through regulating ROS generation and induces G<sub>2</sub>/M phase arrest. Transcriptomic profiling coupled with validation experiments reveals that CTNPC8 exerts its anti-NPC activity primarily by modulating the Akt/mTOR pathway. The present study provided a valuable strategy for discovering new antitumor agents through hybrid molecular design, nominating CTNPC8 as a promising hit compound for anti-NPC research.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æœ‰è¶£çš„è§€é»ï¼Œé¡¯ç¤ºåˆ©ç”¨å¤©ç„¶ç”¢ç‰©çš„æ··åˆç­–ç•¥ä¾†é–‹ç™¼æ–°å‹æŠ—ç™Œè—¥ç‰©å¯èƒ½æœƒå°å¥åº·å’Œç–¾ç—…é é˜²å¸¶ä¾†æ–°çš„å•Ÿç¤ºã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶ä¸­æåˆ°çš„CTNPC8åŒ–åˆç‰©åœ¨æŠ—ç™Œæ´»æ€§ä¸Šè¡¨ç¾å‡ºè‰²ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚é€éé€™ç¨®æ–¹æ³•ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½å¤ æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ï¼Œå¹«åŠ©å°æŠ—å„ç¨®ç™Œç—‡ï¼Œå°¤å…¶æ˜¯é‚£äº›ç›®å‰æ²»ç™‚é¸æ“‡æœ‰é™çš„ç™Œç—‡é¡å‹ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼ä¸€ç¨®æ–°å‹çš„æŠ—ç™ŒåŒ–åˆç‰©ï¼Œç‰¹åˆ¥é‡å°é¼»å’½ç™Œï¼ˆNPCï¼‰ã€‚ç ”ç©¶è€…å€‘é—œæ³¨å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ é€™ä¸€å¤©ç„¶æŠ—ç™Œæˆåˆ†ï¼Œçµåˆå…¶ä»–åŒ–åˆç‰©ï¼Œå‰µé€ å‡ºå…·æœ‰æ›´å¼·æŠ—ç™Œæ•ˆæœçš„æ–°åˆ†å­ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£æŠ—ç™Œæ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ç‚ºç™Œç—‡æ‚£è€…æä¾›æ–°çš„æ²»ç™‚é¸æ“‡ï¼Œå°¤å…¶æ˜¯é‡å°é›£ä»¥æ²»ç™‚çš„ç™Œç—‡ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å€‘è¨­è¨ˆä¸¦åˆæˆäº†ä¸€ç³»åˆ—ä»¥è˜¿è””ç¡«ç´ ç‚ºåŸºç¤çš„åˆ†å­æ··åˆç‰©ï¼Œä¸¦å°å…¶æŠ—è…«ç˜¤æ´»æ€§é€²è¡Œè©•ä¼°ã€‚å¯¦é©—ä¸»è¦é‡å°é¼»å’½ç™Œç´°èƒæ¨¡å‹é€²è¡Œï¼Œé€éä¸€ç³»åˆ—çš„æ©Ÿåˆ¶ç ”ç©¶ï¼Œæ¢ç´¢CTNPC8çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›å¯¦é©—ä¸åƒ…åŒ…æ‹¬ç´°èƒå¯¦é©—ï¼Œé‚„æ¶‰åŠè½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£CTNPC8å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ä¿¡è™Ÿå‚³éè·¯å¾‘ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼ŒCTNPC8åœ¨æŠ—é¼»å’½ç™Œæ–¹é¢å…·æœ‰é¡¯è‘—çš„æ´»æ€§ï¼Œä¸¦ä¸”å…¶æ•ˆæœè¶…éäº†åŸå§‹çš„çˆ¶åŒ–åˆç‰©å’Œé †é‰‘ã€‚CTNPC8èƒ½å¤ é€šéèª¿ç¯€æ´»æ€§æ°§ï¼ˆROSï¼‰çš„ç”Ÿæˆä¾†èª˜å°ç·šç²’é«”ä»‹å°çš„ç´°èƒå‡‹äº¡ï¼Œä¸¦ä½¿ç´°èƒé€±æœŸåœæ»¯åœ¨G2/MæœŸã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾CTNPC8ä¸»è¦é€šéèª¿ç¯€Akt/mTORé€šè·¯ä¾†ç™¼æ®å…¶æŠ—é¼»å’½ç™Œçš„ä½œç”¨ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†é–‹ç™¼æ–°å‹æŠ—è…«ç˜¤è—¥ç‰©æä¾›äº†é‡è¦çš„åŸºç¤ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€å€‹æœ‰è¶£çš„è§€é»ï¼Œé¡¯ç¤ºåˆ©ç”¨å¤©ç„¶ç”¢ç‰©çš„æ··åˆç­–ç•¥ä¾†é–‹ç™¼æ–°å‹æŠ—ç™Œè—¥ç‰©å¯èƒ½æœƒå°å¥åº·å’Œç–¾ç—…é é˜²å¸¶ä¾†æ–°çš„å•Ÿç¤ºã€‚ç‰¹åˆ¥æ˜¯ï¼Œç ”ç©¶ä¸­æåˆ°çš„CTNPC8åŒ–åˆç‰©åœ¨æŠ—ç™Œæ´»æ€§ä¸Šè¡¨ç¾å‡ºè‰²ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚é€éé€™ç¨®æ–¹æ³•ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½å¤ æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ï¼Œå¹«åŠ©å°æŠ—å„ç¨®ç™Œç—‡ï¼Œå°¤å…¶æ˜¯é‚£äº›ç›®å‰æ²»ç™‚é¸æ“‡æœ‰é™çš„ç™Œç—‡é¡å‹ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼ä¸€ç¨®æ–°å‹çš„æŠ—ç™ŒåŒ–åˆç‰©ï¼Œç‰¹åˆ¥é‡å°é¼»å’½ç™Œï¼ˆNPCï¼‰ã€‚ç ”ç©¶è€…å€‘é—œæ³¨å¦‚ä½•åˆ©ç”¨è˜¿è””ç¡«ç´ é€™ä¸€å¤©ç„¶æŠ—ç™Œæˆåˆ†ï¼Œçµåˆå…¶ä»–åŒ–åˆç‰©ï¼Œå‰µé€ å‡ºå…·æœ‰æ›´å¼·æŠ—ç™Œæ•ˆæœçš„æ–°åˆ†å­ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£æŠ—ç™Œæ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ç‚ºç™Œç—‡æ‚£è€…æä¾›æ–°çš„æ²»ç™‚é¸æ“‡ï¼Œå°¤å…¶æ˜¯é‡å°é›£ä»¥æ²»ç™‚çš„ç™Œç—‡ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å€‘è¨­è¨ˆä¸¦åˆæˆäº†ä¸€ç³»åˆ—ä»¥è˜¿è””ç¡«ç´ ç‚ºåŸºç¤çš„åˆ†å­æ··åˆç‰©ï¼Œä¸¦å°å…¶æŠ—è…«ç˜¤æ´»æ€§é€²è¡Œè©•ä¼°ã€‚å¯¦é©—ä¸»è¦é‡å°é¼»å’½ç™Œç´°èƒæ¨¡å‹é€²è¡Œï¼Œé€éä¸€ç³»åˆ—çš„æ©Ÿåˆ¶ç ”ç©¶ï¼Œæ¢ç´¢CTNPC8çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›å¯¦é©—ä¸åƒ…åŒ…æ‹¬ç´°èƒå¯¦é©—ï¼Œé‚„æ¶‰åŠè½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£CTNPC8å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„ä¿¡è™Ÿå‚³éè·¯å¾‘ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼ŒCTNPC8åœ¨æŠ—é¼»å’½ç™Œæ–¹é¢å…·æœ‰é¡¯è‘—çš„æ´»æ€§ï¼Œä¸¦ä¸”å…¶æ•ˆæœè¶…éäº†åŸå§‹çš„çˆ¶åŒ–åˆç‰©å’Œé †é‰‘ã€‚CTNPC8èƒ½å¤ é€šéèª¿ç¯€æ´»æ€§æ°§ï¼ˆROSï¼‰çš„ç”Ÿæˆä¾†èª˜å°ç·šç²’é«”ä»‹å°çš„ç´°èƒå‡‹äº¡ï¼Œä¸¦ä½¿ç´°èƒé€±æœŸåœæ»¯åœ¨G2/MæœŸã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾CTNPC8ä¸»è¦é€šéèª¿ç¯€Akt/mTORé€šè·¯ä¾†ç™¼æ®å…¶æŠ—é¼»å’½ç™Œçš„ä½œç”¨ã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†é–‹ç™¼æ–°å‹æŠ—è…«ç˜¤è—¥ç‰©æä¾›äº†é‡è¦çš„åŸºç¤ã€‚",
    "fb_post": "ğŸŒ± ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­ç«Ÿç„¶æ½›è—è‘—æŠ—ç™Œçš„ç§˜å¯†æ­¦å™¨ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶è®“äººè€³ç›®ä¸€æ–°ï¼Œç§‘å­¸å®¶å€‘æ­£åœ¨åˆ©ç”¨ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶æˆåˆ†ï¼Œä¾†é–‹ç™¼æ–°å‹çš„æŠ—ç™Œè—¥ç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°é›£ä»¥æ²»ç™‚çš„é¼»å’½ç™Œï¼ˆNPCï¼‰ã€‚\n\né€™é …ç ”ç©¶çš„é‡é»æ˜¯å‰µé€ å‡ºä¸€ç¨®æ–°çš„åŒ–åˆç‰©CTNPC8ï¼Œç ”ç©¶åœ˜éšŠå°‡è˜¿è””ç¡«ç´ å’Œå…¶ä»–æˆåˆ†æ··åˆï¼Œå°‹æ‰¾æ›´å¼·çš„æŠ—ç™Œæ•ˆæœã€‚ä»–å€‘è¨­è¨ˆäº†ä¸€ç³»åˆ—å¯¦é©—ï¼Œä¸»è¦é‡å°é¼»å’½ç™Œç´°èƒé€²è¡Œæ¸¬è©¦ï¼Œä¸¦æ¢ç´¢CTNPC8çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nçµæœé¡¯ç¤ºï¼ŒCTNPC8åœ¨å°æŠ—é¼»å’½ç™Œæ–¹é¢çš„æ•ˆæœéå¸¸é¡¯è‘—ï¼Œç”šè‡³è¶…éäº†ä¸€äº›å‚³çµ±çš„åŒ–ç™‚è—¥ç‰©ï¼å®ƒèƒ½å¤ é€éèª¿ç¯€ç´°èƒå…§çš„æ´»æ€§æ°§ä¾†èª˜å°ç´°èƒæ­»äº¡ï¼Œä¸¦å½±éŸ¿ç´°èƒçš„é€±æœŸï¼Œè®“ç™Œç´°èƒç„¡æ³•ç¹¼çºŒå¢é•·ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»è®“ä½ å¸¶èµ°ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æ˜¯æŠ—ç™Œçš„å¤©ç„¶æˆåˆ†ã€‚\n2. CTNPC8åœ¨æŠ—é¼»å’½ç™Œçš„æ•ˆæœè¶…éå‚³çµ±è—¥ç‰©ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental process and main results of a study on a compound called CTNPC8, derived from natural ingredients like sulforaphane (found in broccoli). Include simplified illustrations of experimental subjects such as cancer cells, arrows or flow lines to indicate the experimental steps, and a section highlighting the main results, such as protective effects or changes observed. Use a light background with soft colors for a scientific and informative look.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "é¼»å’½ç™Œ Nasopharyngeal Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41235157/"
  },
  {
    "id": "41181585",
    "title_en": "Sulforaphane alleviates hepatocyte pyroptosis via activating Nrf2-HO-1 signaling during septic acute liver injury.",
    "pub_date": "2025",
    "abstract_en": "Acute liver injury (ALI) caused by sepsis is a fatal disease with a high mortality rate and poor prognosis. Sulforaphane (SFN) is a natural isothiocyanate that has robust antioxidant and anti-inflammatory properties. The aim of this study was to identify the pharmacological effects and therapeutic mechanisms of SFN in lipopolysaccharide (LPS)-induced ALI. The role of SFN in ALI was investigated using a mouse model of LPS-induced ALI. Briefly, eighteen mice were divided into three groups: control, LPS, and LPS + SFN, which were intraperitoneally injected for 2Â days before LPS treatment. 24Â h after the LPS injection, blood and liver tissues were collected for further analysis. The hematoxylin and eosin (HE) staining showed a lot of visible necrosis areas, inflammatory cell infiltration, and congestion in liver. Meanwhile, Ly6G and F4/80 staining showed increased infiltration of neutrophils and macrophages in liver, these results indicated that LPS induced sever ALI. As inflammatory response plays a vital role in the pathogenesis of LPS-induced ALI, we detected the occurrence of pyroptosis in liver by ribonucleic acid (RNA) sequencing. The results showed that pyroptosis was significantly promoted by LPS, as indicated by gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses, revealing the activation of pyroptosis, interleukin (IL)-1 production, IL-18 production, and inflammatory signaling pathways. Then, we explored the effect of SFN on LPS-induced ALI. The results showed that SFN obviously reduced LPS-induced plasma alanine aminotransferase and aspartate aminotransferase level, pathological injuries and TdT-mediated dUTP nick-end labeling (TUNEL) positive cells, indicating protective effect of SFN on ALI. Furthermore, SFN also showed robust effect on LPS-induced inflammatory response in liver, as reflected by suppressing the infiltration of neutrophils and macrophages, and downregulating mRNA levels of C-X-C motif chemokine ligand 9, IL-6, monocyte chemoattractant protein-1, and tumor necrosis factor-Î± in liver of LPS treated mice. Furthermore, SFN blocked hepatocyte pyroptosis, and suppressed plasma IL-1Î² and IL-18 levels of LPS treated mice. Mechanistically, SFN selectively activated nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling to mediate pyroptotic cell death. SFN also reversed the inhibited superoxide dismutase activity and induced malondialdehyde content in liver of LPS exposed mice. SFN ameliorated liver injury and inflammation during LPS-induced ALI by suppressing hepatocyte pyroptosis via the activation of Nrf2/HO-1 signaling. This study provides new evidence for the potential treatment of ALI with SFN.",
    "para1": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸ä½³ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨é€™ç¨®æƒ…æ³ä¸‹çš„æ½›åœ¨ç™‚æ•ˆï¼Œå¯èƒ½ç‚ºé é˜²å’Œæ²»ç™‚æ€¥æ€§è‚æå‚·æä¾›æ–°çš„æ€è·¯ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶åŒ–åˆç‰©ï¼Œå…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ç‰¹æ€§ï¼Œé€™ä½¿å¾—å®ƒåœ¨é¢å°è‚è‡Ÿæå‚·æ™‚ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•ç‚ç—‡åæ‡‰å’Œç´°èƒæå‚·ï¼Œå¾è€Œæ”¹å–„ç—…æƒ…ã€‚é€™äº›ç™¼ç¾æœ‰åŠ©æ–¼æˆ‘å€‘ç†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†å°æŠ—èˆ‡æ•—è¡€ç—‡ç›¸é—œçš„è‚æå‚·ï¼Œä¸¦å¯èƒ½ä¿ƒé€²æœªä¾†çš„è‡¨åºŠæ‡‰ç”¨ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„æ€¥æ€§è‚æå‚·çš„è—¥ç†ä½œç”¨åŠå…¶æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‚è‡Ÿçš„ç‚ç—‡åæ‡‰å’Œç´°èƒæ­»äº¡ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ•—è¡€ç—‡å¼•èµ·çš„æ€¥æ€§è‚æå‚·æƒ…å¢ƒä¸‹ã€‚é€™é …ç ”ç©¶ä¸åƒ…é—œæ³¨è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œé‚„å¸Œæœ›æ­ç¤ºå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ï¼Œç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›ç§‘å­¸ä¾æ“šã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬ç”±è„‚å¤šé†£å¼•èµ·çš„æ€¥æ€§è‚æå‚·ã€‚ç ”ç©¶åœ˜éšŠå°‡18éš»å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPSåŠ è˜¿è””ç¡«ç´ çµ„ã€‚åœ¨LPSè™•ç†å‰ï¼Œé€™ä¸‰çµ„å°é¼ æ¥å—äº†ç‚ºæœŸå…©å¤©çš„è…¹è…”æ³¨å°„ã€‚LPSæ³¨å°„å¾Œ24å°æ™‚ï¼Œç ”ç©¶äººå“¡æ”¶é›†äº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æã€‚é€éçµ„ç¹”å­¸æŸ“è‰²å’ŒåŸºå› æ¸¬åºç­‰æ–¹æ³•ï¼Œç ”ç©¶è€…è©•ä¼°äº†è‚è‡Ÿçš„æå‚·ç¨‹åº¦å’Œç‚ç—‡åæ‡‰ï¼Œä¸¦è§€å¯Ÿåˆ°ç´°èƒæ­»äº¡çš„æƒ…æ³ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½ç”±LPSå¼•èµ·çš„è‚è‡Ÿæå‚·æŒ‡æ¨™ï¼Œå¦‚è¡€æ¼¿ä¸­çš„ä¸™æ°¨é…¸æ°¨åŸºè½‰ç§»é…¶å’Œå¤©å†¬æ°¨é…¸æ°¨åŸºè½‰ç§»é…¶æ°´å¹³ï¼Œä¸¦æ¸›å°‘ç—…ç†æå‚·å’Œç´°èƒæ­»äº¡çš„æƒ…æ³ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æŠ‘åˆ¶è‚è‡Ÿä¸­çš„ç‚ç—‡åæ‡‰ï¼Œæ¸›å°‘ä¸­æ€§ç²’ç´°èƒå’Œå·¨å™¬ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦é™ä½å¤šç¨®ä¿ƒç‚å› å­çš„è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéæ¿€æ´»ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†ä¿è­·è‚è‡Ÿï¼Œæ¸›è¼•æ€¥æ€§è‚æå‚·å’Œç‚ç—‡ï¼Œç‚ºæœªä¾†çš„æ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "explanation_zh": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸ä½³ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨é€™ç¨®æƒ…æ³ä¸‹çš„æ½›åœ¨ç™‚æ•ˆï¼Œå¯èƒ½ç‚ºé é˜²å’Œæ²»ç™‚æ€¥æ€§è‚æå‚·æä¾›æ–°çš„æ€è·¯ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶åŒ–åˆç‰©ï¼Œå…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ç‰¹æ€§ï¼Œé€™ä½¿å¾—å®ƒåœ¨é¢å°è‚è‡Ÿæå‚·æ™‚ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•ç‚ç—‡åæ‡‰å’Œç´°èƒæå‚·ï¼Œå¾è€Œæ”¹å–„ç—…æƒ…ã€‚é€™äº›ç™¼ç¾æœ‰åŠ©æ–¼æˆ‘å€‘ç†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶æˆåˆ†ä¾†å°æŠ—èˆ‡æ•—è¡€ç—‡ç›¸é—œçš„è‚æå‚·ï¼Œä¸¦å¯èƒ½ä¿ƒé€²æœªä¾†çš„è‡¨åºŠæ‡‰ç”¨ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„æ€¥æ€§è‚æå‚·çš„è—¥ç†ä½œç”¨åŠå…¶æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‚è‡Ÿçš„ç‚ç—‡åæ‡‰å’Œç´°èƒæ­»äº¡ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ•—è¡€ç—‡å¼•èµ·çš„æ€¥æ€§è‚æå‚·æƒ…å¢ƒä¸‹ã€‚é€™é …ç ”ç©¶ä¸åƒ…é—œæ³¨è˜¿è””ç¡«ç´ çš„æ•ˆæœï¼Œé‚„å¸Œæœ›æ­ç¤ºå…¶èƒŒå¾Œçš„ç”Ÿç‰©å­¸æ©Ÿåˆ¶ï¼Œç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›ç§‘å­¸ä¾æ“šã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬ç”±è„‚å¤šé†£å¼•èµ·çš„æ€¥æ€§è‚æå‚·ã€‚ç ”ç©¶åœ˜éšŠå°‡18éš»å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPSåŠ è˜¿è””ç¡«ç´ çµ„ã€‚åœ¨LPSè™•ç†å‰ï¼Œé€™ä¸‰çµ„å°é¼ æ¥å—äº†ç‚ºæœŸå…©å¤©çš„è…¹è…”æ³¨å°„ã€‚LPSæ³¨å°„å¾Œ24å°æ™‚ï¼Œç ”ç©¶äººå“¡æ”¶é›†äº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æã€‚é€éçµ„ç¹”å­¸æŸ“è‰²å’ŒåŸºå› æ¸¬åºç­‰æ–¹æ³•ï¼Œç ”ç©¶è€…è©•ä¼°äº†è‚è‡Ÿçš„æå‚·ç¨‹åº¦å’Œç‚ç—‡åæ‡‰ï¼Œä¸¦è§€å¯Ÿåˆ°ç´°èƒæ­»äº¡çš„æƒ…æ³ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½ç”±LPSå¼•èµ·çš„è‚è‡Ÿæå‚·æŒ‡æ¨™ï¼Œå¦‚è¡€æ¼¿ä¸­çš„ä¸™æ°¨é…¸æ°¨åŸºè½‰ç§»é…¶å’Œå¤©å†¬æ°¨é…¸æ°¨åŸºè½‰ç§»é…¶æ°´å¹³ï¼Œä¸¦æ¸›å°‘ç—…ç†æå‚·å’Œç´°èƒæ­»äº¡çš„æƒ…æ³ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æŠ‘åˆ¶è‚è‡Ÿä¸­çš„ç‚ç—‡åæ‡‰ï¼Œæ¸›å°‘ä¸­æ€§ç²’ç´°èƒå’Œå·¨å™¬ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦é™ä½å¤šç¨®ä¿ƒç‚å› å­çš„è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéæ¿€æ´»ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†ä¿è­·è‚è‡Ÿï¼Œæ¸›è¼•æ€¥æ€§è‚æå‚·å’Œç‚ç—‡ï¼Œç‚ºæœªä¾†çš„æ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "fb_post": "ğŸŒ±ä½ çŸ¥é“è˜¿è””ä¹Ÿèƒ½å¹«åŠ©è‚è‡Ÿå—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¯èƒ½å°æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æœ‰ä¿è­·ä½œç”¨ï¼\n\nç ”ç©¶è€…å€‘é‡å°ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‚è‡Ÿæå‚·é€²è¡Œäº†æ·±å…¥æ¢è¨ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‚è‡Ÿçš„ç‚ç—‡åæ‡‰å’Œç´°èƒæ­»äº¡ã€‚ä»–å€‘ä½¿ç”¨å°é¼ æ¨¡å‹ï¼Œå°‡å°é¼ åˆ†æˆä¸‰çµ„ï¼Œåˆ†åˆ¥æ¥å—ä¸åŒçš„è™•ç†ï¼Œæ¥è‘—è§€å¯Ÿå®ƒå€‘çš„è‚è‡Ÿç‹€æ³ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½è‚è‡Ÿæå‚·çš„æŒ‡æ¨™ï¼Œä¸¦æ¸›å°‘ç‚ç—‡åæ‡‰ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½é€éæ¿€æ´»ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†ä¿è­·è‚è‡Ÿï¼Œæ¸›è¼•æå‚·å’Œç‚ç—‡ã€‚\n\nâœ¨é€™è£¡æœ‰å¹¾å€‹é‡é»è®“ä½ å¸¶èµ°ï¼š\n1ï¸âƒ£ è˜¿è””ç¡«ç´ å¯èƒ½æ˜¯å°æŠ—æ€¥æ€§è‚æå‚·çš„æ–°å¸Œæœ›ï¼\n2ï¸âƒ£ å®ƒèƒ½é™ä½ç‚ç—‡æŒ‡æ¨™ï¼Œæ¸›å°‘ç´°èƒæ­»äº¡ã€‚\n3ï¸âƒ£ é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ï¼Œå€¼å¾—é—œæ³¨ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of the study on sulforaphane. The image should have a light background with soft colors. Include symbolic representations of broccoli or sulforaphane, simplified illustrations of experimental subjects (like mice or cells), arrows or flow lines indicating the steps of the experiment, and a section labeled 'Main Results' that highlights protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§è‚æå‚· Acute Liver Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41181585/"
  },
  {
    "id": "41099966",
    "title_en": "Sulforaphane improves exercise-induced NRF2 signaling in older adults: an in vivo-ex vivo approach.",
    "pub_date": "2025 Oct",
    "abstract_en": "Redox signaling is a key mechanism of exercise-induced adaptation. However, studies have demonstrated impaired responses to acute exercise in older organisms. Adjunctive therapies to augment exercise effects may overcome these deficits. Sulforaphane (SFN), a phytochemical from cruciferous vegetables, stimulates NRF2. This study tested the hypothesis that combining acute exercise (in vivo stimulus) with ex vivo SFN treatment would induce greater NRF2 activation and signaling in older adults compared to either treatment alone. Twenty-five older adults (12 men, 13 women; mean age: 67â€‰Â±â€‰5Â years) performed 30-min cycling exercise (AET). Blood was drawn before and immediately after the AET to isolate PBMCs and incubate with and without SFN (5Â ÂµM) treatment (four conditions: DMSO (CON), SFN, exercise (EX), and EXâ€‰+â€‰SFN). PBMCs were harvested after 2-h or 5-h incubation for measures of NRF2 or gene expression for NQO1, HO-1, GR, and GCLC targets, respectively. All treatments (SFN, EX, EXâ€‰+â€‰SFN) increased NRF2 activation compared to CON (pâ€‰<â€‰0.05). The response to EXâ€‰+â€‰SFN was significantly greater than either SFN or EX alone (2.1-fold versus 1.5-fold, pâ€‰=â€‰0.01). SFN stimulation resulted in a significant upregulation of all four genes compared to control (pâ€‰<â€‰0.001). EXâ€‰+â€‰SFN treatment stimulated a greater increase in gene expression compared to EX (pâ€‰<â€‰0.05); however, SFN did not differ statistically from EXâ€‰+â€‰SFN, suggesting a possible ceiling effect of the SFN concentration in terms of gene expression. There were no significant sex differences in any of the responses. These data suggest that combining exercise with SFN may amplify the strength of NRF2/ARE redox signaling in older adults. ClinicalTrials.gov ID: NCT04848792.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¹´é•·è€…çš„é‹å‹•èƒ½åŠ›å’Œå¥åº·ç‹€æ³ã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œèº«é«”å°é‹å‹•çš„åæ‡‰å¯èƒ½æœƒæ¸›å¼±ï¼Œé€™ä½¿å¾—å¹´é•·è€…åœ¨é€²è¡Œé‹å‹•æ™‚å¯èƒ½ç„¡æ³•ç²å¾—èˆ‡å¹´è¼•äººç›¸åŒçš„å¥½è™•ã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ å¢å¼·é‹å‹•æ•ˆæœçš„è¼”åŠ©ç™‚æ³•ï¼Œå°æ–¼æ”¹å–„å¹´é•·è€…çš„å¥åº·ç‹€æ³è‡³é—œé‡è¦ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ èˆ‡é‹å‹•çµåˆçš„æ½›åœ¨ç›Šè™•ï¼Œå¯èƒ½ç‚ºå¹´é•·è€…æä¾›æ›´æœ‰æ•ˆçš„å¥åº·ä¿ƒé€²ç­–ç•¥ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰èˆ‡é‹å‹•çµåˆå°å¹´é•·è€…çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•å¢å¼·NRF2çš„æ´»åŒ–å’Œä¿¡è™Ÿå‚³éã€‚NRF2æ˜¯ä¸€ç¨®é‡è¦çš„ç´°èƒå› å­ï¼Œèˆ‡æŠ—æ°§åŒ–å’Œç´°èƒä¿è­·æœ‰é—œã€‚ç ”ç©¶è€…å¸Œæœ›é€éçµåˆæ€¥æ€§é‹å‹•å’Œè˜¿è””ç¡«ç´ çš„è™•ç†ï¼Œä¾†æé«˜å¹´é•·è€…çš„NRF2æ´»åŒ–ç¨‹åº¦ï¼Œå¾è€Œæ”¹å–„ä»–å€‘çš„å¥åº·ç‹€æ³ã€‚é€™é …ç ”ç©¶çš„é‡é»åœ¨æ–¼äº†è§£é€™ç¨®çµåˆæ˜¯å¦èƒ½æ¯”å–®ç¨çš„é‹å‹•æˆ–è˜¿è””ç¡«ç´ è™•ç†æ›´æœ‰æ•ˆã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œåƒèˆ‡è€…ç‚º25ä½å¹´é•·è€…ï¼ˆ12ä½ç”·æ€§å’Œ13ä½å¥³æ€§ï¼Œå¹³å‡å¹´é½¡67æ­²ï¼‰ï¼Œä»–å€‘é€²è¡Œäº†30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ã€‚ç ”ç©¶è€…åœ¨é‹å‹•å‰å’Œé‹å‹•å¾Œç«‹å³æŠ½å–è¡€æ¶²ï¼Œä»¥åˆ†é›¢å¤–å‘¨è¡€å–®æ ¸ç´°èƒï¼ˆPBMCsï¼‰ï¼Œä¸¦å°‡é€™äº›ç´°èƒåˆ†åˆ¥èˆ‡å’Œä¸èˆ‡è˜¿è””ç¡«ç´ ï¼ˆ5 ÂµMï¼‰è™•ç†é€²è¡ŒåŸ¹é¤Šã€‚ç ”ç©¶è¨­è¨ˆäº†å››ç¨®è™•ç†æ¢ä»¶ï¼šå°ç…§çµ„ï¼ˆDMSOï¼‰ã€è˜¿è””ç¡«ç´ çµ„ã€é‹å‹•çµ„å’Œé‹å‹•åŠ è˜¿è””ç¡«ç´ çµ„ã€‚éš¨å¾Œï¼Œç ”ç©¶è€…åœ¨2å°æ™‚æˆ–5å°æ™‚å¾Œæ”¶é›†PBMCsï¼Œæ¸¬é‡NRF2çš„æ´»åŒ–å’Œèˆ‡NQO1ã€HO-1ã€GRåŠGCLCç›¸é—œçš„åŸºå› è¡¨é”ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ‰€æœ‰è™•ç†çµ„ï¼ˆè˜¿è””ç¡«ç´ ã€é‹å‹•ã€é‹å‹•åŠ è˜¿è””ç¡«ç´ ï¼‰å‡é¡¯è‘—æé«˜äº†NRF2çš„æ´»åŒ–ç¨‹åº¦ï¼Œç›¸è¼ƒæ–¼å°ç…§çµ„æœ‰æ˜é¡¯çš„å¢å¼·æ•ˆæœã€‚ç‰¹åˆ¥æ˜¯é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„çµ„åˆï¼Œå…¶NRF2çš„æ´»åŒ–ç¨‹åº¦é¡¯è‘—é«˜æ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ æˆ–é‹å‹•è™•ç†ã€‚è˜¿è””ç¡«ç´ çš„åˆºæ¿€é‚„é¡¯è‘—ä¸Šèª¿äº†æ‰€æœ‰å››å€‹åŸºå› çš„è¡¨é”ã€‚é›–ç„¶é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„è™•ç†åœ¨åŸºå› è¡¨é”ä¸Šä¹Ÿé¡¯ç¤ºå‡ºæ›´å¤§çš„å¢å¼·ï¼Œä½†è˜¿è””ç¡«ç´ çš„æ•ˆæœèˆ‡é‹å‹•åŠ è˜¿è””ç¡«ç´ ä¹‹é–“ä¸¦ç„¡é¡¯è‘—å·®ç•°ï¼Œé€™å¯èƒ½æš—ç¤ºäº†è˜¿è””ç¡«ç´ æ¿ƒåº¦åœ¨åŸºå› è¡¨é”ä¸Šçš„ä¸€ç¨®é£½å’Œæ•ˆæ‡‰ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­æ²’æœ‰ç™¼ç¾æ€§åˆ¥å°åæ‡‰çš„é¡¯è‘—å½±éŸ¿ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¹´é•·è€…çš„é‹å‹•èƒ½åŠ›å’Œå¥åº·ç‹€æ³ã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œèº«é«”å°é‹å‹•çš„åæ‡‰å¯èƒ½æœƒæ¸›å¼±ï¼Œé€™ä½¿å¾—å¹´é•·è€…åœ¨é€²è¡Œé‹å‹•æ™‚å¯èƒ½ç„¡æ³•ç²å¾—èˆ‡å¹´è¼•äººç›¸åŒçš„å¥½è™•ã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ å¢å¼·é‹å‹•æ•ˆæœçš„è¼”åŠ©ç™‚æ³•ï¼Œå°æ–¼æ”¹å–„å¹´é•·è€…çš„å¥åº·ç‹€æ³è‡³é—œé‡è¦ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ èˆ‡é‹å‹•çµåˆçš„æ½›åœ¨ç›Šè™•ï¼Œå¯èƒ½ç‚ºå¹´é•·è€…æä¾›æ›´æœ‰æ•ˆçš„å¥åº·ä¿ƒé€²ç­–ç•¥ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰èˆ‡é‹å‹•çµåˆå°å¹´é•·è€…çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å¦‚ä½•å¢å¼·NRF2çš„æ´»åŒ–å’Œä¿¡è™Ÿå‚³éã€‚NRF2æ˜¯ä¸€ç¨®é‡è¦çš„ç´°èƒå› å­ï¼Œèˆ‡æŠ—æ°§åŒ–å’Œç´°èƒä¿è­·æœ‰é—œã€‚ç ”ç©¶è€…å¸Œæœ›é€éçµåˆæ€¥æ€§é‹å‹•å’Œè˜¿è””ç¡«ç´ çš„è™•ç†ï¼Œä¾†æé«˜å¹´é•·è€…çš„NRF2æ´»åŒ–ç¨‹åº¦ï¼Œå¾è€Œæ”¹å–„ä»–å€‘çš„å¥åº·ç‹€æ³ã€‚é€™é …ç ”ç©¶çš„é‡é»åœ¨æ–¼äº†è§£é€™ç¨®çµåˆæ˜¯å¦èƒ½æ¯”å–®ç¨çš„é‹å‹•æˆ–è˜¿è””ç¡«ç´ è™•ç†æ›´æœ‰æ•ˆã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œåƒèˆ‡è€…ç‚º25ä½å¹´é•·è€…ï¼ˆ12ä½ç”·æ€§å’Œ13ä½å¥³æ€§ï¼Œå¹³å‡å¹´é½¡67æ­²ï¼‰ï¼Œä»–å€‘é€²è¡Œäº†30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ã€‚ç ”ç©¶è€…åœ¨é‹å‹•å‰å’Œé‹å‹•å¾Œç«‹å³æŠ½å–è¡€æ¶²ï¼Œä»¥åˆ†é›¢å¤–å‘¨è¡€å–®æ ¸ç´°èƒï¼ˆPBMCsï¼‰ï¼Œä¸¦å°‡é€™äº›ç´°èƒåˆ†åˆ¥èˆ‡å’Œä¸èˆ‡è˜¿è””ç¡«ç´ ï¼ˆ5 ÂµMï¼‰è™•ç†é€²è¡ŒåŸ¹é¤Šã€‚ç ”ç©¶è¨­è¨ˆäº†å››ç¨®è™•ç†æ¢ä»¶ï¼šå°ç…§çµ„ï¼ˆDMSOï¼‰ã€è˜¿è””ç¡«ç´ çµ„ã€é‹å‹•çµ„å’Œé‹å‹•åŠ è˜¿è””ç¡«ç´ çµ„ã€‚éš¨å¾Œï¼Œç ”ç©¶è€…åœ¨2å°æ™‚æˆ–5å°æ™‚å¾Œæ”¶é›†PBMCsï¼Œæ¸¬é‡NRF2çš„æ´»åŒ–å’Œèˆ‡NQO1ã€HO-1ã€GRåŠGCLCç›¸é—œçš„åŸºå› è¡¨é”ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ‰€æœ‰è™•ç†çµ„ï¼ˆè˜¿è””ç¡«ç´ ã€é‹å‹•ã€é‹å‹•åŠ è˜¿è””ç¡«ç´ ï¼‰å‡é¡¯è‘—æé«˜äº†NRF2çš„æ´»åŒ–ç¨‹åº¦ï¼Œç›¸è¼ƒæ–¼å°ç…§çµ„æœ‰æ˜é¡¯çš„å¢å¼·æ•ˆæœã€‚ç‰¹åˆ¥æ˜¯é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„çµ„åˆï¼Œå…¶NRF2çš„æ´»åŒ–ç¨‹åº¦é¡¯è‘—é«˜æ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ æˆ–é‹å‹•è™•ç†ã€‚è˜¿è””ç¡«ç´ çš„åˆºæ¿€é‚„é¡¯è‘—ä¸Šèª¿äº†æ‰€æœ‰å››å€‹åŸºå› çš„è¡¨é”ã€‚é›–ç„¶é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„è™•ç†åœ¨åŸºå› è¡¨é”ä¸Šä¹Ÿé¡¯ç¤ºå‡ºæ›´å¤§çš„å¢å¼·ï¼Œä½†è˜¿è””ç¡«ç´ çš„æ•ˆæœèˆ‡é‹å‹•åŠ è˜¿è””ç¡«ç´ ä¹‹é–“ä¸¦ç„¡é¡¯è‘—å·®ç•°ï¼Œé€™å¯èƒ½æš—ç¤ºäº†è˜¿è””ç¡«ç´ æ¿ƒåº¦åœ¨åŸºå› è¡¨é”ä¸Šçš„ä¸€ç¨®é£½å’Œæ•ˆæ‡‰ã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¸­æ²’æœ‰ç™¼ç¾æ€§åˆ¥å°åæ‡‰çš„é¡¯è‘—å½±éŸ¿ã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿå¹´é•·è€…çš„é‹å‹•æ•ˆæœå¯èƒ½ä¸å¦‚å¹´è¼•äººï¼Œä½†æœ‰ä¸€ç¨®ç¥å¥‡çš„æˆåˆ†ï¼Œæˆ–è¨±èƒ½å¹«åŠ©æ”¹å–„é€™å€‹æƒ…æ³ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰èˆ‡é‹å‹•çš„çµåˆï¼Œçœ‹çœ‹å®ƒèƒ½å¦æå‡å¹´é•·è€…çš„å¥åº·ç‹€æ³ã€‚ ç ”ç©¶ä¸­ï¼Œ25ä½å¹´é•·è€…é€²è¡Œäº†30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ï¼Œä¸¦åœ¨é‹å‹•å‰å¾Œé€²è¡Œäº†è¡€æ¶²æª¢æ¸¬ã€‚ç ”ç©¶è€…ç™¼ç¾ï¼Œç„¡è«–æ˜¯å–®ç¨çš„é‹å‹•é‚„æ˜¯è˜¿è””ç¡«ç´ è™•ç†ï¼Œéƒ½èƒ½é¡¯è‘—æé«˜ä¸€ç¨®å«åšNRF2çš„ç´°èƒå› å­ï¼Œé€™å°æŠ—æ°§åŒ–å’Œç´°èƒä¿è­·éå¸¸é‡è¦ã€‚æœ€æœ‰è¶£çš„æ˜¯ï¼Œé‹å‹•åŠ ä¸Šè˜¿è””ç¡«ç´ çš„çµ„åˆï¼Œèƒ½è®“NRF2çš„æ´»åŒ–ç¨‹åº¦æ›´é«˜ï¼é€™æ„å‘³è‘—ï¼Œé€™ç¨®çµ„åˆå¯èƒ½æœƒç‚ºå¹´é•·è€…å¸¶ä¾†æ›´å¥½çš„å¥åº·ä¿ƒé€²æ•ˆæœã€‚ è®“æˆ‘å€‘ä¾†çœ‹çœ‹é€™äº›é‡è¦çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å¢å¼·é‹å‹•æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å°å¹´é•·è€…ã€‚\n2. é‹å‹•èˆ‡è˜¿è””ç¡«ç´ çš„çµåˆï¼Œèƒ½æœ‰æ•ˆæé«˜NRF2çš„æ´»åŒ–ç¨‹åº¦ã€‚\n3. é€™é …ç ”ç©¶ç‚ºå¹´é•·è€…çš„å¥åº·ä¿ƒé€²æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a simple infographic explaining the experiment and main results of the study on sulforaphane (SFN) and exercise in older adults. Use flat design style with a white or light-colored background and soft color palette. Include symbols representing broccoli or sulforaphane, simplified illustrations of human participants or cells, arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as the protective effects and changes observed in NRF2 activation.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41099966/"
  },
  {
    "id": "40763479",
    "title_en": "Sulforaphane modulates macrophage polarization via JAK1/STAT1 inhibition to promote tendon repair in tendinopathy.",
    "pub_date": "2025 Oct",
    "abstract_en": "Imbalanced M1/M2 macrophage polarization is central to tendinopathy pathogenesis. Sulforaphane (SFN), a natural compound with anti-inflammatory properties, may modulate macrophage polarization. This study utilized a collagenase-induced mouse model of tendinopathy to evaluate the therapeutic effects of local SFN administration on tendinopathy in vivo. Furthermore, the effects of SFN on macrophage polarization were investigated in vitro, and RNA sequencing was used to explore the mechanisms by which SFN regulates macrophage polarization in vivo. Finally, an ex vivo human pathological tendon culture system was employed to explore the therapeutic effects of SFN on tendinopathic lesions. In this study, we found that SFN modulated the polarization of M1 macrophages towards M2 macrophages, thereby effectively modulating the inflammatory response. RNA sequencing and Western blot analyses indicated that the effect of SFN was mediated through the JAK1/STAT1 signaling pathway. In a collagenase-induced mouse model of tendinopathy, local injection of SFN led to a significant improvement in tendon tissue structure, with the collagen matrix restoring its natural dense parallel arrangement. Furthermore, there was an increase in local M2 macrophages and a decrease in M1 macrophages, which promoted the resolution of inflammation. Finally, the immunomodulatory effect of SFN on macrophages was also validated in tendon tissue from patients with tendinopathy. SFN can effectively alleviate tendinopathy by promoting the polarization of M1 macrophages towards M2 macrophages, an effect achieved through the inhibition of the JAK1/STAT1 signaling pathway, thereby providing a promising therapeutic approach for the treatment of tendinopathy.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚Œè…±ç—…çš„æ²»ç™‚ä¸Šã€‚è‚Œè…±ç—…æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œé€šå¸¸ä¼´éš¨è‘—ç–¼ç—›å’ŒåŠŸèƒ½éšœç¤™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éèª¿ç¯€å…ç–«ç´°èƒçš„åŠŸèƒ½ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡åæ‡‰ï¼Œé€²è€Œæ”¹å–„è‚Œè…±çš„å¥åº·ç‹€æ…‹ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨æ²»ç™‚è‚Œè…±ç—…æ™‚ï¼Œå¯èƒ½å¯ä»¥è€ƒæ…®ä½¿ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†èª¿æ•´èº«é«”çš„å…ç–«åæ‡‰ï¼Œå¾è€Œé”åˆ°æ›´å¥½çš„ç™‚æ•ˆã€‚é€™æ¨£çš„ç™¼ç¾ä¸åƒ…å°é‹å‹•å“¡æœ‰å¹«åŠ©ï¼Œå°æ–¼ä»»ä½•å—åˆ°è‚Œè…±ç—…å›°æ“¾çš„äººä¾†èªªï¼Œä¹Ÿå¯èƒ½æ˜¯å€‹å¥½æ¶ˆæ¯ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•é€éèª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ä¾†æ”¹å–„è‚Œè…±ç—…çš„ç—…ç†ç‹€æ…‹ã€‚å·¨å™¬ç´°èƒæ˜¯ä¸€ç¨®é‡è¦çš„å…ç–«ç´°èƒï¼Œç•¶å®ƒå€‘çš„æ¥µåŒ–å¤±è¡¡æ™‚ï¼Œå¯èƒ½æœƒåŠ é‡ç‚ç—‡åæ‡‰ï¼Œé€²è€Œå½±éŸ¿è‚Œè…±çš„ä¿®å¾©ã€‚å› æ­¤ï¼Œé€™é …ç ”ç©¶å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›ç´°èƒçš„è¡Œç‚ºï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶æ½›åœ¨çš„æ²»ç™‚æ©Ÿåˆ¶ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®ç”±è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦è©•ä¼°å±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨é«”å¤–é€²è¡Œäº†å·¨å™¬ç´°èƒçš„æ¥µåŒ–å¯¦é©—ï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºæŠ€è¡“ä¾†æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•èª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ã€‚æœ€å¾Œï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨äº†äººé¡ç—…ç†è‚Œè…±çš„åŸ¹é¤Šç³»çµ±ï¼Œé€²ä¸€æ­¥é©—è­‰è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…è®Šçš„æ²»ç™‚æ•ˆæœã€‚é€™æ¨£çš„å¤šé‡å¯¦é©—è¨­è¨ˆæœ‰åŠ©æ–¼å…¨é¢äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æœ‰æ•ˆåœ°èª¿ç¯€M1å‹å·¨å™¬ç´°èƒå‘M2å‹å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼Œå¾è€Œæ¸›å°‘ç‚ç—‡åæ‡‰ã€‚RNAæ¸¬åºå’Œè¥¿æ–¹å°è·¡åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨æ˜¯é€šéæŠ‘åˆ¶JAK1/STAT1ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚åœ¨è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¸­ï¼Œå±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ é¡¯è‘—æ”¹å–„äº†è‚Œè…±çµ„ç¹”çš„çµæ§‹ï¼Œä¸¦ä¿ƒé€²äº†M2å‹å·¨å™¬ç´°èƒçš„å¢åŠ å’ŒM1å‹å·¨å™¬ç´°èƒçš„æ¸›å°‘ï¼Œé€™æœ‰åŠ©æ–¼ç‚ç—‡çš„æ¶ˆé€€ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…åœ¨è‚Œè…±ç—…æ‚£è€…çš„çµ„ç¹”ä¸­ä¹Ÿé©—è­‰äº†è˜¿è””ç¡«ç´ å°å·¨å™¬ç´°èƒçš„å…ç–«èª¿ç¯€ä½œç”¨ï¼Œé¡¯ç¤ºå…¶åœ¨è‚Œè…±ç—…æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚Œè…±ç—…çš„æ²»ç™‚ä¸Šã€‚è‚Œè…±ç—…æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œé€šå¸¸ä¼´éš¨è‘—ç–¼ç—›å’ŒåŠŸèƒ½éšœç¤™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éèª¿ç¯€å…ç–«ç´°èƒçš„åŠŸèƒ½ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡åæ‡‰ï¼Œé€²è€Œæ”¹å–„è‚Œè…±çš„å¥åº·ç‹€æ…‹ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨æ²»ç™‚è‚Œè…±ç—…æ™‚ï¼Œå¯èƒ½å¯ä»¥è€ƒæ…®ä½¿ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†èª¿æ•´èº«é«”çš„å…ç–«åæ‡‰ï¼Œå¾è€Œé”åˆ°æ›´å¥½çš„ç™‚æ•ˆã€‚é€™æ¨£çš„ç™¼ç¾ä¸åƒ…å°é‹å‹•å“¡æœ‰å¹«åŠ©ï¼Œå°æ–¼ä»»ä½•å—åˆ°è‚Œè…±ç—…å›°æ“¾çš„äººä¾†èªªï¼Œä¹Ÿå¯èƒ½æ˜¯å€‹å¥½æ¶ˆæ¯ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…çš„æ²»ç™‚æ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•é€éèª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ä¾†æ”¹å–„è‚Œè…±ç—…çš„ç—…ç†ç‹€æ…‹ã€‚å·¨å™¬ç´°èƒæ˜¯ä¸€ç¨®é‡è¦çš„å…ç–«ç´°èƒï¼Œç•¶å®ƒå€‘çš„æ¥µåŒ–å¤±è¡¡æ™‚ï¼Œå¯èƒ½æœƒåŠ é‡ç‚ç—‡åæ‡‰ï¼Œé€²è€Œå½±éŸ¿è‚Œè…±çš„ä¿®å¾©ã€‚å› æ­¤ï¼Œé€™é …ç ”ç©¶å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿é€™äº›ç´°èƒçš„è¡Œç‚ºï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å…¶æ½›åœ¨çš„æ²»ç™‚æ©Ÿåˆ¶ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®ç”±è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¾†æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦è©•ä¼°å±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨é«”å¤–é€²è¡Œäº†å·¨å™¬ç´°èƒçš„æ¥µåŒ–å¯¦é©—ï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºæŠ€è¡“ä¾†æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•èª¿ç¯€å·¨å™¬ç´°èƒçš„æ¥µåŒ–ã€‚æœ€å¾Œï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨äº†äººé¡ç—…ç†è‚Œè…±çš„åŸ¹é¤Šç³»çµ±ï¼Œé€²ä¸€æ­¥é©—è­‰è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…è®Šçš„æ²»ç™‚æ•ˆæœã€‚é€™æ¨£çš„å¤šé‡å¯¦é©—è¨­è¨ˆæœ‰åŠ©æ–¼å…¨é¢äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æœ‰æ•ˆåœ°èª¿ç¯€M1å‹å·¨å™¬ç´°èƒå‘M2å‹å·¨å™¬ç´°èƒçš„æ¥µåŒ–ï¼Œå¾è€Œæ¸›å°‘ç‚ç—‡åæ‡‰ã€‚RNAæ¸¬åºå’Œè¥¿æ–¹å°è·¡åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨æ˜¯é€šéæŠ‘åˆ¶JAK1/STAT1ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚åœ¨è† åŸé…¶èª˜å°çš„è€é¼ æ¨¡å‹ä¸­ï¼Œå±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ é¡¯è‘—æ”¹å–„äº†è‚Œè…±çµ„ç¹”çš„çµæ§‹ï¼Œä¸¦ä¿ƒé€²äº†M2å‹å·¨å™¬ç´°èƒçš„å¢åŠ å’ŒM1å‹å·¨å™¬ç´°èƒçš„æ¸›å°‘ï¼Œé€™æœ‰åŠ©æ–¼ç‚ç—‡çš„æ¶ˆé€€ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…åœ¨è‚Œè…±ç—…æ‚£è€…çš„çµ„ç¹”ä¸­ä¹Ÿé©—è­‰äº†è˜¿è””ç¡«ç´ å°å·¨å™¬ç´°èƒçš„å…ç–«èª¿ç¯€ä½œç”¨ï¼Œé¡¯ç¤ºå…¶åœ¨è‚Œè…±ç—…æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "fb_post": "ğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„æŸç¨®æˆåˆ†ï¼Œå¯èƒ½å°è‚Œè…±ç—…æœ‰å¹«åŠ©ï¼é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…çš„æ²»ç™‚æ•ˆæœï¼Œè®“æˆ‘å€‘ä¸€èµ·ä¾†çœ‹çœ‹é€™äº›æœ‰è¶£çš„ç™¼ç¾ï¼\n\nç ”ç©¶è€…å€‘é—œæ³¨çš„æ˜¯ï¼Œè‚Œè…±ç—…é€™ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œé€šå¸¸æœƒé€ æˆç–¼ç—›å’ŒåŠŸèƒ½éšœç¤™ã€‚ä»–å€‘ç™¼ç¾ï¼Œé€éèª¿ç¯€ä¸€ç¨®é‡è¦å…ç–«ç´°èƒâ€”â€”å·¨å™¬ç´°èƒçš„è¡Œç‚ºï¼Œå¯èƒ½èƒ½æ”¹å–„è‚Œè…±çš„å¥åº·ç‹€æ…‹ã€‚é€™äº›å·¨å™¬ç´°èƒåœ¨ç‚ç—‡åæ‡‰ä¸­æ‰®æ¼”è‘—é—œéµè§’è‰²ï¼Œç•¶å®ƒå€‘çš„æ¥µåŒ–å¤±è¡¡æ™‚ï¼Œç‚ç—‡å¯èƒ½æœƒåŠ é‡ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦å±€éƒ¨æ³¨å°„äº†è˜¿è””ç¡«ç´ ã€‚ä»–å€‘é‚„åœ¨å¯¦é©—å®¤ä¸­é€²è¡Œäº†ç´°èƒçš„æ¥µåŒ–å¯¦é©—ï¼Œä¸¦åˆ©ç”¨å…ˆé€²çš„æŠ€è¡“ä¾†è§€å¯Ÿè˜¿è””ç¡«ç´ çš„èª¿ç¯€æ•ˆæœã€‚æœ€çµ‚ï¼Œä»–å€‘ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆåœ°å¹«åŠ©å·¨å™¬ç´°èƒè½‰è®Šç‚ºæœ‰åŠ©æ–¼æ¸›å°‘ç‚ç—‡çš„é¡å‹ï¼Œä¸¦ä¸”æ”¹å–„äº†è‚Œè…±çš„çµæ§‹ã€‚\n\nâœ¨ ç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‚Œè…±ç—…ï¼Œé€éèª¿ç¯€å…ç–«åæ‡‰ã€‚\n2. å®ƒèƒ½ä¿ƒé€²æœ‰ç›Šçš„å·¨å™¬ç´°èƒé¡å‹ï¼Œå¹«åŠ©æ¸›å°‘ç‚ç—‡ã€‚\n3. å°æ–¼é‹å‹•å“¡åŠæ‰€æœ‰å—åˆ°è‚Œè…±ç—…å›°æ“¾çš„äººï¼Œé€™æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„å¥½æ¶ˆæ¯ï¼",
    "image_prompt": "Create a flat design infographic explaining the experiment and main results of a study on the effects of sulforaphane on tendon disorders. Include simple illustrations of broccoli or a symbol for sulforaphane, simplified representations of experimental subjects like humans, animals, or cells. Use arrows or flow lines to indicate the steps of the experiment. Include a section labeled 'Main Results' highlighting protective effects or changes observed, using a light background with soft colors.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚Œè…±ç—… Tendinopathy",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40763479/"
  },
  {
    "id": "41060333",
    "title_en": "Sulforaphane from broccoli, an epigenetic modulator in cancer cells.",
    "pub_date": "2025 Oct",
    "abstract_en": "The consumption of cruciferous vegetables offers several health benefits due to some of their compounds. Sulforaphane (SFN), a compound found in cabbage and broccoli, has received special attention in recent years due to its anticancer activities. The main objective of this systematic review is to examine the epigenetic and genetic effects of SFN on cancers (in vitro and in vivo) which contribute to its anticancer activities. We only analyzed studies that combined its epigenetic effects and anticancer activities due to the multitude of studies on SFN over the past few years. We found that SFN is able to regulate epigenetic mechanisms and promote the prevention and treatment of several cancers. Definitely, it prevents tumor growth and acts as a histone deacetylase (HDAC) inhibitor, a DNA methyltransferase (DNMT) inhibitor, and a microRNA regulator in several cancers. These epigenetic regulations lead indirectly to a hyperregulation or deregulation of the expression of genes involved in carcinogenesis. SFN hasn't any major epigenetic effect on normal cells. This review revealed that the anticancer activities attributable to SFN are largely related to its ability to modulate cancer cell epigenome. These capabilities to modulate the epigenome make SFN a promising anticancer agent with significant therapeutic potential.",
    "para1": "é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–å°å¥åº·æœ‰è¨±å¤šå¥½è™•ï¼Œé€™ä¸»è¦æ˜¯å› ç‚ºå®ƒå€‘å«æœ‰ä¸€äº›ç‰¹æ®Šçš„åŒ–åˆç‰©ã€‚å…¶ä¸­ï¼Œè˜¿è””ç¡«ç´ å› å…¶æŠ—ç™Œç‰¹æ€§è€Œå—åˆ°ç‰¹åˆ¥é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚æ–¹é¢ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿åŸºå› å’Œè¡¨è§€éºå‚³å­¸ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†é™ä½ç™Œç—‡é¢¨éšªï¼Œä¸¦æ”¹å–„æ²»ç™‚æ•ˆæœã€‚",
    "para2": "é€™é …ç³»çµ±æ€§å›é¡§çš„ä¸»è¦ç›®çš„æ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç™Œç—‡çš„è¡¨è§€éºå‚³å’ŒåŸºå› å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•åœ¨ç´°èƒå…§éƒ¨èª¿æ§åŸºå› è¡¨é”ï¼Œé€²è€Œå½±éŸ¿ç™Œç—‡çš„ç™¼å±•ã€‚ç”±æ–¼è¿‘å¹´ä¾†æœ‰è¨±å¤šé—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™é …å›é¡§ç‰¹åˆ¥é›†ä¸­åœ¨å…¶è¡¨è§€éºå‚³æ•ˆæ‡‰èˆ‡æŠ—ç™Œæ´»å‹•çš„çµåˆä¸Šï¼Œä»¥ä¾¿æ›´å…¨é¢åœ°ç†è§£å…¶æ½›åœ¨çš„å¥åº·ç›Šè™•ã€‚",
    "para3": "é€™é …ç ”ç©¶åˆ†æäº†å¤šé …é—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™äº›ç ”ç©¶åŒ…æ‹¬äº†é«”å¤–ï¼ˆin vitroï¼‰å’Œé«”å…§ï¼ˆin vivoï¼‰çš„å¯¦é©—ã€‚ç ”ç©¶è€…è‘—é‡æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•èª¿æ§ç™Œç´°èƒçš„è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦è©•ä¼°å…¶åœ¨é é˜²å’Œæ²»ç™‚ç™Œç—‡æ–¹é¢çš„æ½›åŠ›ã€‚é€™äº›å¯¦é©—ä¸åƒ…æ¶‰åŠç™Œç´°èƒï¼Œé‚„è€ƒé‡äº†æ­£å¸¸ç´°èƒçš„å½±éŸ¿ï¼Œä»¥ç¢ºä¿ç ”ç©¶çµæœçš„å…¨é¢æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿æ§è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦åœ¨å¤šç¨®ç™Œç—‡ä¸­ä¿ƒé€²é é˜²å’Œæ²»ç™‚ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ èƒ½æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä½œç‚ºçµ„è›‹ç™½å»ä¹™é†¯åŒ–é…¶ï¼ˆHDACï¼‰å’ŒDNAç”²åŸºè½‰ç§»é…¶ï¼ˆDNMTï¼‰çš„æŠ‘åˆ¶åŠ‘ï¼Œé‚„èƒ½èª¿æ§å¾®å°RNAã€‚é€™äº›è¡¨è§€éºå‚³èª¿æ§ä½œç”¨é–“æ¥å½±éŸ¿äº†èˆ‡ç™Œç—‡ç™¼ç”Ÿç›¸é—œçš„åŸºå› è¡¨é”ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å°æ­£å¸¸ç´°èƒçš„ä¸»è¦è¡¨è§€éºå‚³å½±éŸ¿ä¸¦ä¸æ˜é¡¯ï¼Œå› æ­¤å…¶æŠ—ç™Œæ½›åŠ›é¡¯å¾—å°¤ç‚ºçªå‡ºã€‚",
    "explanation_zh": "é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–å°å¥åº·æœ‰è¨±å¤šå¥½è™•ï¼Œé€™ä¸»è¦æ˜¯å› ç‚ºå®ƒå€‘å«æœ‰ä¸€äº›ç‰¹æ®Šçš„åŒ–åˆç‰©ã€‚å…¶ä¸­ï¼Œè˜¿è””ç¡«ç´ å› å…¶æŠ—ç™Œç‰¹æ€§è€Œå—åˆ°ç‰¹åˆ¥é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚æ–¹é¢ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿åŸºå› å’Œè¡¨è§€éºå‚³å­¸ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†é™ä½ç™Œç—‡é¢¨éšªï¼Œä¸¦æ”¹å–„æ²»ç™‚æ•ˆæœã€‚\n\né€™é …ç³»çµ±æ€§å›é¡§çš„ä¸»è¦ç›®çš„æ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç™Œç—‡çš„è¡¨è§€éºå‚³å’ŒåŸºå› å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•åœ¨ç´°èƒå…§éƒ¨èª¿æ§åŸºå› è¡¨é”ï¼Œé€²è€Œå½±éŸ¿ç™Œç—‡çš„ç™¼å±•ã€‚ç”±æ–¼è¿‘å¹´ä¾†æœ‰è¨±å¤šé—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™é …å›é¡§ç‰¹åˆ¥é›†ä¸­åœ¨å…¶è¡¨è§€éºå‚³æ•ˆæ‡‰èˆ‡æŠ—ç™Œæ´»å‹•çš„çµåˆä¸Šï¼Œä»¥ä¾¿æ›´å…¨é¢åœ°ç†è§£å…¶æ½›åœ¨çš„å¥åº·ç›Šè™•ã€‚\n\né€™é …ç ”ç©¶åˆ†æäº†å¤šé …é—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™äº›ç ”ç©¶åŒ…æ‹¬äº†é«”å¤–ï¼ˆin vitroï¼‰å’Œé«”å…§ï¼ˆin vivoï¼‰çš„å¯¦é©—ã€‚ç ”ç©¶è€…è‘—é‡æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•èª¿æ§ç™Œç´°èƒçš„è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦è©•ä¼°å…¶åœ¨é é˜²å’Œæ²»ç™‚ç™Œç—‡æ–¹é¢çš„æ½›åŠ›ã€‚é€™äº›å¯¦é©—ä¸åƒ…æ¶‰åŠç™Œç´°èƒï¼Œé‚„è€ƒé‡äº†æ­£å¸¸ç´°èƒçš„å½±éŸ¿ï¼Œä»¥ç¢ºä¿ç ”ç©¶çµæœçš„å…¨é¢æ€§ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿æ§è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦åœ¨å¤šç¨®ç™Œç—‡ä¸­ä¿ƒé€²é é˜²å’Œæ²»ç™‚ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ èƒ½æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸¦ä½œç‚ºçµ„è›‹ç™½å»ä¹™é†¯åŒ–é…¶ï¼ˆHDACï¼‰å’ŒDNAç”²åŸºè½‰ç§»é…¶ï¼ˆDNMTï¼‰çš„æŠ‘åˆ¶åŠ‘ï¼Œé‚„èƒ½èª¿æ§å¾®å°RNAã€‚é€™äº›è¡¨è§€éºå‚³èª¿æ§ä½œç”¨é–“æ¥å½±éŸ¿äº†èˆ‡ç™Œç—‡ç™¼ç”Ÿç›¸é—œçš„åŸºå› è¡¨é”ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å°æ­£å¸¸ç´°èƒçš„ä¸»è¦è¡¨è§€éºå‚³å½±éŸ¿ä¸¦ä¸æ˜é¡¯ï¼Œå› æ­¤å…¶æŠ—ç™Œæ½›åŠ›é¡¯å¾—å°¤ç‚ºçªå‡ºã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœä¸åƒ…ç¾å‘³ï¼Œé‚„å¯èƒ½å°å¥åº·å¤§æœ‰å¹«åŠ©ï¼ğŸ¥¦âœ¨æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„åŒ–åˆç‰©ï¼Œé€™å€‹å°æ±è¥¿åœ¨æŠ—ç™Œæ–¹é¢å¼•èµ·äº†ä¸å°‘é—œæ³¨ã€‚ç ”ç©¶è€…å€‘æƒ³äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æˆ‘å€‘çš„åŸºå› è¡¨é”ï¼Œä¸¦é€²ä¸€æ­¥å½±éŸ¿ç™Œç—‡çš„ç™¼å±•ã€‚\n\né€™é …ç ”ç©¶å›é¡§äº†è¨±å¤šé—œæ–¼è˜¿è””ç¡«ç´ çš„å¯¦é©—ï¼Œå¾ç´°èƒå…§çš„èª¿æ§åˆ°ç™Œç´°èƒçš„å½±éŸ¿éƒ½æœ‰æ¶‰åŠã€‚ä»–å€‘ç™¼ç¾è˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œé‚„èƒ½èª¿æ§ä¸€äº›èˆ‡ç™Œç—‡ç›¸é—œçš„åŸºå› ï¼Œé€™è®“å®ƒåœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­é¡¯å¾—ç‰¹åˆ¥æœ‰æ½›åŠ›ï¼\n\næœ€é‡è¦çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å°æ­£å¸¸ç´°èƒçš„å½±éŸ¿ä¸¦ä¸æ˜é¡¯ï¼Œé€™æ„å‘³è‘—å®ƒçš„æŠ—ç™Œæ•ˆæœå¯èƒ½æ›´ç‚ºçªå‡ºã€‚ä»¥ä¸‹æ˜¯ä½ å¯ä»¥å¸¶èµ°çš„å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœï¼Œå…·æœ‰æ½›åœ¨çš„æŠ—ç™Œç‰¹æ€§ã€‚\n2. å®ƒèƒ½èª¿æ§åŸºå› è¡¨é”ï¼Œå½±éŸ¿ç™Œç—‡çš„ç™¼å±•ã€‚\n3. å°æ­£å¸¸ç´°èƒçš„å½±éŸ¿ä¸å¤§ï¼Œé¡¯ç¤ºå…¶æŠ—ç™Œæ½›åŠ›ã€‚\n\nå¿«ä¾†å¤šåƒé’èŠ±æ¤°èœï¼Œè®“æˆ‘å€‘ä¸€èµ·ç‚ºå¥åº·åŠ åˆ†ï¼ğŸ’ªğŸ’š",
    "image_prompt": "Create an informative infographic illustrating the research on sulforaphane. Include symbols for broccoli and sulforaphane, simplified representations of experimental subjects like human cells or animals. Use arrows or flow lines to indicate the experimental process. Add a section labeled 'Key Findings' highlighting protective effects or changes observed in the study. The style should be flat design with a white or light background and soft colors.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41060333/"
  },
  {
    "id": "40553560",
    "title_en": "Antibacterial effects of sulforaphane - AÂ phytonutrient derived from broccoli asÂ promising candidate in the combat ofÂ bacterial infections.",
    "pub_date": "2025 Oct",
    "abstract_en": "Bacterial pathogens, particularly antibiotic-resistant strains may constitute major challenges for the successful treatment of infected patients. Therefore, novel antibiotics or alternative, antibiotics-independent compounds with antimicrobial properties such as phytonutrients are needed. Our systematic literature review summarizes current knowledge on antibacterial effects of sulforaphane (SFN) in vitro and in vivo, including human studies. The isothiocyanate SFN is abundant in plants from the BrassicaceaeÂ family including broccoli. The 28 reports reviewed herein revealed that SFN i.) exerted antimicrobial effects against a variety of Gram-positive and Gram-negative bacteria; ii.) counteracted distinct virulence factors such as biofilm formation and toxin production (e.g. Shiga toxin); iii.)Â enhanced antibacterial immune cell responses mounting in anti-oxidant and anti-inflammatory actions thereby supporting bacterial killing and dampening inflammatory cell and tissue damage; iv.) prevented from aspirin-induced small intestinal cell injury; and v.) alleviated Helicobacter pylori-induced gastritis. In conclusion, given its antibacterial, immune-modulatory, and disease-alleviating effects, SFN constitutesÂ a promising alternative antibiotic-independent candidate for the treatment of bacterial infections, warranting further consideration in clinical trials.",
    "para1": "éš¨è‘—æŠ—ç”Ÿç´ æŠ—è—¥æ€§èŒæ ªçš„å¢åŠ ï¼Œæ²»ç™‚æ„ŸæŸ“çš„æŒ‘æˆ°ä¹Ÿè¶Šä¾†è¶Šå¤§ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„æŠ—ç”Ÿç´ æˆ–å…¶ä»–ä¸ä¾è³´æŠ—ç”Ÿç´ çš„æŠ—èŒåŒ–åˆç‰©è®Šå¾—éå¸¸é‡è¦ã€‚é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œè˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœçš„æœ€æ–°è³‡è¨Šï¼Œé€™å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨å°æŠ—æŠ—è—¥æ€§ç´°èŒæ„ŸæŸ“æ–¹é¢ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆå°æŠ—å„ç¨®ç´°èŒï¼Œç‰¹åˆ¥æ˜¯é‚£äº›å°æŠ—ç”Ÿç´ æœ‰æŠ—è—¥æ€§çš„ç´°èŒã€‚é€éç³»çµ±æ€§æ–‡ç»å›é¡§ï¼Œç ”ç©¶è€…ç¸½çµäº†ç›®å‰å°æ–¼è˜¿è””ç¡«ç´ åœ¨é«”å¤–å’Œé«”å…§çš„æŠ—èŒæ•ˆæœçš„äº†è§£ï¼ŒåŒ…æ‹¬äººé¡ç ”ç©¶çš„çµæœã€‚",
    "para3": "å¯¦é©—çš„é€²è¡Œæ–¹å¼æ˜¯é€éå›é¡§28ç¯‡ç›¸é—œå ±å‘Šï¼Œé€™äº›å ±å‘Šæ¶µè“‹äº†è˜¿è””ç¡«ç´ å°ä¸åŒç´°èŒçš„æŠ—èŒæ•ˆæœã€‚ç ”ç©¶è€…åˆ†æäº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èŒçš„ç”Ÿç‰©è†œå½¢æˆã€æ¯’ç´ ç”¢ç”Ÿç­‰ç—…åŸæ€§å› ç´ ï¼Œä»¥åŠå®ƒå°å…ç–«ç³»çµ±çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ï¼Œé€™äº›éƒ½å¯èƒ½æœ‰åŠ©æ–¼ç´°èŒçš„æ¸…é™¤å’Œæ¸›å°‘çµ„ç¹”æå‚·ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šç¨®é©è˜­æ°é™½æ€§å’Œé™°æ€§ç´°èŒå…·æœ‰æŠ—èŒæ•ˆæœï¼Œä¸¦èƒ½å°æŠ—ä¸åŒçš„ç—…åŸæ€§å› ç´ ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½å¢å¼·å…ç–«ç´°èƒçš„åæ‡‰ï¼Œä¸¦æ¸›å°‘ç”±é˜¿æ–¯åŒ¹éˆå¼•èµ·çš„å°è…¸ç´°èƒæå‚·ï¼Œç”šè‡³ç·©è§£ç”±å¹½é–€èºæ—‹æ¡¿èŒå¼•èµ·çš„èƒƒç‚ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å‰æ™¯çš„æ›¿ä»£æŠ—ç”Ÿç´ ï¼Œå€¼å¾—åœ¨è‡¨åºŠè©¦é©—ä¸­é€²ä¸€æ­¥æ¢è¨ã€‚",
    "explanation_zh": "éš¨è‘—æŠ—ç”Ÿç´ æŠ—è—¥æ€§èŒæ ªçš„å¢åŠ ï¼Œæ²»ç™‚æ„ŸæŸ“çš„æŒ‘æˆ°ä¹Ÿè¶Šä¾†è¶Šå¤§ã€‚å› æ­¤ï¼Œå°‹æ‰¾æ–°çš„æŠ—ç”Ÿç´ æˆ–å…¶ä»–ä¸ä¾è³´æŠ—ç”Ÿç´ çš„æŠ—èŒåŒ–åˆç‰©è®Šå¾—éå¸¸é‡è¦ã€‚é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œè˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœçš„æœ€æ–°è³‡è¨Šï¼Œé€™å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨å°æŠ—æŠ—è—¥æ€§ç´°èŒæ„ŸæŸ“æ–¹é¢ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆå°æŠ—å„ç¨®ç´°èŒï¼Œç‰¹åˆ¥æ˜¯é‚£äº›å°æŠ—ç”Ÿç´ æœ‰æŠ—è—¥æ€§çš„ç´°èŒã€‚é€éç³»çµ±æ€§æ–‡ç»å›é¡§ï¼Œç ”ç©¶è€…ç¸½çµäº†ç›®å‰å°æ–¼è˜¿è””ç¡«ç´ åœ¨é«”å¤–å’Œé«”å…§çš„æŠ—èŒæ•ˆæœçš„äº†è§£ï¼ŒåŒ…æ‹¬äººé¡ç ”ç©¶çš„çµæœã€‚\n\nå¯¦é©—çš„é€²è¡Œæ–¹å¼æ˜¯é€éå›é¡§28ç¯‡ç›¸é—œå ±å‘Šï¼Œé€™äº›å ±å‘Šæ¶µè“‹äº†è˜¿è””ç¡«ç´ å°ä¸åŒç´°èŒçš„æŠ—èŒæ•ˆæœã€‚ç ”ç©¶è€…åˆ†æäº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èŒçš„ç”Ÿç‰©è†œå½¢æˆã€æ¯’ç´ ç”¢ç”Ÿç­‰ç—…åŸæ€§å› ç´ ï¼Œä»¥åŠå®ƒå°å…ç–«ç³»çµ±çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ï¼Œé€™äº›éƒ½å¯èƒ½æœ‰åŠ©æ–¼ç´°èŒçš„æ¸…é™¤å’Œæ¸›å°‘çµ„ç¹”æå‚·ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šç¨®é©è˜­æ°é™½æ€§å’Œé™°æ€§ç´°èŒå…·æœ‰æŠ—èŒæ•ˆæœï¼Œä¸¦èƒ½å°æŠ—ä¸åŒçš„ç—…åŸæ€§å› ç´ ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½å¢å¼·å…ç–«ç´°èƒçš„åæ‡‰ï¼Œä¸¦æ¸›å°‘ç”±é˜¿æ–¯åŒ¹éˆå¼•èµ·çš„å°è…¸ç´°èƒæå‚·ï¼Œç”šè‡³ç·©è§£ç”±å¹½é–€èºæ—‹æ¡¿èŒå¼•èµ·çš„èƒƒç‚ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å‰æ™¯çš„æ›¿ä»£æŠ—ç”Ÿç´ ï¼Œå€¼å¾—åœ¨è‡¨åºŠè©¦é©—ä¸­é€²ä¸€æ­¥æ¢è¨ã€‚",
    "fb_post": "ğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””è£¡çš„æˆåˆ†ä¸åƒ…èƒ½å¢æ·»æ–™ç†é¢¨å‘³ï¼Œé‚„å¯èƒ½æˆç‚ºæŠ—è—¥æ€§ç´°èŒçš„å…‹æ˜Ÿï¼éš¨è‘—æŠ—ç”Ÿç´ æŠ—è—¥æ€§å•é¡Œæ—¥ç›Šåš´é‡ï¼Œç§‘å­¸å®¶å€‘æ­£åœ¨å°‹æ‰¾æ–°çš„è§£æ±ºæ–¹æ¡ˆã€‚æœ€è¿‘çš„ä¸€é …ç ”ç©¶èšç„¦æ–¼è˜¿è””ç¡«ç´ ï¼Œé€™æ˜¯ä¸€ç¨®å¤©ç„¶çš„åŒ–åˆç‰©ï¼Œç ”ç©¶è€…å€‘æƒ³çŸ¥é“å®ƒæ˜¯å¦èƒ½æœ‰æ•ˆå°æŠ—é‚£äº›å°æŠ—ç”Ÿç´ æœ‰æŠ—è—¥æ€§çš„ç´°èŒã€‚\n\né€™é …ç ”ç©¶é€éå›é¡§28ç¯‡ç›¸é—œæ–‡ç»ï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°ä¸åŒç´°èŒçš„å½±éŸ¿ï¼ŒåŒ…æ‹¬å®ƒå¦‚ä½•å½±éŸ¿ç´°èŒçš„ç”Ÿç‰©è†œå½¢æˆå’Œæ¯’ç´ ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œç ”ç©¶ä¹Ÿæ¢è¨äº†è˜¿è””ç¡«ç´ å°å…ç–«ç³»çµ±çš„å½±éŸ¿ï¼Œåƒæ˜¯æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ï¼Œé€™äº›éƒ½å¯èƒ½å¹«åŠ©æˆ‘å€‘æ¸…é™¤ç´°èŒä¸¦ä¿è­·çµ„ç¹”ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šç¨®ç´°èŒå…·æœ‰æŠ—èŒæ•ˆæœï¼Œç”šè‡³èƒ½å¢å¼·å…ç–«ç´°èƒçš„åæ‡‰ï¼Œæ¸›å°‘ç”±é˜¿æ–¯åŒ¹éˆå¼•èµ·çš„å°è…¸ç´°èƒæå‚·ï¼Œé‚„èƒ½ç·©è§£å¹½é–€èºæ—‹æ¡¿èŒå¼•èµ·çš„èƒƒç‚ã€‚é€™äº›ç™¼ç¾è®“äººæœŸå¾…ï¼Œè˜¿è””ç¡«ç´ æˆ–è¨±æœƒæˆç‚ºæœªä¾†æŠ—è—¥æ€§ç´°èŒæ„ŸæŸ“çš„æ›¿ä»£æ–¹æ¡ˆï¼\n\nâœ¨ ä½ å¯ä»¥å¸¶èµ°çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—æŠ—è—¥æ€§ç´°èŒã€‚\n2. å®ƒèƒ½å¢å¼·å…ç–«ç³»çµ±çš„åæ‡‰ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„è‡¨åºŠè©¦é©—é‹ªè·¯ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main results of a study on the antibacterial effects of sulforaphane from radishes. Include simple illustrations of radishes or sulforaphane, simplified representations of experimental subjects like human cells or animals, arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' highlighting protective effects and observed changes.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¹½é–€èºæ—‹æ¡¿èŒæ„ŸæŸ“ Helicobacter pylori Infection",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40553560/"
  },
  {
    "id": "40597512",
    "title_en": "In vitro gastrointestinal digestion of broccolis sprout extract: Impact on the bioaccesibility of sulforaphane and total phenolic.",
    "pub_date": "2025 Oct",
    "abstract_en": "Broccoli sprout extract is rich in phenolic compounds and sulforaphane (SFN) and the gastrointestinal digestion process can affect the bioaccessibility of these substances. This study aimed to evaluate the antioxidant capacity and the content of total phenolic compounds (TPC) and SFN in broccoli sprout extract before and during in vitro gastrointestinal digestion (GID). The antioxidant capacity was determined using different assays (FRAP, ABTS and DPPH), and the TPC and sulforaphane content was measured using the Folin-Ciocalteu method and high performance liquid chromatography (HPLC), respectively. The in vitro digestion analyses followed the INFOGEST 2.0 protocol. Additionally, microbiological characterization and chemical composition analysis of broccoli sprouts were conducted. The microbiological analyses indicated that the sprouts were safe for consumption, with high amounts of TPC, antioxidant capacity, and SFN content. The TPC content decreased significantly (pÂ <Â 0.001) after GID, from 1740.0Â Î¼gÂ eq. GAE/g before digestion to 536.5Â Î¼gÂ eq. GAE/g in the gastric phase and 211.0Â Î¼gÂ eq. GAE/g in the enteric phase. The antioxidant capacity also decreased significantly after simulated digestion compared to initial values. A lower (pÂ <Â 0.001) SFN content was identified in the gastric phase (18.6Â mg/g) compared to the intestinal phase (27.8Â mg/g), although both showed lower SFN levels than the undigested sample, which contained 72.2Â mg/g of SFN. In conclusion, simulated digestion significantly reduced the amount of TPC and SFN, likely due to degradation or biotransformation of the compounds under digestion conditions.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œé’èŠ±æ¤°èœèŠ½æå–ç‰©åœ¨æ¶ˆåŒ–éç¨‹ä¸­æŠ—æ°§åŒ–èƒ½åŠ›åŠå…¶æˆåˆ†è®ŠåŒ–çš„è¦‹è§£ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰æ½›åœ¨çš„å•Ÿç¤ºã€‚é’èŠ±æ¤°èœèŠ½ä¸­å¯Œå«çš„è˜¿è””ç¡«ç´ å’Œå¤šé…šåŒ–åˆç‰©è¢«èªç‚ºå…·æœ‰æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œå¯èƒ½å°æ¸›å°‘æ…¢æ€§ç–¾ç—…çš„é¢¨éšªæœ‰æ‰€å¹«åŠ©ã€‚ç„¶è€Œï¼Œé€™äº›æœ‰ç›Šæˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­æœƒå—åˆ°å½±éŸ¿ï¼Œé€™æ„å‘³è‘—æˆ‘å€‘åœ¨æ”å–é€™äº›é£Ÿç‰©æ™‚ï¼Œå¯èƒ½éœ€è¦è€ƒæ…®å¦‚ä½•æœ€å¤§åŒ–å…¶å¥åº·æ•ˆç›Šã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„æŠ—æ°§åŒ–èƒ½åŠ›åŠå…¶å¤šé…šåŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ¨¡æ“¬çš„è…¸èƒƒæ¶ˆåŒ–éç¨‹ä¸­é€™äº›æˆåˆ†çš„è®ŠåŒ–ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›é‡è¦æˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­æ˜¯å¦æœƒè¢«é™è§£æˆ–è½‰åŒ–ï¼Œå¾è€Œå½±éŸ¿å…¶å¥åº·æ•ˆç›Šã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ï¼Œä¸¦é€éé«”å¤–è…¸èƒƒæ¶ˆåŒ–åˆ†æä¾†è©•ä¼°å…¶æŠ—æ°§åŒ–èƒ½åŠ›å’Œæˆåˆ†è®ŠåŒ–ã€‚ç ”ç©¶è€…æ¡ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†æ¸¬é‡æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒ…æ‹¬FRAPã€ABTSå’ŒDPPHç­‰æ¸¬è©¦ï¼Œä¸¦ä½¿ç”¨Folin-Ciocalteuæ–¹æ³•å’Œé«˜æ•ˆæ¶²ç›¸è‰²è­œï¼ˆHPLCï¼‰ä¾†æ¸¬é‡å¤šé…šåŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„é€²è¡Œäº†å¾®ç”Ÿç‰©ç‰¹å¾µåˆ†æï¼Œä»¥ç¢ºä¿é’èŠ±æ¤°èœèŠ½çš„å®‰å…¨æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ¨¡æ“¬æ¶ˆåŒ–éç¨‹é¡¯è‘—é™ä½äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„å¤šé…šåŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œåœ¨æ¶ˆåŒ–éç¨‹ä¸­ï¼Œå¤šé…šåŒ–åˆç‰©çš„å«é‡å¾æ¶ˆåŒ–å‰çš„1740.0 Î¼g eq. GAE/gé™è‡³èƒƒç›¸çš„536.5 Î¼g eq. GAE/gå’Œè…¸ç›¸çš„211.0 Î¼g eq. GAE/gï¼ŒæŠ—æ°§åŒ–èƒ½åŠ›ä¹Ÿé¡¯è‘—ä¸‹é™ã€‚æ­¤å¤–ï¼Œèƒƒç›¸çš„è˜¿è””ç¡«ç´ å«é‡ç‚º18.6 mg/gï¼Œè€Œè…¸ç›¸ç‚º27.8 mg/gï¼Œé€™å…©è€…å‡ä½æ–¼æœªæ¶ˆåŒ–æ¨£æœ¬çš„72.2 mg/gã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œé’èŠ±æ¤°èœèŠ½æå–ç‰©åœ¨æ¶ˆåŒ–éç¨‹ä¸­æŠ—æ°§åŒ–èƒ½åŠ›åŠå…¶æˆåˆ†è®ŠåŒ–çš„è¦‹è§£ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰æ½›åœ¨çš„å•Ÿç¤ºã€‚é’èŠ±æ¤°èœèŠ½ä¸­å¯Œå«çš„è˜¿è””ç¡«ç´ å’Œå¤šé…šåŒ–åˆç‰©è¢«èªç‚ºå…·æœ‰æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œå¯èƒ½å°æ¸›å°‘æ…¢æ€§ç–¾ç—…çš„é¢¨éšªæœ‰æ‰€å¹«åŠ©ã€‚ç„¶è€Œï¼Œé€™äº›æœ‰ç›Šæˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­æœƒå—åˆ°å½±éŸ¿ï¼Œé€™æ„å‘³è‘—æˆ‘å€‘åœ¨æ”å–é€™äº›é£Ÿç‰©æ™‚ï¼Œå¯èƒ½éœ€è¦è€ƒæ…®å¦‚ä½•æœ€å¤§åŒ–å…¶å¥åº·æ•ˆç›Šã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„æŠ—æ°§åŒ–èƒ½åŠ›åŠå…¶å¤šé…šåŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ¨¡æ“¬çš„è…¸èƒƒæ¶ˆåŒ–éç¨‹ä¸­é€™äº›æˆåˆ†çš„è®ŠåŒ–ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›é‡è¦æˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­æ˜¯å¦æœƒè¢«é™è§£æˆ–è½‰åŒ–ï¼Œå¾è€Œå½±éŸ¿å…¶å¥åº·æ•ˆç›Šã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ï¼Œä¸¦é€éé«”å¤–è…¸èƒƒæ¶ˆåŒ–åˆ†æä¾†è©•ä¼°å…¶æŠ—æ°§åŒ–èƒ½åŠ›å’Œæˆåˆ†è®ŠåŒ–ã€‚ç ”ç©¶è€…æ¡ç”¨äº†å¤šç¨®æ–¹æ³•ä¾†æ¸¬é‡æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒ…æ‹¬FRAPã€ABTSå’ŒDPPHç­‰æ¸¬è©¦ï¼Œä¸¦ä½¿ç”¨Folin-Ciocalteuæ–¹æ³•å’Œé«˜æ•ˆæ¶²ç›¸è‰²è­œï¼ˆHPLCï¼‰ä¾†æ¸¬é‡å¤šé…šåŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„é€²è¡Œäº†å¾®ç”Ÿç‰©ç‰¹å¾µåˆ†æï¼Œä»¥ç¢ºä¿é’èŠ±æ¤°èœèŠ½çš„å®‰å…¨æ€§ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ¨¡æ“¬æ¶ˆåŒ–éç¨‹é¡¯è‘—é™ä½äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„å¤šé…šåŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œåœ¨æ¶ˆåŒ–éç¨‹ä¸­ï¼Œå¤šé…šåŒ–åˆç‰©çš„å«é‡å¾æ¶ˆåŒ–å‰çš„1740.0 Î¼g eq. GAE/gé™è‡³èƒƒç›¸çš„536.5 Î¼g eq. GAE/gå’Œè…¸ç›¸çš„211.0 Î¼g eq. GAE/gï¼ŒæŠ—æ°§åŒ–èƒ½åŠ›ä¹Ÿé¡¯è‘—ä¸‹é™ã€‚æ­¤å¤–ï¼Œèƒƒç›¸çš„è˜¿è””ç¡«ç´ å«é‡ç‚º18.6 mg/gï¼Œè€Œè…¸ç›¸ç‚º27.8 mg/gï¼Œé€™å…©è€…å‡ä½æ–¼æœªæ¶ˆåŒ–æ¨£æœ¬çš„72.2 mg/gã€‚",
    "fb_post": "ğŸŒ± ä½ çŸ¥é“é’èŠ±æ¤°èœèŠ½è£¡çš„è˜¿è””ç¡«ç´ æœ‰å¤šå²å®³å—ï¼Ÿé€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼Œé’èŠ±æ¤°èœèŠ½æå–ç‰©åœ¨æ¶ˆåŒ–éç¨‹ä¸­çš„æŠ—æ°§åŒ–èƒ½åŠ›å’Œæˆåˆ†è®ŠåŒ–ï¼Œå°å¥åº·æœ‰å¾ˆå¤§çš„å•Ÿç¤ºï¼\n\nç ”ç©¶åœ˜éšŠå°ˆæ³¨æ–¼æ¢è¨é’èŠ±æ¤°èœèŠ½è£¡çš„æŠ—æ°§åŒ–æˆåˆ†ï¼Œç‰¹åˆ¥æ˜¯åœ¨æˆ‘å€‘æ¶ˆåŒ–é£Ÿç‰©çš„éç¨‹ä¸­ï¼Œé€™äº›æˆåˆ†æ˜¯å¦æœƒè¢«é™è§£æˆ–æ”¹è®Šã€‚ä»–å€‘ç”¨äº†ä¸€äº›ç§‘å­¸æ–¹æ³•ä¾†æ¸¬é‡é€™äº›æˆåˆ†çš„è®ŠåŒ–ï¼Œçµæœé¡¯ç¤ºï¼Œåœ¨æ¨¡æ“¬çš„æ¶ˆåŒ–éç¨‹ä¸­ï¼Œé’èŠ±æ¤°èœèŠ½ä¸­çš„å¤šé…šåŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡æ˜é¡¯ä¸‹é™ï¼Œé€™å¯èƒ½æœƒå½±éŸ¿å®ƒå€‘çš„å¥åº·æ•ˆç›Šã€‚\n\nğŸ” ä¸»è¦çš„ç™¼ç¾æœ‰ï¼š\n1. æ¶ˆåŒ–éç¨‹ä¸­ï¼Œå¤šé…šåŒ–åˆç‰©çš„å«é‡å¾1740.0é™åˆ°èƒƒç›¸çš„536.5å’Œè…¸ç›¸çš„211.0 Î¼gã€‚\n2. è˜¿è””ç¡«ç´ çš„å«é‡åœ¨èƒƒç›¸å’Œè…¸ç›¸ä¹Ÿé¡¯è‘—ä½æ–¼æœªæ¶ˆåŒ–æ¨£æœ¬ã€‚\n3. é€™äº›è®ŠåŒ–å¯èƒ½å½±éŸ¿é’èŠ±æ¤°èœèŠ½çš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚\n\næ‰€ä»¥ï¼Œä¸‹æ¬¡åƒé’èŠ±æ¤°èœèŠ½æ™‚ï¼Œæˆ–è¨±å¯ä»¥è€ƒæ…®å¦‚ä½•æ­é…ï¼Œè®“å®ƒçš„å¥åº·æ•ˆç›Šæœ€å¤§åŒ–ï¼",
    "image_prompt": "Create an informative illustration that explains the experimental process and main findings of a study on broccoli sprout extract. The image should have a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli and sulforaphane. Simplified icons of experimental subjects like humans, animals, or cells should be present. Use arrows or flow lines to indicate the steps of the experiment. Include a section labeled 'Main Findings' showing the decrease in polyphenol and sulforaphane levels during digestion.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40597512/"
  },
  {
    "id": "41026407",
    "title_en": "The Adaptive Laboratory Evolution Technology Enhances Sulforaphane Production of Lactobacillus plantarum CR12.",
    "pub_date": "2025 Sep",
    "abstract_en": "T he sulforaphane production of wild-type Lactobacillus plantarum CR12 (L. plantarum CR12) is limited. Researchers found that adaptive laboratory evolution (ALE) technology can enhance the production of microorganism by altering the growth environment of microorganisms. However, the effectiveness of enhancing the transformation function of L. plantarum CR12 and the safety of the adaptive strain are unknown. To clarify the above problem, ALE technology was used to enhance the sulforaphane conversion rate of L. plantarum CR12. The results showed that the glucoraphanin conversion rate, sulforaphane production rate, and sulforaphane conversion efficiency of adaptive strain were significantly higher than those of the wild-type strain. The adaptive strain could produce sulforaphane in vivo and regulate the gut microbiota structure. The genomes showed that the adaptive strain consists of a 4,165,885Â bp chromosome with a GC content of 36.8%, encoding 4172 protein-coding genes. Compared with the wild-type strain, the adaptive strain expresses more glycoside hydrolases and glycosyl transferases, indicating that the adaptive strain possesses higher carbohydrate metabolic capability. Genes related to glucoraphanin metabolism (cliT, bglF, and bglA) were detected in both the genomes of the wild-type strain and adaptive strain, indicating that both the wild-type strain and adaptive strain possess sulforaphane production capabilities. Therefore, the adaptive strain can be safely used to increase the in vivo production of sulforaphane, ultimately improving human health. This research is aimed at providing genetic evidence for further formulating rational genetic engineering strategies to transform the wild-type strain into an overproducer.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—æ½›åœ¨çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„è…¸é“å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å°äººé«”æœ‰ç›Šï¼Œèƒ½å¤ ä¿ƒé€²å¥åº·å’Œé é˜²æŸäº›ç–¾ç—…ã€‚é€éæå‡å¾®ç”Ÿç‰©å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–èƒ½åŠ›ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·è…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œé€²è€Œæ”¹å–„æ•´é«”å¥åº·ç‹€æ³ã€‚é€™å°æ–¼å¸Œæœ›é€éé£²é£Ÿä¾†å¢é€²å¥åº·çš„äººå€‘ä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯å°æ–¼é‚£äº›å°‹æ±‚è‡ªç„¶æ–¹å¼ä¾†å¢å¼·å…ç–«ç³»çµ±å’Œç¶­æŒè…¸é“å¥åº·çš„äººä¾†èªªï¼Œé€™é …ç ”ç©¶çš„çµæœå¯èƒ½æœƒå¼•èµ·ä»–å€‘çš„èˆˆè¶£ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•åˆ©ç”¨é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ï¼ˆALEï¼‰ä¾†æå‡ä¹³é…¸èŒLactobacillus plantarum CR12ï¼ˆL. plantarum CR12ï¼‰å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–èƒ½åŠ›ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ç¨®å¾®ç”Ÿç‰©åœ¨æ”¹è®Šç”Ÿé•·ç’°å¢ƒå¾Œï¼Œæ˜¯å¦èƒ½æœ‰æ•ˆæé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ï¼Œä»¥åŠé€™ç¨®æ”¹é€ å¾Œçš„èŒæ ªæ˜¯å¦å®‰å…¨ã€‚é€éé€™é …ç ”ç©¶ï¼Œç ”ç©¶åœ˜éšŠå¸Œæœ›èƒ½å¤ æä¾›æœ‰é—œå¦‚ä½•æ”¹é€²å¾®ç”Ÿç‰©ç”Ÿç”¢èƒ½åŠ›çš„ç§‘å­¸ä¾æ“šï¼Œä¸¦ç‚ºæœªä¾†çš„åŸºå› å·¥ç¨‹ç­–ç•¥å¥ å®šåŸºç¤ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†æ”¹é€ L. plantarum CR12ï¼Œç›®çš„æ˜¯æé«˜å…¶å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚ç ”ç©¶åœ˜éšŠé¦–å…ˆè§€å¯Ÿäº†é‡ç”Ÿå‹èŒæ ªçš„ç”Ÿé•·ç’°å¢ƒï¼Œç„¶å¾Œé€²è¡Œäº†ä¸€ç³»åˆ—çš„å¯¦é©—ä¾†èª¿æ•´é€™äº›ç’°å¢ƒï¼Œä»¥ä¿ƒé€²å¾®ç”Ÿç‰©çš„ç”Ÿé•·å’Œä»£è¬ã€‚æœ€çµ‚ï¼Œç ”ç©¶è€…åˆ†æäº†æ”¹é€ å¾Œçš„èŒæ ªèˆ‡é‡ç”Ÿå‹èŒæ ªåœ¨è˜¿è””ç¡«ç´ ç”¢é‡å’Œè½‰åŒ–æ•ˆç‡ä¸Šçš„å·®ç•°ï¼Œä¸¦æª¢æ¸¬äº†å…¶åŸºå› çµ„çš„è®ŠåŒ–ï¼Œä»¥äº†è§£å…¶ä»£è¬èƒ½åŠ›çš„æå‡ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éé©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–çš„èŒæ ªåœ¨è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€ç”¢é‡å’Œè½‰åŒ–æ•ˆç‡æ–¹é¢å‡é¡¯è‘—é«˜æ–¼é‡ç”Ÿå‹èŒæ ªã€‚æ­¤å¤–ï¼Œé€™ç¨®æ”¹é€ å¾Œçš„èŒæ ªèƒ½å¤ åœ¨é«”å…§ç”¢ç”Ÿè˜¿è””ç¡«ç´ ï¼Œä¸¦èª¿ç¯€è…¸é“å¾®ç”Ÿç‰©çš„çµæ§‹ã€‚åŸºå› çµ„åˆ†æé¡¯ç¤ºï¼Œæ”¹é€ å¾Œçš„èŒæ ªæ“æœ‰æ›´é«˜çš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬èƒ½åŠ›ï¼Œä¸¦ä¸”åœ¨åŸºå› è¡¨é”ä¸Šé¡¯ç¤ºå‡ºæ›´å¤šèˆ‡è˜¿è””ç¡«ç´ ä»£è¬ç›¸é—œçš„é…¶ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œæ”¹é€ å¾Œçš„èŒæ ªåœ¨å®‰å…¨æ€§ä¸Šæ˜¯å¯è¡Œçš„ï¼Œä¸¦ä¸”æœ‰æ½›åŠ›ç”¨æ–¼æé«˜é«”å…§è˜¿è””ç¡«ç´ çš„ç”¢é‡ï¼Œæœ€çµ‚å¯èƒ½å°äººé¡å¥åº·ç”¢ç”Ÿç©æ¥µå½±éŸ¿ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—æ½›åœ¨çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„è…¸é“å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„åŒ–åˆç‰©ï¼Œå·²çŸ¥å°äººé«”æœ‰ç›Šï¼Œèƒ½å¤ ä¿ƒé€²å¥åº·å’Œé é˜²æŸäº›ç–¾ç—…ã€‚é€éæå‡å¾®ç”Ÿç‰©å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–èƒ½åŠ›ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·è…¸é“å¾®ç”Ÿç‰©çš„å¤šæ¨£æ€§ï¼Œé€²è€Œæ”¹å–„æ•´é«”å¥åº·ç‹€æ³ã€‚é€™å°æ–¼å¸Œæœ›é€éé£²é£Ÿä¾†å¢é€²å¥åº·çš„äººå€‘ä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯å°æ–¼é‚£äº›å°‹æ±‚è‡ªç„¶æ–¹å¼ä¾†å¢å¼·å…ç–«ç³»çµ±å’Œç¶­æŒè…¸é“å¥åº·çš„äººä¾†èªªï¼Œé€™é …ç ”ç©¶çš„çµæœå¯èƒ½æœƒå¼•èµ·ä»–å€‘çš„èˆˆè¶£ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•åˆ©ç”¨é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ï¼ˆALEï¼‰ä¾†æå‡ä¹³é…¸èŒLactobacillus plantarum CR12ï¼ˆL. plantarum CR12ï¼‰å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–èƒ½åŠ›ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ç¨®å¾®ç”Ÿç‰©åœ¨æ”¹è®Šç”Ÿé•·ç’°å¢ƒå¾Œï¼Œæ˜¯å¦èƒ½æœ‰æ•ˆæé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ï¼Œä»¥åŠé€™ç¨®æ”¹é€ å¾Œçš„èŒæ ªæ˜¯å¦å®‰å…¨ã€‚é€éé€™é …ç ”ç©¶ï¼Œç ”ç©¶åœ˜éšŠå¸Œæœ›èƒ½å¤ æä¾›æœ‰é—œå¦‚ä½•æ”¹é€²å¾®ç”Ÿç‰©ç”Ÿç”¢èƒ½åŠ›çš„ç§‘å­¸ä¾æ“šï¼Œä¸¦ç‚ºæœªä¾†çš„åŸºå› å·¥ç¨‹ç­–ç•¥å¥ å®šåŸºç¤ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†æ”¹é€ L. plantarum CR12ï¼Œç›®çš„æ˜¯æé«˜å…¶å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚ç ”ç©¶åœ˜éšŠé¦–å…ˆè§€å¯Ÿäº†é‡ç”Ÿå‹èŒæ ªçš„ç”Ÿé•·ç’°å¢ƒï¼Œç„¶å¾Œé€²è¡Œäº†ä¸€ç³»åˆ—çš„å¯¦é©—ä¾†èª¿æ•´é€™äº›ç’°å¢ƒï¼Œä»¥ä¿ƒé€²å¾®ç”Ÿç‰©çš„ç”Ÿé•·å’Œä»£è¬ã€‚æœ€çµ‚ï¼Œç ”ç©¶è€…åˆ†æäº†æ”¹é€ å¾Œçš„èŒæ ªèˆ‡é‡ç”Ÿå‹èŒæ ªåœ¨è˜¿è””ç¡«ç´ ç”¢é‡å’Œè½‰åŒ–æ•ˆç‡ä¸Šçš„å·®ç•°ï¼Œä¸¦æª¢æ¸¬äº†å…¶åŸºå› çµ„çš„è®ŠåŒ–ï¼Œä»¥äº†è§£å…¶ä»£è¬èƒ½åŠ›çš„æå‡ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éé©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–çš„èŒæ ªåœ¨è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€ç”¢é‡å’Œè½‰åŒ–æ•ˆç‡æ–¹é¢å‡é¡¯è‘—é«˜æ–¼é‡ç”Ÿå‹èŒæ ªã€‚æ­¤å¤–ï¼Œé€™ç¨®æ”¹é€ å¾Œçš„èŒæ ªèƒ½å¤ åœ¨é«”å…§ç”¢ç”Ÿè˜¿è””ç¡«ç´ ï¼Œä¸¦èª¿ç¯€è…¸é“å¾®ç”Ÿç‰©çš„çµæ§‹ã€‚åŸºå› çµ„åˆ†æé¡¯ç¤ºï¼Œæ”¹é€ å¾Œçš„èŒæ ªæ“æœ‰æ›´é«˜çš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬èƒ½åŠ›ï¼Œä¸¦ä¸”åœ¨åŸºå› è¡¨é”ä¸Šé¡¯ç¤ºå‡ºæ›´å¤šèˆ‡è˜¿è””ç¡«ç´ ä»£è¬ç›¸é—œçš„é…¶ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œæ”¹é€ å¾Œçš„èŒæ ªåœ¨å®‰å…¨æ€§ä¸Šæ˜¯å¯è¡Œçš„ï¼Œä¸¦ä¸”æœ‰æ½›åŠ›ç”¨æ–¼æé«˜é«”å…§è˜¿è””ç¡«ç´ çš„ç”¢é‡ï¼Œæœ€çµ‚å¯èƒ½å°äººé¡å¥åº·ç”¢ç”Ÿç©æ¥µå½±éŸ¿ã€‚",
    "fb_post": "ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰ä¸€ç¨®å«è˜¿è””ç¡«ç´ çš„æˆåˆ†å—ï¼Ÿé€™é …ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼Œé€™ç¨®æˆåˆ†å°è…¸é“å¥åº·æœ‰è‘—æ½›åœ¨çš„å¥½è™•ï¼ç ”ç©¶åœ˜éšŠæ¢ç´¢äº†å¦‚ä½•åˆ©ç”¨ä¸€ç¨®å«é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ï¼ˆALEï¼‰ä¾†æå‡ä¸€ç¨®ä¹³é…¸èŒï¼ˆLactobacillus plantarum CR12ï¼‰å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–èƒ½åŠ›ã€‚ä»–å€‘èª¿æ•´äº†é€™ç¨®èŒçš„ç”Ÿé•·ç’°å¢ƒï¼Œå¸Œæœ›èƒ½å¢åŠ è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚æœ€çµ‚ï¼Œä»–å€‘ç™¼ç¾ç¶“éæ”¹é€ çš„èŒæ ªåœ¨è˜¿è””ç¡«ç´ çš„ç”¢é‡å’Œè½‰åŒ–æ•ˆç‡ä¸Šéƒ½è¡¨ç¾å¾—æ¯”åŸå§‹èŒæ ªå¥½å¾—å¤šï¼é€™ä¸åƒ…æ„å‘³è‘—é€™ç¨®æ”¹é€ å¾Œçš„èŒæ ªå®‰å…¨ï¼Œé‚„å¯èƒ½æœ‰åŠ©æ–¼å¢å¼·æˆ‘å€‘çš„è…¸é“å¥åº·ã€‚ \n\nğŸ’¡ é€™è£¡æœ‰å¹¾å€‹ä½ å¯ä»¥å¸¶èµ°çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ã€‚\n2. é€éå¾®ç”Ÿç‰©æ”¹é€ ï¼Œå¯ä»¥æå‡è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›äº†æ–°çš„æ–¹å‘ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on sulforaphane from broccoli. Include simplified illustrations of broccoli and sulforaphane, a simplified representation of the experimental subjects (like humans or cells), arrows or flow lines to indicate the experimental steps, and a section labeled 'Main Results' highlighting the increased production and conversion efficiency of sulforaphane by the modified Lactobacillus plantarum CR12 strain.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41026407/"
  }
]